Clinical trial NCT02600611
Conditions: Skin Structures and Soft Tissue Infections
Sponsor: Motif Bio
Start date: 2015-11-01; Completion date: 2017-01-30
Enrollment: 600 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.

Detailed description:
This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin. Patients will receive either iclaprim or vancomycin for 5 to 14 days. Patients will be evaluated daily up to early time point (ETP), then every 48 to 72 hours through the end of treatment. Patients will also be evaluated at the test of cure (TOC) visit (7 to 14 days post-EOT), and will have a Late Follow-Up (LFU) visit (28 to 32 days post-first dose).

Arms: arm 1: iclaprim 80 mg intravenous every 12 hours arm 2: vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
Interventions: intervention 1: iclaprim intervention 2: vancomycin
Intervention descriptions: intervention 1: Experimental treatment intervention 2: Active comparator

Protocol documents:
Prot_000.pdf: 
CONFIDENTIAL AND PROPRIETARY 
Information described herein is confidential and may be disclosed  
only with the express written permission of Motif BioSciences 
This study will be performed in compliance with Good Clinical Practices. 
 
A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous 
iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infections suspected 
or confirmed to be due to Gram-positive pathogens. 
REVIVE-1 
 
 
Product: 
Iclaprim 
Protocol/Amendment No.: 
ICL-23-ABSSSI1-01 
Phase:  
3 
 
 
for 
Motif BioSciences 
330 Madison Avenue 
6th Floor, Suite 665 
New York, NY 10017 
United States 
 
 
by 
Covance, Inc. 
 
 
 
 
 
 
Date of Original Protocol: 
21 OCT 2015 
Date of Amendment 1: 
3 DEC 2015 
 
 
Protocol Version (3 Dec 2015) 
Page 1 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
STUDY IDENTIFICATION 
Sponsor’s Medical Monitor: 
David Huang 
330 Madison Avenue, 6th Floor, Suite 665 
New York, NY 10017 
Phone (During Business Hours): +1 936 577-5770 
Phone (After Business Hours):  +1 936 577-5770 
Email address: David.Huang@motifbio.com 
 
CRO Medical Monitor: 
Patrick McLeroth 
206 Carnegie Center 
Princeton, NJ 08540 
Phone (During Business Hours): +1 609 452-4562 
Phone (After Business Hours):  +1 609 216-4187 
Email address: Patrick.McLeroth@Covance.com 
 
Sponsor’s Study Contact: 
David Huang 
330 Madison Avenue, 6th Floor, Suite 665 
New York, NY 10017 
Phone (During Business Hours): +1 936 577-5770 
Phone (After Business Hours):  +1 936 577-5770 
Email address: David.Huang@motifbio.com 
 
Protocol Biostatistician: 
Toyoko Oguri 
206 Carnegie Center 
Princeton, NJ 08540 
Phone: +1 609 452-4149   
Email address: Toyoko.Oguri@Covance.com 
 
Protocol Version (3 Dec 2015) 
Page 2 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
SUMMARY OF CHANGES 
 
Synopsis (Objectives) 
• 
Added mCE population to secondary objectives numbers 1 to 5. 
• 
Added the following secondary objective: 
Resolution or near resolution (≥90%) of ABSSSI at EOT and TOC among patients with severe 
infection at baseline defined by meeting one or more of the following criteria: 
a. 
fulfilled the published definition for systemic inflammatory response syndrome (SIRS) 
by having ≥2 of the following findings: body temperature >38°C or <36°C,  heart rate 
>90 bpm,  respiration rate >20 breaths/minute, and  WBC >12000/mm3 or <4000/mm3 
or >10% bands; 
b. Evaluated as having severe tenderness or severe erythema at the infection site; and 
c. 
Positive blood cultures at baseline. 
 
Synopsis (Methodology/Study Design) 
• 
Changed window for EOT evaluations from “+/- 2 days” to “+2 days.” 
• 
Clarified that normal saline dummy infusions will be used to maintain the blind where 
vancomycin is dosed at a different interval than q12h. 
• 
Added text from protocol body indicating that for patients in whom Gram staining of culturable 
material or cultures indicates that Gram-negative coverage is required, and for patients in whom 
anaerobic pathogens are suspected or confirmed as pathogens at the infected site, aztreonam and 
metronidazole may be administered, respectively. 
 
Synopsis [Number of Patients (planned and analyzed)] 
• 
Provided justification for adequate power with current sample size for secondary endpoint of 
clinical cure at TOC. 
 
Synopsis (Exclusion Criteria) 
• 
Updated exclusion criteria to clarify that patients who receive more than one dose of a short-acting 
(i.e., q12h dosing or less) systemic antibiotic(s) active against Gram-positive pathogens within the 
last 7 days would be excluded from the study, unless there is documented evidence of treatment 
failure OR demonstrated resistance of Gram-positive pathogens to the prior antibiotic therapy. 
 
Synopsis (Study Medication) 
• 
Changed volume of iclaprim and vancomycin from 300 to 500 mL. 
• 
Clarified that iclaprim subjects with moderate hepatic impairment (Child-Pugh Class B) will be 
administered 40 mg of iclaprim (in 500 mL normal saline, infused over 2 hours q12h for 5 to 14 
days). 
• 
Updated vancomycin infusion time to 2 hours. 
• 
Updated information regarding vancomycin dosing intervals and how blind will be maintained. 
Dosing interval will be every q12h, q24h, q48h, or dosed by daily level based on creatinine 
clearance. Patients randomized to vancomycin who require dosing intervals of q24h, q48h, or 
dosed by daily level due to renal impairment will receive dummy infusions (normal saline) at 12 
hour intervals when they are not to receive vancomycin.  
• 
Clarified that vancomycin patients with an organism whose MIC is ≤1 mg/L should maintain a 
trough of 10 to 15 mg/L. 
• 
Updated use of dummy infusions, which will be used for patients randomized to vancomycin who 
have a dosing frequency other than q12h (no longer for differing infusion times). 
 
Synopsis (Study Populations) 
• 
Added description of mCE population: all patients excluded from the PP population only because 
they have received prohibited concomitant or preceding antibiotic therapy active against 
Gram-positive pathogens. 
Protocol Version (3 Dec 2015) 
Page 3 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
• 
Clarified that PP population excludes patients with Gram-negative bloodstream infections who 
were discontinued in order to treat the Gram-negative pathogen. 
 
Synopsis (Evaluation: Efficacy) 
• 
Added mCE population to secondary endpoints. 
• 
Added resolution or near resolution (≥90%) of ABSSSI at EOT and TOC as a secondary endpoint. 
 
Synopsis (Statistical Methods) 
• 
Added mCE population to secondary efficacy analyses. 
• 
Added resolution or near resolution (≥90%) of ABSSSI at EOT and TOC as a secondary endpoint. 
 
Section 5.4.3 (Rationale for Iclaprim dose regimen) 
• 
Added justification for 50% reduction in dose for iclaprim patients with moderate hepatic 
impairment. 
 
Section 5.4.4 (Rationale for choice of comparator) 
• 
Clarified that the maintenance of a trough of 10 to 15 mg/L is the recommendation for 
vancomycin patients with an organism whose MIC is ≤1 mg/L. 
• 
Added justification for maximum vancomycin dose of 1750 mg. 
 
Section 6 (Study Objectives) 
• 
Added mCE population to secondary objectives numbers 1 to 5. 
• 
Added the following secondary objective: 
Resolution or near resolution (≥90%) of ABSSSI at EOT and TOC among patients with severe 
infection at baseline defined by meeting one or more of the following criteria: 
a. 
fulfilled the published definition for systemic inflammatory response syndrome (SIRS) 
by having ≥2 of the following findings: body temperature >38°C or <36°C,  heart rate 
>90 bpm,  respiration rate >20 breaths/minute, and  WBC >12000/mm3 or <4000/mm3 
or >10% bands; 
b. Evaluated as having severe tenderness or severe erythema at the infection site; and 
c. 
Positive blood cultures at baseline. 
 
Section 7.1 (Overall Study Design and Plan Description) 
• 
Changed window for EOT evaluations from “+/- 2 days” to “+2 days.” 
• 
Updated use of dummy infusions, which will be used for patients randomized to vancomycin who 
have a dosing frequency other than q12h (no longer for differing infusion times). 
 
Section 7.2.1 (Efficacy Endpoints) 
• 
Added mCE population to secondary endpoints. 
• 
Added resolution or near resolution (≥90%) of ABSSSI at EOT and TOC as a secondary endpoint. 
 
Section 7.3.2 (Exclusion Criteria) 
• 
Added exclusion criteria “recurrent cellulitis treated with oral suppressive therapy” (as an ABSSSI 
category under exclusion criterion #1). 
• 
Updated exclusion criterion #6 to clarify that patients who receive more than one dose of a 
short-acting (i.e., q12h dosing or less) systemic antibiotic(s) active against Gram-positive 
pathogens within the last 7 days would be excluded from the study, unless there is documented 
evidence of treatment failure OR demonstrated resistance of Gram-positive pathogens to the prior 
antibiotic therapy (antibiotics given for surgical prophylaxis are not included in this). Clarified 
that patients with prior short-acting systemic antibiotic(s) (i.e., q12h dosing or less) should not 
comprise >25% of the clinical trial population. 
• 
Removed the following exclusion criterion: Infections due to a Gram-positive organisms known to 
be resistant to vancomycin and/or mixed ABSSSI in which the Gram-negative organisms are 
known to be resistant to aztreonam. 
Protocol Version (3 Dec 2015) 
Page 4 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
• 
For exclusion criterion #14, changed bradycardia from <50 bpm to <40 bpm and changed 
QC/QTcF normal range from QTcF >470 msec to QTcF >500 msec. 
 
Section 7.3.3.2 (Withdrawal from study medication and termination of study participation) 
• 
Added criteria for study treatment discontinuation for patients with a baseline blood culture that is 
growing a Gram-negative organism. 
• 
Added criteria for study treatment discontinuation for patients with treatment-emergent acute 
kidney injury: Patients who have a confirmed increase in serum creatinine (SCr) of 0.5 mg/dL 
from baseline, if SCr was normal at baseline, or (2) a 50% increase in SCr from baseline, if the 
upper limit of SCr was not normal at baseline. This does not apply to patients on hemodialysis, 
continuous renal replacement therapy (e.g., CVVH, CVVHD), or peritoneal dialysis 
 
Section 7.4.1.1 (Investigational product, dosage and mode of administration) 
• 
Changed volume of iclaprim from 300 to 500 mL. 
• 
Clarified that iclaprim subjects with moderate hepatic impairment (Child-Pugh Class B) will be 
administered 40 mg of iclaprim (in 500 mL normal saline, infused over 2 hours q12h for 5 to 14 
days). 
 
Section 7.4.1.2 (Reference therapy, dosage, and mode of administration) 
• 
Added maximum vancomycin dose of 1750 mg. 
• 
Clarified that vancomycin dosing would be based on actual body weight. 
• 
Changed volume of vancomycin from 300 to 500 mL. 
• 
Updated vancomycin infusion time to 2 hours. 
• 
Updated information regarding vancomycin dosing intervals and how blind will be maintained. 
Dosing interval will be every q12h, q24h, q48h, or dosed by daily level based on creatinine 
clearance. Patients randomized to vancomycin who require dosing intervals of q24h, q48h, or 
dosed by daily level due to renal impairment will receive dummy infusions (normal saline) at 12 
hour intervals when they are not to receive vancomycin.  
• 
Clarified that patients who are on intermittent hemodialysis will be dosed after dialysis based on 
their pre-hemodialysis level. Patients who are on continuous renal replacement therapy will be 
dosed q24h. 
• 
Clarified that patients with an organism whose MIC is ≤1 mg/L should maintain a trough of 10 to 
15 mg/L. 
• 
Updated use of dummy infusions, which will be used for patients randomized to vancomycin who 
have a dosing frequency other than q12h (no longer for differing infusion times). 
• 
Clarified process for determining initial dosing interval for patients with renal impairment 
(including the addition of a table). 
• 
Provided details for monitoring trough levels in patients with a creatinine clearance of 
≥25 mL/min and in patients with a creatinine clearance < 25 mL/min. 
 
Section 7.4.2 (Identity of Investigational Product) 
• 
Changed formulation from “10 mL vial” to “two 5 mL ampule.” 
• 
Added iclaprim mesylate concentration (16.3 mg/mL) 
 
Section 7.5.1 (Schedule of Study Procedures) 
• 
Row for “Draw trough levels” was added to Schedule of Study Procedures, as well as associated 
footnotes (footnotes 20 & 21). 
• 
Clarified that patients who have a worsening of clinical signs and symptoms of ABSSSI during 
study medication treatment such that additional or alternative systemic antibacterial therapy is 
warranted must be withdrawn from study medication. 
• 
Clarified that if a patient has a blood culture that grows a Gram-negative pathogen from Visit 1 
blood cultures, the patient must be withdrawn from study medication and started on the 
appropriate antibiotics for complicated bacteremia. 
Protocol Version (3 Dec 2015) 
Page 5 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
• 
Clarified that if a patient has a blood culture that grows a Gram-negative pathogen from Visit 2 
blood cultures, the patient must be withdrawn from study medication and started on the 
appropriate antibiotics for complicated bacteremia. 
• 
Clarified that if a patient has a blood culture that grows a Gram-positive pathogen from Visit 1 
and/or Visit 2 blood cultures, another 2 sets of blood cultures must be obtained at both Visit 3 and 
Visit 4. 
• 
Clarified that vancomycin patients with an organism whose MIC is ≤1 mg/L should maintain a 
trough of 10 to 15 mg/L. 
• 
Changed window for EOT evaluations from “+/- 2 days” to “+2 days.” 
 
Section 7.5.2.1 [Baseline/screening/randomization (Visit 1)] 
• 
Clarified that the Principal Investigator, Study Coordinator or designee may enter and randomize 
patients after contacting the central randomization system. 
 
Section 7.5.3.1.1 [Daily assessments until ETP (Visit 2)] 
• 
Clarified that patients who have a worsening of clinical signs and symptoms of ABSSSI during 
study medication treatment such that additional or alternative systemic antibacterial therapy is 
warranted must be withdrawn from study medication. 
• 
Clarified that if a patient has a blood culture that grows a Gram-negative pathogen from Visit 1 
blood cultures, the patient must be withdrawn from study medication and started on the 
appropriate antibiotics for complicated bacteremia. 
• 
Clarified that for vancomycin patients with a creatinine clearance < 25mL/min, a daily trough 
level should be obtained and the unblinded team should monitor and re-dose the patient when that 
level is below 20 mg/L. 
 
Section 7.5.3.1.2 [Early timepoint (Visit 3)] 
• 
Clarified that patients who have a worsening of clinical signs and symptoms of ABSSSI during 
study medication treatment such that additional or alternative systemic antibacterial therapy is 
warranted must be withdrawn from study medication. 
• 
Clarified that if a patient has a blood culture that grows a Gram-negative pathogen from Visit 2 
blood cultures, the patient must be withdrawn from study medication and started on the 
appropriate antibiotics for complicated bacteremia. 
• 
Clarified that if a patient has a blood culture that grows a Gram-positive pathogen from Visit 1 
and/or Visit 2 blood cultures, another 2 sets of blood cultures must be obtained at both Visit 3 and 
Visit 4. 
 
Section 7.5.3.1.3 [Assessments until EOT every 48 to 72 hours (Visit 4)] 
• 
Clarified that patients who have a worsening of clinical signs and symptoms of ABSSSI during 
study medication treatment such that additional or alternative systemic antibacterial therapy is 
warranted must be withdrawn from study medication. 
• 
Clarified that if a patient has a blood culture that grows a Gram-positive pathogen from Visit 1 
and/or Visit 2 blood cultures, another 2 sets of blood cultures must be obtained at both Visit 3 and 
Visit 4. 
• 
Changed window for EOT evaluations from “+/- 2 days” to “+2 days.” 
• 
Clarified that vancomycin patients with a creatinine clearance ≥25 mL/min should have their 
vancomycin level checked with the 5th dose due to difficulty interpreting levels checked prior to 
achieving steady state. 
 
Section 7.6.1 (Efficacy Assessments) 
• 
Added mCE row to Table 4 (Summary of Assessments). 
• 
Added resolution or near resolution (≥90%) of ABSSSI at EOT and TOC as a secondary endpoint. 
 
Section 7.6.1.2 (Secondary Efficacy Assessments) 
• 
Added resolution or near resolution (≥90%) of ABSSSI at EOT and TOC as a secondary endpoint. 
 
Protocol Version (3 Dec 2015) 
Page 6 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
Section 7.6.1.2.3 (Microbiology Assessment) 
• 
Clarified that if a patient has a blood culture that grows a Gram-negative pathogen from Visit 1 
blood cultures, the patient must be withdrawn from study medication and started on the 
appropriate antibiotics for complicated bacteremia. 
• 
Clarified that if a patient has signs of bacteremia at any Visit, 2 sets of aerobic/anaerobic blood 
cultures that are collected at different sites should be obtained 10 minutes apart. 
• 
Clarified that if a patient has a blood culture that grows a Gram-negative pathogen from Visit 2 
blood cultures, the patient must be withdrawn from study medication and started on the 
appropriate antibiotics for complicated bacteremia. 
• 
Clarified that if a patient has a blood culture that grows a Gram-positive pathogen from Visit 1 
and/or Visit 2 blood cultures, another 2 sets of blood cultures must be obtained at both Visit 3 and 
Visit 4. 
 
Section 7.6.2.2.2 (Reporting Serious Adverse Events) 
• 
Updated telephone numbers and fax numbers. 
 
Section 7.6.2.5 (Safety Laboratory Determinations) 
• 
Corrected “pharmacy manual” to “Laboratory Manual.” 
 
Section 7.6.2.6.3 (Electrocardiogram) 
• 
Corrected “pharmacy manual” to “ECG Manual.” 
 
Section 7.9.1 (Determination of Sample Size) 
• 
Provided justification for adequate power with current sample size for secondary endpoint of 
clinical cure at TOC. 
 
Section 7.9.2 (Patient Populations Analyzed) 
• 
Added description of mCE population: all patients excluded from the PP population only because 
they have received prohibited concomitant or preceding antibiotic therapy active against 
Gram-positive pathogens. 
• 
Clarified that PP population excludes patients with Gram-negative bloodstream infections who 
were discontinued in order to treat the Gram-negative pathogen. 
 
Section 7.9.3.2 (Secondary Efficacy Outcome Measures) 
• 
Added mCE population to secondary endpoints. 
• 
Added resolution or near resolution (≥90%) of ABSSSI at EOT and TOC as a secondary endpoint. 
 
Section 10 (References) 
• 
Added reference numbers 7, 12-15, and 19-21 
 
Appendix A (Clinical Laboratory Evaluations) 
• 
Changed “Bile” to “Bilirubin/urobilinogen.” 
 
Appendix D (Vancomycin Dosing Nomogram) 
• 
Added general text regarding iclaprim and vancomycin dosing. 
• 
In “Creatinine Clearance” column, changed “>75” to “≥ 75” and changed “35-50” to “35-49.” 
• 
Removed infusion duration table. 
• 
Clarified that vancomycin dosing would be based on actual body weight. 
• 
Added graphic of a sample dosing sequence to clarify how blind will be maintained at different 
vancomycin dosing intervals. 
 
Appendix E (Child-Pugh Scoring System) 
• 
Corrected Albumin range of “2.8-2.5” to “2.8-3.4.” 
• 
Added point total interpretation. 
 
Protocol Version (3 Dec 2015) 
Page 7 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
Appendix F (Short-Acting Systemic Antibiotics Active Against Gram-Positive Pathogens) 
• 
Added appendix to supplement Exclusion Criterion #6. 
 
Additional minor editorial updates were also made but not detailed in the Summary of Changes. 
 
Protocol Version (3 Dec 2015) 
Page 8 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
SYNOPSIS 
Study Number: 
ICL-23-ABSSSI1 
Title of Study: 
A Phase 3, randomized, double-blind, multicenter study to evaluate the safety 
and efficacy of intravenous iclaprim versus vancomycin in the treatment of 
acute bacterial skin and skin structure infections suspected or confirmed to be 
due to Gram-positive pathogens. (REVIVE-1) 
Indication: 
Acute bacterial skin and skin structure infections (ABSSSIs) suspected or 
confirmed to be due to Gram-positive pathogens. 
Number of 
Investigators and 
Study Centers: 
Approximately 80 study centers in the United States, the EU, and other 
countries around the world. 
Development Phase: 
3 
Objectives: 
Primary Objective: 
The primary objective of this study is to demonstrate that iclaprim is 
non-inferior to vancomycin in achieving a ≥20% reduction in lesion size at 48 
to 72 hours (Early Time Point [ETP]) compared to baseline in all randomized 
patients (ITT). 
 
Secondary Objectives: 
The secondary objectives of this study are to demonstrate non-inferiority of 
iclaprim compared to vancomycin in the ITT, mITT, mCE, PP, and mPP 
populations for the following: 
1. Resolution or near resolution of ABSSSI (clinical cure, defined by a 
≥90% reduction in lesion size from the size at baseline, no increase in 
lesion size since ETP, and no requirement for additional antibiotics 
[except aztreonam and metronidazole] or unplanned significant 
surgical procedures after ETP other than bedside wound care) at Test 
of Cure (TOC) visit (7 to14 days after the end of treatment); 
2. Resolution or near resolution (≥90%) of ABSSSI at End of Therapy 
(EOT); 
3. Resolution or near resolution (≥90%) of ABSSSI at EOT and TOC 
among patients with severe infection at baseline defined by meeting 
one or more of the following criteria: 
a. 
fulfilled the published definition for systemic inflammatory 
response syndrome (SIRS) by having ≥2 of the following 
findings: body temperature >38°C or <36°C,  heart rate >90 
bpm,    respiration rate >20 breaths/minute, and    WBC 
>12000/mm3 or <4000/mm3 or >10% bands; 
b. Evaluated as having severe tenderness or severe erythema at 
the infection site; and 
c. 
Positive blood cultures at baseline. 
4. Time to resolution of systemic and local signs and symptoms of 
ABSSSI. 
Additional secondary objectives are to: 
5. Assess microbiological outcome in the mITT, mCE, and mPP 
populations at EOT and TOC; 
6. Establish 
the 
PK 
profile 
for 
iclaprim 
using 
population 
pharmacokinetics; and 
7. Establish the safety profile of iclaprim in patients with ABSSSI. 
Study Population: 
Patients ≥18 years of age of either gender with ABSSSIs suspected or 
confirmed to be due to Gram-positive pathogens. 
Methodology/ 
Study Design: 
This is a multicenter, randomized, double-blind study of the efficacy and safety 
of iclaprim compared to vancomycin. Patients will receive either iclaprim or 
vancomycin for 5 to 14 days. Patients will be evaluated daily up to ETP, then 
Protocol Version (3 Dec 2015) 
Page 9 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
every 48 to 72 hours through the end of treatment. If the last dose of study drug 
falls on a day when an evaluation was not planned, an additional evaluation visit 
will need to be performed on that day (ie. All EOT evaluations should be 
performed on the last day [+2 days] of drug dose). Patients will also be 
evaluated at the TOC visit (7 to 14 days post-EOT), and will have a Late 
Follow-Up (LFU) phone call (28 to 32 days post-first dose). 
 
After completing screening procedures, including obtaining cultures from a 
clinical specimen prior to antibacterial therapy, a total of 600 patients (300 per 
treatment group) will be randomized (1:1) to receive either: (1) iclaprim 80 mg 
every 12 hours or (2) weight-based vancomycin. The duration of treatment for 
both groups will be 5 days (minimum duration) to 14 days (maximum duration). 
 
The investigators, clinical study personnel, sponsor, and the patients will remain 
blinded with respect to the study drug treatment allocation. The unblinded 
pharmacist or his/her designee will be responsible for preparation of infusions. 
Normal saline dummy infusions will be used to maintain the blind where 
vancomycin is dosed at a different interval than q12h.   
 
For patients in whom Gram staining of culturable material or cultures indicates 
that Gram-negative coverage is required, and for patients in whom anaerobic 
pathogens are suspected or confirmed as pathogens at the infected site, 
aztreonam and metronidazole may be administered, respectively. Concomitant 
antibiotics aztreonam and metronidazole will be used in compliance with their 
respective prescribing information at the discretion of the investigator during 
the study treatment phase. 
 
Systemic antibiotics (other than aztreonam and metronidazole) or topical 
antibiotics at the site of the ABSSSI under investigation, steroids >20 mg/day 
prednisolone or equivalent; and Type I A and Type III-antiarrhythmic drugs are 
prohibited. 
 
Clinical Assessments: 
 
The primary endpoint for clinical response (defined as the reduction in lesion 
size ≥20% compared to baseline) will be evaluated in all randomized patients at 
ETP (48 to 72 hours post-first dose). Patients who have died or who received 
rescue antibacterial therapy prior to that time will be included as treatment 
failures. In addition, clinical outcome will be evaluated by the investigator at 
EOT and TOC (7 to 14 days post EOT). The assessments of clinical outcome 
will be categorized as cure, failure, or indeterminate. 
 
Microbiological Assessments: 
 
An adequate clinical specimen for microbiologic evaluation will be obtained at 
baseline prior to randomization. Additional clinical specimens will be obtained, 
if clinically feasible and if the patient has persistent clinical signs or symptoms, 
at ETP, EOT and TOC. If the patient is discontinued from the study due to 
treatment failure, a clinical specimen will be obtained at that time. Specimens 
will be evaluated by the local microbiology laboratory; in addition, isolates will 
be subcultured and sent to a central microbiology laboratory for confirmation of 
pathogen identity and minimum inhibitory concentrations (MICs). 
 
Two sets of blood samples for aerobic/anaerobic cultures 10 minutes apart from 
different sites peripherally will be obtained within 24 hours prior to the first 
dose of study drug. Blood cultures from intravascular devices are not permitted. 
Protocol Version (3 Dec 2015) 
Page 10 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
Any potential pathogen will be subcultured and the isolates shipped to the 
central laboratory. Anti-streptolysin O titers will also be taken within 24 hours 
of the start of treatment. 
 
Microbiological response will be assessed at the patient level and at the 
microbiological level on the basis of results of the cultures, the susceptibilities 
of identified organisms, and the clinical outcome of the patient. Microbiological 
response by patient will be determined at ETP, EOT, and TOC visits and 
categorized as eradication, presumed eradication, persistence, presumed 
persistence, indeterminate, superinfection, or recurrent infection in patients with 
a Gram-positive pathogen isolated at baseline. 
 
Pharmacokinetic Assessments: 
 
Pharmacokinetic samples will be obtained from patients on 3 occasions, 
following the first dose of study medication, at ETP, and at EOT. After the 
study is complete, the database locked, and the data unblinded, patients 
randomized to iclaprim will have their samples assayed. 
 
Safety and tolerability assessments: 
 
All patients who receive any study drug will be evaluated for safety on the basis 
of medical history and physical examinations, reports of clinical AEs, routine 
electrocardiography, and clinically significant findings from routine liver 
function tests, serum chemistry, hematology, coagulation, and urinalysis (UA) 
tests. All adverse events will be recorded throughout the study period, up to and 
including the LFU phone call. While blinded to treatment assignment, the 
investigator will categorize the severity of each AE and the potential for 
relationship to study drug. Serious AEs (SAEs) include those that were life 
threatening, led to prolongation of the existing hospitalization, a congenital 
anomaly/birth defect, or caused persistent or significant disability, incapacity, or 
death. Treatment-emergent AEs (TEAEs) will be defined as those that start or 
worsen in severity during or after the first dose of study drug administration 
through end of study. 
Number of Patients 
(planned and 
analyzed): 
A total of 600 patients (approximately 300 per treatment group) will be 
randomized (1:1) for this study. 
 
Using Farrington and Manning’s method for non-inferiority (NI) testing with a 
1 sided alpha of 0.025, assuming a 75% early clinical response rate in each 
group and a 10% non-inferiority bound delta, a sample size of 295 ITT patients 
per treatment group is required for 80% power. In addition, using similar 
methods of NI testing with a 1-sided alpha of 0.025, assuming a 90% early 
clinical response rate at TOC in each group and a 10% NI bound delta, a sample 
size of 300 patients in the ITT population per treatment group is required for 
82% power. If the initial endpoint of clinical response at ETP does not achieve 
statistical significance, no further statistical testing will be done. 
Diagnosis and Main 
Criteria for 
Inclusion: 
The following are the main inclusion criteria: written informed consent; 
≥18 years of age; a bacterial infection of the skin with a lesion size area of at 
least 75 cm2 with major cutaneous abscess, cellulitis/erysipelas, and/or wound 
infections (caused by external trauma [eg, needle sticks or insect bites]); and the 
presence of purulent or seropurulent drainage before or after surgical 
intervention of a wound or at least 3 of the following signs and symptoms: 
discharge, erythema (extending at least 2 cm beyond a wound edge in one 
direction), swelling and/or induration, heat and/or localized warmth, and/or pain 
and/or tenderness to palpation. 
Protocol Version (3 Dec 2015) 
Page 11 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
Exclusion Criteria: 
The following are the main exclusion criteria: ABSSSI of the following 
categories: severely impaired arterial blood supply such that amputation of the 
infected anatomical site is likely, infected diabetic foot ulcers, infected 
decubitus ulcers, infected human or animal bites, necrotizing fasciitis or 
gangrene, uncomplicated skin or skin structure infection, self-limiting 
infections, skin and/or skin structure infection that can be treated by surgery 
alone, infections associated with a prosthetic device, and suspected or 
confirmed osteomyelitis; known or suspected concurrent infection or conditions 
requiring systemic anti-microbial treatment, prophylaxis, or suppression 
therapy; received more than one dose of a short-acting (i.e., q12h dosing or less) 
systemic antibiotic(s) active against Gram-positive pathogens within the last 7 
days, unless there is documented evidence of treatment failure OR demonstrated 
resistance of Gram-positive pathogens to the prior antibiotic therapy. 
Study Medications: 
Iclaprim will be administered at a dose of 80 mg in 500 mL normal saline, 
infused over 2 hours q12h (every 12 hours) for 5 to 14 days. For subjects with 
moderate hepatic impairment (Child-Pugh Class B), iclaprim will be 
administered at a dose of 40 mg in 500 mL normal saline, infused over 2 hours 
q12h for 5 to 14 days. 
 
Vancomycin will be dosed as follows: 15 mg/kg body weight in 500 mL normal 
saline infused over 2 hours for 5 to 14 days. Dosing interval will be every q12h, 
q24h, q48h, or dosed by daily level based on creatinine clearance. Patients 
randomized to vancomycin who require dosing intervals of q24h, q48h, or 
dosed by daily level due to renal impairment will receive dummy infusions 
(normal saline) at 12 hour intervals when they are not to receive vancomycin. 
 
Vancomycin dosing will be adjusted based on trough levels to maintain a trough 
of either 10 to 15 mg/L for patients with an organism whose MIC is ≤1 mg/L or 
15 to 20 mg/L for patients with an organism whose MIC is >1 mg/L. Dose 
adjustments made due to trough monitoring will need to be performed in such a 
manner as to ensure that the blind is maintained. Normal saline dummy 
infusions will be used to maintain the blind for patients randomized to 
vancomycin who have a dosing frequency other than Q12h. 
Dose and Regimen: 
Iclaprim is a dihydrofolate reductase inhibitor being studied for the treatment of 
ABSSSI. The dosing regimen of iclaprim is 80 mg q12h via an intravenous 
administration. Each dose will be infused over 2 hours, and the duration of 
treatment will be 5 days (minimum duration) to 14 days (maximum duration). 
Duration of 
Treatment: 
The total duration of treatment in the study for each patient is 5 to 14 days. 
Duration of Patient 
Participation in 
Study: 
The total duration of participation in the study for each patient is 29 to 33 days. 
Protocol Version (3 Dec 2015) 
Page 12 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
Study Populations:  
Intent-to-treat (ITT) population — All randomized patients (primary population 
for efficacy analyses). Patients will be analyzed in treatment group to which 
they were randomized. 
 
Microbiological intent-to-treat (mITT) population — All randomized patients 
who have a Gram-positive baseline bacterial pathogen identified as the cause of 
ABSSSI. 
 
Modified clinically evaluable (mCE) population consists of all patients 
excluded from the PP population only because they have received prohibited 
concomitant or preceding antibiotic therapy active against Gram-positive 
pathogens. 
 
Per-protocol (PP) population — ITT patients who receive at least 80% of their 
planned doses and provide adequate data for assessment for each of the 
following timepoints: ETP, EOT and TOC. This excludes patients with 
Gram-negative bloodstream infections who were discontinued in order to treat 
the Gram-negative pathogen. 
 
PP microbiologically evaluable population (mPP) — mITT patients who receive 
at least 80% of their planned doses and provide adequate data for assessment for 
each of the following timepoints: ETP, EOT, and TOC. 
 
Safety population — All patients who receive any study drug during the trial 
(primary population for safety analyses). Patients will be analyzed according to 
the treatment they received. 
Evaluation: Efficacy  The primary efficacy endpoint is the proportion of randomized patients who 
achieve an early clinical response (defined as reduction in the lesion size ≥20% 
compared to baseline) at 48 to 72 hours (ETP) and will be evaluated among all 
randomized patients (ITT population). The primary efficacy analysis will be the 
non-inferiority (NI) of iclaprim (group 1) to vancomycin (group 2) for the 
proportion of patients with a ≥20% reduction in lesion size at ETP compared to 
baseline. 
 
The primary NI efficacy analysis will be repeated in the mITT, mCE, the PP, 
and the mPP populations as secondary outcomes. 
The secondary endpoints are: 
1. Resolution or near resolution of ABSSSI (ie, clinical cure, defined by a 
>90% reduction in lesion size from the size at baseline, no increase in 
lesion size since ETP, and no requirement for additional antibiotics 
[except aztreonam and metronidazole] or unplanned significant 
surgical procedures after ETP other than bedside wound care) at TOC 
for iclaprim (80 mg q12h) compared with vancomycin (weight-based 
dose) for ITT, mITT, mCE, PP, and mPP populations 
2. Resolution or near resolution (≥90%) of ABSSSI at EOT for ITT, 
mITT, mCE, PP, and mPP populations 
3. Resolution or near resolution (≥90%) of ABSSSI at EOT and TOC 
among patients with severe infection at baseline for ITT, mITT, mCE 
PP, and mPP populations 
4. Time to resolution of signs and symptoms of ABSSSI from start of 
Protocol Version (3 Dec 2015) 
Page 13 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
treatment for ITT, mITT, mCE, PP, and mPP populations 
5. Patient-level bacteriological response rate at EOT and TOC for mITT, 
mCE, and mPP populations 
6. Pathogen-level bacteriological response rate at EOT and TOC for 
mITT, mCE, and mPP populations 
Evaluation: Safety 
Treatment emergent AEs, SAEs, hematology, clinical chemistry, UAs, vital 
signs, physical examinations, electrocardiograms (ECGs), and liver function 
tests will be evaluated. 
Evaluation: 
Pharmacokinetics 
Iclaprim plasma concentrations will be used to determine population PK 
parameters, including Cmax, AUC to infinity (AUC0-∞), clearance, and volume of 
distribution. Interindividual variability (IIV) will be determined for PK 
parameters, as well as residual variability. The potential influence of clinical 
characteristics (age, size, sex, hepatic function, renal function, concomitant 
medications, etc.) on PK parameters will be evaluated. Further details will be 
detailed in a separate population PK analysis plan. 
Statistical Methods: 
In general, statistical tests will be two-sided, and at the level of significance 
alpha = 0.05. The non-inferiority assessment will be made with a one-sided test 
at significance level of 0.025. Confidence intervals (CIs) will be calculated at a 
95% confidence level. 
 
Continuous data will be summarized by treatment group using the number of 
patients in the analysis population (N), mean, standard deviation (SD), median, 
and range, and categorical data will be summarized by treatment group using N 
and percentage. 
 
Primary Efficacy Analysis: 
 
The primary efficacy analysis will be the NI (at significance level 0.025) of 
iclaprim (group 1) to vancomycin (group 2) for the proportion of ITT patients 
with a ≥20% reduction in lesion size at ETP compared to baseline. The NI 
bound will be 10%. Let P1 be the proportion for iclaprim and P2 be the 
proportion for vancomycin. Equivalently, if the lower bound of the two-sided 
95% CI for P1 – P2 is greater than -0.100 based on the Z test with unpooled 
variance estimate, NI will be concluded. 
 
Secondary Efficacy Analyses: 
 
The primary NI efficacy analysis will be repeated in the mITT, mCE, the PP, 
and the mPP populations. The secondary endpoints are resolution or near 
resolution of ABSSSI (ie, clinical cure) at TOC for iclaprim (80 mg q12h) 
compared with vancomycin (weight-based dose), resolution or near resolution 
(≥90%) of ABSSSI at EOT, resolution or near resolution (≥90%) of ABSSSI at 
EOT and TOC among patients with severe infection at baseline, time to 
resolution of signs and symptoms of ABSSSI, by-patient bacteriological 
response rate at EOT and TOC, and by-pathogen bacteriological response rate at 
EOT and TOC. 
 
Safety Analyses: 
 
All patients who received any amount of iclaprim or vancomycin during the 
trial will be evaluated for safety. Safety evaluation include incidence of TEAEs, 
laboratory test results (including liver function tests), vital signs, ECG results, 
and physical examination findings. All summaries of safety data will be based 
Protocol Version (3 Dec 2015) 
Page 14 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
on the safety population (all treated patients). No formal statistical analysis of 
the safety data will be performed. 
Summary tables will be provided for all AEs by treatment group. The incidence 
of AEs, related AEs, SAEs, and AEs leading to discontinuation of the study 
treatment will be presented by Medical Dictionary for Regulatory Activities 
system organ class (SOC) and preferred term. In addition, the incidence of AEs 
by severity will be presented by SOC and preferred term.  
The AE summary tables will include patient counts. Therefore, if a patient 
experiences more than one episode of a particular AE, the patient will be 
counted only once for that event. If a patient has more than one AE that is coded 
to the same preferred term, the patient will be counted only once for that 
preferred term. Similarly, if a patient has more than one AE within a SOC, the 
patient will be counted only once in that SOC. 
Laboratory test variables will be summarized by treatment group and visit using 
descriptive statistics (number of patients, mean, SD, minimum, maximum, as 
well as mean change from baseline, SD for mean and standard error for mean 
change, minimum, median, maximum, and number and percent of patients 
within specified categories). Shift tables (ie, cross-tabulations of below the 
lower limit of the normal range, within the limits of the normal range and above 
the upper limit of the normal range at baseline versus scheduled visits) will be 
presented by laboratory test. Laboratory tests with categorical results that 
cannot be analyzed by change from baseline or shift table analysis will not be 
included in these summaries, but will be listed. Data obtained from laboratory 
tests not required by the protocol will not be summarized, but will be listed.  
Descriptive statistics of vital signs and ECG results at each visit will be 
presented by treatment group. Physical examination findings will be listed for 
each patient. 
 
Protocol Version (3 Dec 2015) 
Page 15 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
TABLE OF CONTENTS 
1. 
CONTACTS ......................................................................................................................................... 19 
1.1 
Emergency Contacts ................................................................................................................ 19 
2. 
INVESTIGATOR/SPONSOR AGREEMENT ..................................................................................... 20 
3. 
LIST OF ABBREVIATIONS ............................................................................................................... 21 
4. 
ETHICAL CONSIDERATIONS .......................................................................................................... 23 
4.1 
Institutional Review Board or Independent Ethics Committee ................................................ 23 
4.2 
Ethical Conduct of the Study ................................................................................................... 23 
4.3 
Patient Information and Consent.............................................................................................. 23 
5. 
INTRODUCTION ................................................................................................................................ 24 
5.1 
Acute Bacterial Skin and Skin Structure Infections ................................................................. 24 
5.2 
Properties of Iclaprim .............................................................................................................. 24 
5.3 
Overview of Nonclinical and Clinical Studies ......................................................................... 24 
5.3.1 
Nonclinical studies ................................................................................................. 24 
5.3.2 
Phase 1 Clinical studies .......................................................................................... 25 
5.3.3 
Phase 2 cSSSI Study .............................................................................................. 25 
5.3.4 
Phase 3 cSSSI Studies ............................................................................................ 26 
5.4 
Rationale .................................................................................................................................. 27 
5.4.1 
Rationale for the Current Study ............................................................................. 27 
5.4.2 
Rationale for patient population ............................................................................. 27 
5.4.3 
Rationale for Iclaprim dose regimen ...................................................................... 27 
5.4.4 
Rationale for choice of comparator ........................................................................ 28 
6. 
STUDY OBJECTIVES......................................................................................................................... 29 
7. 
INVESTIGATION PLAN .................................................................................................................... 30 
7.1 
Overall Study Design and Plan Description ............................................................................. 30 
7.2 
Study Endpoints ....................................................................................................................... 32 
7.2.1 
Efficacy Endpoints ................................................................................................. 32 
7.2.2 
Safety Endpoints .................................................................................................... 32 
7.3 
Selection of Study Population .................................................................................................. 32 
7.3.1 
Inclusion Criteria ................................................................................................... 32 
7.3.2 
Exclusion Criteria .................................................................................................. 34 
7.3.3 
Withdrawal of Patients ........................................................................................... 36 
7.4 
Treatment of Patients ............................................................................................................... 37 
7.4.1 
Treatments Administered ....................................................................................... 37 
7.4.2 
Identity of Investigational Product ......................................................................... 38 
7.4.3 
Method of Assigning Patients to Treatment Groups and Measures to 
Minimize/Avoid Bias ............................................................................................. 39 
7.4.4 
Prior and Concomitant Medications ....................................................................... 40 
7.4.5 
Treatment Compliance ........................................................................................... 41 
7.5 
Study Procedures ..................................................................................................................... 41 
7.5.1 
Schedule of Study Procedures ................................................................................ 41 
7.5.2 
Screening Procedures ............................................................................................. 44 
7.5.3 
Treatment Period Procedures ................................................................................. 45 
7.5.4 
Procedures for Premature Discontinuation from the Study Treatment Regimen ... 49 
Protocol Version (3 Dec 2015) 
Page 16 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
7.6 
Efficacy and Safety Variables .................................................................................................. 49 
7.6.1 
Efficacy Assessments ............................................................................................. 49 
7.6.2 
Safety Assessments ................................................................................................ 53 
7.7 
Pharmacokinetic Analysis ........................................................................................................ 60 
7.7.1 
Collection and Handling of Samples ...................................................................... 60 
7.8 
Data Handling and Record Keeping ........................................................................................ 60 
7.8.1 
Data Quality Assurance ......................................................................................... 60 
7.8.2 
Case Report Forms and Source Documentations ................................................... 60 
7.8.3 
Direct Access to Source Data ................................................................................. 61 
7.8.4 
Archiving Study Records ....................................................................................... 61 
7.9 
Statistical Methods ................................................................................................................... 61 
7.9.1 
Determination of Sample Size ............................................................................... 62 
7.9.2 
Patient Populations Analyzed ................................................................................ 62 
7.9.3 
Efficacy Analysis ................................................................................................... 62 
7.9.4 
Safety Analysis ...................................................................................................... 63 
7.9.5 
Population Pharmacokinetics ................................................................................. 64 
7.9.6 
Interim Analysis ..................................................................................................... 64 
8. 
RISKS AND BENEFITS ...................................................................................................................... 65 
9. 
INVESTIGATORS REGULATORY OBLIGATIONS ....................................................................... 66 
9.1 
Prestudy Documentation .......................................................................................................... 66 
9.2 
Electronic Data Capture ........................................................................................................... 66 
9.3 
Adverse Event Reporting ......................................................................................................... 66 
9.4 
Review of Source Records ....................................................................................................... 66 
9.5 
Monitoring of the Study ........................................................................................................... 67 
9.6 
Protocol Amendments .............................................................................................................. 67 
9.7 
Investigator Meeting ................................................................................................................ 67 
9.8 
Change in Investigator ............................................................................................................. 67 
9.9 
Termination of the Study ......................................................................................................... 67 
9.10 
Final Study Report ................................................................................................................... 68 
9.11 
Confidentiality ......................................................................................................................... 68 
9.12 
Records Retention .................................................................................................................... 68 
9.13 
Publications .............................................................................................................................. 68 
9.14 
Patient Injury............................................................................................................................ 69 
10. REFERENCES ..................................................................................................................................... 70 
11. APPENDICES ...................................................................................................................................... 72 
 
Protocol Version (3 Dec 2015) 
Page 17 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
LIST OF TABLES 
Table 1: ASSIST-1 & ASSIST-2 Cure Rates ................................................................................................ 26 
Table 2 Vancomycin Dosing Intervals Based on Renal Clearance ............................................................... 38 
Table 3: Schedule of Study Procedures ......................................................................................................... 42 
Table 4: Summary of Assessments ................................................................................................................ 50 
 
 
LIST OF FIGURES 
Figure 1: Study Design .................................................................................................................................. 31 
 
 
Protocol Version (3 Dec 2015) 
Page 18 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
1. 
CONTACTS 
1.1 
Emergency Contacts 
Contact the person indicated below for questions concerning serious adverse events and other emergencies: 
 
CRO Medical Monitor: 
 
Name:   Patrick McLeroth 
Country:  USA 
Phone:  +1 609 216-4187 
Fax: +1 609 987-9262 
Business Hours:  8 am to 6 pm Eastern Standard Time 
Protocol Version (3 Dec 2015) 
Page 19 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
2. 
INVESTIGATOR/SPONSOR AGREEMENT 
I have read this protocol and agree that it contains all necessary details for carrying out the study as 
described. I will conduct this protocol as outlined therein, including all statements regarding 
confidentiality. I will make a reasonable effort to complete the study within the time designated. I will 
provide copies of the protocol and access to all information furnished by the sponsor to study personnel 
under my supervision. I will discuss this material with them to ensure that they are fully informed about the 
drug and the study. I understand that the study may be terminated or enrolment suspended at any time by 
the sponsor, with or without cause, or by me if it becomes necessary to protect the best interests of the 
study patients. I agree to conduct this study in full accordance with all applicable regulations and Good 
Clinical Practice (GCP). 
 
 
 
 
 
 
 
 
Principal Investigator 
 
 
 
 
Date 
 
 
Sponsor Signature: 
 
 
 
 
 
 
 
 
Name 
Date 
David Huang 
Motif, Chief Medical Officer 
 
Protocol Version (3 Dec 2015) 
Page 20 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
3. 
LIST OF ABBREVIATIONS 
List of Abbreviations 
Abbreviation 
Definition 
ABSSSI 
acute bacterial skin and skin structure infection 
AE 
adverse event 
ALP 
alkaline phosphatase 
ALT 
alanine aminotransferase 
ASO 
anti-streptolysin O 
AST 
aspartate aminotransferase 
AUC 
area under the concentration-time curve 
AUC∞ 
area under the concentration-time curve to infinity 
b.i.d. 
twice daily 
BL 
Baseline 
BUN 
blood urea nitrogen 
CBC 
complete blood count 
CD4 
cluster of differentiation 
CFR 
US Code of Federal Regulations 
CI 
confidence interval 
Cmax 
maximum concentration 
Cmin 
minimum concentration 
CO2 
carbon dioxide 
CPK 
creatine phosphokinase 
CrCL 
creatinine clearance 
CRF 
case report form 
CRO 
clinical research organization 
CRP 
C-reactive protein 
CSA 
clinical study agreement 
cSSSI 
complicated skin and skin structure infections 
CYP 
cytochrome P450 
DHFR 
dihydrofolate reductase 
ECG 
electrocardiogram 
eCRF 
electronic case report form 
EDC 
electronic data capture 
EMA 
European Medicines Agency 
EOT 
End of Therapy 
ETP 
early timepoint 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
GGT 
gamma glutamyl transferase 
hCG 
beta-human chorionic gonadotropin 
HIV 
human immunodeficiency virus 
IC50 
inhibitory concentration at 50% 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonisation 
IEC 
Independent Ethics Committee 
IRB 
Institutional Review Board 
ITT 
intent-to-treat 
IV 
intravenous 
IXRS 
Interactive Phone and Web Response System 
LDH 
lactate dehydrogenase 
LFU 
Late Follow-Up 
MCH 
mean corpuscular hemoglobin 
Protocol Version (3 Dec 2015) 
Page 21 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
List of Abbreviations 
Abbreviation 
Definition 
MCHC 
mean corpuscular hemoglobin concentration 
MCV 
mean corpuscular volume 
MedDRA 
Medical Dictionary for Regulatory Activities 
MIC 
minimum inhibitory concentration 
mITT 
microbiological intent-to-treat 
mPP 
Per-protocol microbiologically evaluable population 
MRSA 
methicillin-resistant staphylococci 
N 
analysis population 
NI 
non-inferiority 
NSVT 
nonsustained ventricular tachycardia 
PP 
Per-protocol 
PK 
pharmacokinetic 
PV&DSS 
Covance Pharmacovigilance & Drug Safety Services 
Q12h 
every 12 hours 
QTc 
QT interval corrected for heart rate 
QTcB 
QTc corrected according to Bazett 
QTcF 
QTc corrected according to Fridericia 
RBC 
red blood cell 
REB 
Regional Ethics Board 
SAE 
serious adverse event 
SCr 
serum creatinine 
SD 
standard deviation 
SOC 
system organ class (MedDRA classification) 
T > MIC 
time above the minimum inhibitory concentration 
TEAE 
treatment-emergent adverse event 
TOC 
Test of Cure 
UA 
urinalysis 
US 
United States 
WBC 
white blood cells 
 
Protocol Version (3 Dec 2015) 
Page 22 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
4. 
ETHICAL CONSIDERATIONS 
4.1 
Institutional Review Board or Independent Ethics Committee 
In accordance with the United States (US) Code of Federal Regulations (CFR) Title 21 Section 56 
(21 CFR 56), the protocol, advertisement, and Informed Consent Form (ICF) will be reviewed and 
approved by the Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Regional 
Ethics Board (REB). The sponsor will supply relevant material for the investigator to submit to the IRB for 
the protocol’s review and approval. Verification of the IRB’s unconditional approval of the protocol and 
the written ICF statement will be transmitted to the investigator. 
The IRB will be informed by the investigator of subsequent protocol amendments and of Suspected 
Unexpected Serious Adverse Reactions. Approval for protocol amendments will be transmitted in writing 
to the investigator. If requested, the investigator will permit audits by the IRB and regulatory inspections by 
providing direct access to source data/documents. 
The investigator will provide the IRB with progress reports at appropriate intervals (not to exceed one year) 
and a Study Progress Report following the completion, termination, or discontinuation of the investigator’s 
participation in the study. 
4.2 
Ethical Conduct of the Study 
The study procedures outlined in this protocol will be conducted in accordance with the CFR governing 
Protection of Human Subjects (21 CFR 50), Financial Disclosure by Clinical Investigators (21 CFR 54), 
IRBs (21 CFR 56), Investigational New Drug Application (21 CFR 312), and Applications for Food and 
Drug Administration (FDA) Approval to Market a New Drug (21 CFR 314), as appropriate. As such, these 
sections of US Title 21 CFR, along with the applicable International Conference on Harmonisation (ICH) 
Guidelines, are commonly known as Good Clinical Practices (GCP), which are consistent with the 
Declaration of Helsinki. 
This study will be conducted in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki and that are consistent with GCP and the applicable regulatory requirements. 
4.3 
Patient Information and Consent 
Written informed consent for the study will be obtained from all patients before protocol-specific 
procedures are carried out. The ICF generated by the sponsor will be approved (along with the protocol) by 
the IRB. 
The investigator (or designee) will explain the nature of the study and the action of the test product. The 
patients will be informed that participation is voluntary and that they can withdraw from the study at any 
time. In accordance with 21 CFR 50, the informed consent process shall be documented by the use of a 
written ICF approved by the designated IRB and will be signed by the patient prior to protocol-specific 
procedures being performed. 
The patient will be given a copy of the signed ICF and the original will be maintained with the patient’s 
records. 
Protocol Version (3 Dec 2015) 
Page 23 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
5. 
INTRODUCTION 
5.1 
Acute Bacterial Skin and Skin Structure Infections 
Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) are predominantly caused by the following 
Gram-positive pathogens: Staphylococcus aureus, including methicillin-resistant staphylococci (MRSA), 
beta hemolytic streptococci (most commonly S. pyogenes and S. agalactiae), enterococcus spp., and 
viridans group streptococci. 
Due to the rapid emergence of hospital- and community-acquired strains of resistant bacteria, there is an 
urgent need to identify and develop compounds that are active against drug-resistant and emerging 
pathogens, such as MRSA, which are associated with increased rates of morbidity and mortality and, 
therefore, with significantly increased pharmacoeconomic costs. 
5.2 
Properties of Iclaprim 
Iclaprim (MTF-100) is a potent and selective inhibitor of dihydrofolate reductase (DHFR) of important 
bacterial pathogens, including antibiotic-resistant strains. Iclaprim inhibits human DHFR minimally, 
resulting in a selectivity index of more than 4 orders of magnitude. These results, together with more than 
2 decades of clinical experience with trimethoprim (a related diaminopyrimidine), provide the proof of 
concept that selective DHFR inhibitors are safe and efficacious. 
A major advantage of iclaprim over many existing antibiotics is its potent bactericidal activity against a 
broad spectrum of Gram-positive bacteria, including MRSA, vancomycin-intermediate S. aureus, 
vancomycin-resistant enterococci (VRE), and quinolone-resistant strains. Moreover, iclaprim exhibits 
potent activity against most trimethoprim-resistant strains. Iclaprim is active against the majority of the 
Gram-positive pathogens in ABSSSI. 
Further details about iclaprim can be found in the Investigator's Brochure. 
5.3 
Overview of Nonclinical and Clinical Studies 
5.3.1 
Nonclinical studies 
Iclaprim is rapidly bactericidal against Gram-positive clinical isolates and displays a significant 
postantibiotic effect. Based on in vitro data, the propensity for resistance development is predicted to be 
low. Iclaprim was active against pathogens susceptible and resistant to standard antibiotics when 
administered by either intravenous (IV) or oral (p.o.) routes in in vivo rodent infection models. 
In a 4-week toxicity study in male and female rats, single daily IV bolus doses up to 60 mg/kg were given. 
Little evidence of systemic toxicity was observed, even at the highest dose tested (60 mg/kg/day). 
However, poor local injection site tolerability precluded the determination of a no observed adverse effect 
level (NOAEL). However, the Non-Toxic-Effect level was at least 30 mg/kg/day. In a 4-week toxicity 
study in male and female marmosets, single daily infusions up to 30 mg/kg over 20 minutes were well 
tolerated, with the exception of a slight irritation response at the injection site. Therefore, the NOAEL was 
considered to be 30 mg/kg/day. 
In safety pharmacology studies with IV bolus doses up to 30 mg/kg in rats, no behavioral changes or effects 
on spontaneous locomotor activity were observed. Telemetric monitoring of cardiovascular effects in the 
conscious dog with single IV bolus doses up to 10 mg/kg showed no signs of any gross electrocardiogram 
(ECG) waveform abnormality or rhythm disturbance. Iclaprim reversibly inhibited the human 
ether-a-go-go related gene mediated potassium current in transfected Chinese hamster ovary cells with an 
inhibitory concentration at 50% (IC50) of 0.9 µM. Iclaprim did not significantly inhibit the sodium and 
calcium channels, with an IC50 of 95 µM and 46 µM, respectively. Iclaprim was not mutagenic in the 
Ames test and showed no mutagenic or clastogenic activity in the mouse lymphoma, rat micronucleus, or 
Protocol Version (3 Dec 2015) 
Page 24 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
mammalian chromosome aberration tests. 
5.3.2 
Phase 1 Clinical studies 
Iclaprim has been administered in single-dose studies up to 3.2 mg/kg and in repeated escalating IV dose 
studies up to 1.6 mg/kg. 
Following IV administration, iclaprim rapidly and extensively distributes into tissues and shows a terminal 
elimination half-life of about 3 hours. Pharmacokinetic (PK) properties are independent of the dose; 
maximum concentration (Cmax) and area under the concentration-time curve (AUC) increased 
proportionately with the dose. Iclaprim is excreted, mainly in the urine, as conjugated metabolites. 
In a single-dose ECG-study with 1.6 mg/kg and 3.2 mg/kg infused over 30 minutes, iclaprim prolonged the 
QTc interval (QT interval corrected for heart rate) in a dose-dependent manner. Maximal increases 
coincided with Cmax levels and were rapidly reversible. Dosing with 1.6 mg/kg was assessed as acceptable 
for clinical purposes, whereas dosing at 3.2 mg/kg was associated with relevant QTc prolongations 
(>60 msec) and nonspecific T-wave alterations. 
In a second single-dose ECG study using doses of 0.4 mg/kg and 0.8 mg/kg iclaprim base infused over 
30 minutes and 1.6 mg/kg infused over 60 minutes, evaluation of the QTc interval showed a reversible 
dose-dependent effect of iclaprim on the duration of the QTc interval at 0.8 mg/kg and 1.6 mg/kg. 
Importantly, at both the 0.8-mg/kg and 1.6-mg/kg doses, no subject had a maximal QTc value >500 msec. 
When QTc was corrected according to Fridericia (QTcF), no subject exhibited any postinfusion QTcF 
prolongation of >60 msec from Baseline (BL). In addition, in both of the ECG studies, no gender 
differences concerning QTc prolongations were observed, nor were any cardiovascular adverse events 
(AEs) reported. 
A transient Cmax-related mean increase in QTc corrected according to Bazett (QTcB) of approximately 
10 msec was observed after infusion of 0.8 mg/kg iclaprim over 30 minutes. This transient QTc 
prolongation is similar to or less than QTc prolongations observed with other antibiotics, eg, 51 msec for 
IV erythromycin [1], 3 to 11 msec for clarithromycin [2,3,4]; moxifloxacin showed QTc prolongations of 9 
to 17 msec in several studies submitted in their New Drug Application [5]. 
Iclaprim was safe and well tolerated; no treatment-related severe AEs were observed in any of the subjects 
exposed to iclaprim in Phase 1 studies. Safety and tolerability were acceptable at the highest doses tested, 
3.2 mg/kg as a single dose and multiple doses of 1.6 mg/kg twice daily (b.i.d.) for 10 days. 
5.3.3 
Phase 2 cSSSI Study 
In a Phase 2 clinical study of patients with complicated skin and skin structure infections (cSSSI), patients 
were randomized to receive either iclaprim base at a dose of 0.8 mg/kg or 1.6 mg/kg infused over 
30 minutes every 12 hours or vancomycin 1 g every 12 hours. Clinical cure rates in all groups were >90% 
at Day 10 and at the Test of Cure (TOC) visit. 
Drug-related AE rates were 0%, 6%, and 10%, for the 0.8 mg/kg, 1.6 mg/kg, and vancomycin 1 g 
regimens, respectively. Both doses of iclaprim were well tolerated. No treatment-related serious adverse 
events (SAEs) were observed. In 48 patients who had ECGs performed during the study medication 
administration period, central evaluation of these data revealed an increase in QTcB interval >60 msec 
immediately following study medication infusion in 2 patients (1 patient in each of the iclaprim 1.6 mg/kg 
and vancomycin groups), but the corresponding QTcF increases were below 60 msec. No QTc interval 
recorded immediately following completion of the infusion exceeded 480 msec. Furthermore, no 
treatment-emergent cardiac rhythm disturbances were observed. 
Protocol Version (3 Dec 2015) 
Page 25 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
5.3.4 
Phase 3 cSSSI Studies 
Iclaprim was administered at a dose of 0.8 mg/kg b.i.d. for 10 to 14 days in two Phase 3 cSSSI studies. The 
cure rates in the intent-to-treat (ITT) and Per-protocol (PP) populations, respectively, in both studies were 
as follows: 
Table 1: ASSIST-1 & ASSIST-2 Cure Rates 
 
ASSIST-1 
ASSIST-2 
Combined 
 
Iclaprim 
Linezolid 
Iclaprim 
Linezolid 
Iclaprim 
Linezolid 
ITT  
N = 249 
N = 248 
N = 251 
N = 243 
N = 500 
N = 491 
  Clinical cure, n 
(%) 
207 (83.1%) 
220 (88.7%) 
204 (81.3%) 
199 (81.9%) 
411 (82.2%) 
419 (85.3%) 
  95% CI 
78.0% –  
87.3% 
84.2%  – 92.1% 
75.9% – 85.9% 
76.5% – 86.5% 
78.6% – 85.5% 
81.9% – 
88.4% 
  Treatment 
difference 
(iclaprim - 
linezolid) and 
95% CI 
-5.6% [-11.72% to 0.6%] 
-0.6% [-7.7% to 6.5%] 
-3.1% [-7.9% to 1.6%] 
PP 
N = 206 
N = 213 
N = 209 
N = 195 
N = 415 
N = 408 
  Clinical cure, n 
(%) 
195 (94.7%) 
211 (99.1%) 
188 (90.0%) 
188 (96.4%) 
383 (92.3%) 
399 (97.8%) 
  95% CI 
90.7% – 
97.0% 
96.6% –  99.7% 
85.1% – 93.7% 
92.7% – 98.5% 
89.3% – 94.7% 
95.9% – 
99.0% 
  Treatment 
difference 
(iclaprim - 
linezolid) and 
95% CI 
-4.4% [-8.4% to -1.0%] 
-6.5% [-11.8% to -1.2%] 
-5.5% [-8.7% to -2.4%] 
The CI presented in this table were calculated using SAS-generated 95% CI. The ASSIST-1 analysis used the Newcombe-Altman 
formula 
 
For the pivotal Phase 3 studies, ASSIST-1 and ASSIST-2, in the combined data set, the incidence of 
possibly or probably treatment-related AEs was 22.6% for the iclaprim treatment group, compared to 
27.9% for the linezolid group. No treatment-related SAEs were observed in ASSIST-1; 1 SAE in 
ASSIST-2 was considered to be possibly treatment related (elevated alanine aminotransferase [ALT] in one 
iclaprim-treated patient). In general, iclaprim was safe and well tolerated with a similar AE profile to the 
comparator drug linezolid. 
With respect to cardiac effects, results from the combined Phase 3 clinical studies indicated that the 
incidence of QTc prolongations of concern (QTcF >60 ms) in the iclaprim treatment arms were similar to 
those observed in the linezolid treatment arms (3 patients each). Adverse events of QTc prolongation were 
reported infrequently (4 cases in the iclaprim arms and 2 cases in the linezolid arms) and no cases of QTc 
prolongation related cardiac effects classified as treatment related AE were observed in these studies. 
Iclaprim led to a mean increase of the QTc interval by about 5 to 6 msec greater than that observed with 
linezolid, which is considered clinically well tolerated. 
The analysis of liver enzyme level increases in cSSSI patients was complex, as in addition to study drug 
treatment a number of other conditions can contribute to such effects, such as general state of health, 
underlying inflammatory condition, HCV, HBV and HAV, lifestyle (ie, drug / alcohol abuse), besides the 
effects of treatment with the study drug. Overall, the increases in ALT and aspartate aminotransferase 
(AST) levels observed upon IV exposure using the therapeutic dose in the cSSSI population were similar to 
those observed with linezolid treatment and were considered not to be of major clinical significance, since 
they were asymptomatic and without significant concomitant increase in bilirubin: no Hy’s law cases were 
Protocol Version (3 Dec 2015) 
Page 26 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
observed. 
5.4 
Rationale 
5.4.1 
Rationale for the Current Study 
Iclaprim is an antibiotic (DHFR) designed to be effective against bacteria that have developed resistance to 
other antibiotics, including trimethoprim. Iclaprim exhibits potent activity against Gram-positive clinical 
isolates of many genera of staphylococci, including methicillin sensitive staphylococci, MRSA, and beta-
hemolytic streptococci (eg, Group A and B streptococci). It is also effective against vancomycin-
intermediate resistant Staphylococcus aureus, vancomycin-resistant Enterococci, and quinolone-resistant 
strains. 
In 2008, following a Phase 3 trial, Arpida submitted a request to the FDA and the EMA (European 
Medicines Agency) for approval to market the compound. On the basis of submitted data, iclaprim was not 
approved and ceased to be developed. Motif has reviewed all preclinical and clinical data, including the US 
and European regulatory correspondences. Compared to the previous ASSIST protocols, the current study 
(protocol ICL-23-ABSSSI1) will employ a different dosing strategy (fixed iclaprim dose instead of weight-
based iclaprim) and will use a different comparator (vancomycin instead of linezolid). This study will also 
be larger, recruiting 100 more patients, and will be conducted in more sites from a number of different 
countries. Protocols ICL-23-ABSSSI1 and ICL-23-ABSSSI2 will also use a new early timepoint (ETP) to 
evaluated early response as a primary efficacy endpoint, as recommended by the new FDA guidance for 
developing ABSSSI drugs [6]. 
Liver function test elevations of uncertain significance were seen in the previous ASSIST protocols. There 
is a need for additional clinical studies to further demonstrate iclaprim’s safety and efficacy. For this 
reason, this Phase 3 clinical study is intended to demonstrate that the safety, tolerability, and efficacy of 
iclaprim are non-inferior to that of vancomycin. This adequate and well-controlled study will thus provide 
important evidence for the marketing approval application of iclaprim for the treatment of ABSSSIs. 
5.4.2 
Rationale for patient population 
Iclaprim is active against the major pathogens associated with ABSSSI. Therefore, adult patients with signs 
and symptoms of wound infection (caused by external trauma [eg, needle sticks or insect bites]), cellulitis, 
or major cutaneous abscess with surrounding cellulitis are eligible for this study. Evaluation of patients 
with these major infection subtypes of ABSSSI will provide support for the use of iclaprim in the broader 
ABSSSI population. 
5.4.3 
Rationale for Iclaprim dose regimen 
Therapy for ABSSSI is generally 5 to 14 days. An iclaprim dose of 80 mg administered over 2 hours every 
12 hours (q12h) is selected as the dosing regimen to be progressed in pivotal studies based upon exposure 
projections. The selected dose is designed to optimize the efficacy and safety profiles of iclaprim based on 
the following considerations 
• 
When iclaprim was tested in standard rodent models of infection, good efficacy was observed. The 
primary PK/PD predictors for efficacy were determined to be (1) the ratio of the area under the curve 
(AUC) to the minimum inhibitory concentration (MIC), ie, AUC/MIC, and (2) the time above the 
MIC, ie, T > MIC, expressed as a percent of the dosing interval. Thus, optimization of these two 
parameters would be expected to maximize the efficacy of the drug. 
• 
A thorough QTc (TQTc) study indicated that there was an association between the maximum QTc 
value and the maximum plasma iclaprim concentration (Cmax). Thus, minimization of Cmax would be 
expected to correspond to optimal cardiovascular safety of iclaprim. In the TQTc study, doses of 
1 mg/kg and 2 mg/kg administered over 0.5 hours led to dose related increases in the QTc, whereas 
Protocol Version (3 Dec 2015) 
Page 27 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
0.5 mg/kg administered over 0.5 hours did not. The increases in QTc for the 1 mg/kg dose were 
considered to be mild, with a mean (95% confidence interval) change in the placebo- and baseline-
corrected QTcB of 10.3 (3.3, 17.3) msec. This dose was associated with a geometric mean (95% 
confidence interval) Cmax of 792 (682, 919) ng/mL. A reference Cmax of 800 ng/mL was therefore 
used for the evaluation of potential dosing regimens with respect to the risk of QTc prolongation. 
• 
Iclaprim was administered at a dose of 0.8 mg/kg over 0.5 hours g12h in the ASSIST-1 and ASSIST-2 
to 470 patients. Iclaprim was well tolerated in both studies at this dose. Adverse events related to QTc 
prolongation were reported infrequently (4 cases in the iclaprim arms and 2 cases in the linezolid arms) 
and no cases of QTc prolongation-related cardiac effects classified as treatment related AEs were 
observed in these studies. Iclaprim led to a mean increase of the QTc interval by about 5 to 6 msec 
greater than that observed with linezolid, a drug that is considered to be clinically well tolerated. 
• 
A population pharmacokinetic (PK) analysis of the data from the ASSIST studies demonstrated no 
relationship between the clearance (CL) of iclaprim and body weight, suggesting that a fixed rather 
than weight-based dose should be used.  
The ASSIST-1 and ASSIST-2 studies used sparse sampling with a population PK analysis. The post-hoc 
estimates of the individual patient PK parameters were used to simulate the plasma iclaprim concentration-
time profiles for each patient and from those profiles, the corresponding values for Cmaxss, AUC(0-24)ss, 
AUC/MIC, and T > MIC. In these analyses, the MIC value used was based on the MIC90 of S. aureus of 
120 ng/mL identified in worldwide surveillance studies. Various fixed dose regimens were examined with 
respect to maximizing AUC/MIC and T > MIC while minimizing the probability of a steady-state Cmax 
(Cmaxss) ≥800 ng/mL.  The results of these simulations form the basis for the selection of the dose in 
proposed pivotal studies. 
The data from the simulations of the fixed dose regimens (64 mg, 72 mg, and 80 mg) based on the post-hoc 
estimates of iclaprim PK in 470 patients indicate that administration of 80 mg as a 2 hour infusion should 
provide a 28% increase in AUC/MIC and a 32% increase in the T > MIC compared to the dosing regimen 
used in the previous ASSIST trials, while keeping Cmaxss below the reference Cmax of 800 ng/mL from 
the TQTc study and lower than the observed mean values for Cmax at doses > 0.5 mg/kg in the TQTc 
studies. Therefore, the regimen of 80 mg administered over 2 hours q12h would be expected to maximize 
the likelihood of antibacterial efficacy while minimizing the potential for QTc prolongation. 
An iclaprim dose of 40 mg administered over 2 hours every 12 hours (q12h) is selected as the dosing 
regimen for patients with moderate hepatic impairment (Child-Pugh Class B [Appendix E]). An open-label, 
parallel, single dose study to investigate the pharmacokinetics of iclaprim in subjects with hepatic or renal 
dysfunction and in obese subjects showed a 2.5-fold increase in AUC and a 1.4-fold increase in Cmax. Since 
iclaprim clearance was reduced by 50%, a 50% reduction in dose will be used for patients with moderate 
hepatic impairment [7]. 
5.4.4 
Rationale for choice of comparator 
In this study, patients will be randomized in a 1:1 ratio to receive fixed-dose iclaprim (group 1) or 
weight-based vancomycin (group 2). 
Vancomycin is a glycopeptide antibiotic and is active against many Gram-positive bacteria, including 
Staphylococcus aureus [8]. It is indicated in potentially life-threatening infections, is used for therapy of 
severe staphylococcal infections, and remains as the recommended first-line empiric therapy for ABSSSIs 
(purulent and nonpurulent) [8,9]. It is widely available, is cost-effective, and its safety has been well 
established over years of use [9]. 
Vancomycin has been chosen as the comparator in this double-blind study because it is the standard of care 
Gram-positive treatment for ABSSSI according to Infectious Diseases Society of America guidelines, most 
commonly used empiric Gram-positive treatment for ABSSSI, it will help facilitate blinding (compatible 
Protocol Version (3 Dec 2015) 
Page 28 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
infusion times), and recent FDA-approved ABSSSI treatments used vancomycin as the treatment 
comparator during clinical trials. 
According to the most recent recommendations for vancomycin dosing compiled by the Infectious Diseases 
Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious 
Diseases Pharmacists, it is recommended that dose adjustments be based on monitored trough levels to 
maintain the required therapeutic concentration levels [10]. This is the most practical and accurate method 
of assessing vancomycin effectiveness [10]. The recommended trough serum concentrations are either 10 
to 15 mg/L for patients with an organism whose minimum inhibitory concentration (MIC) is ≤1 mg/L or 15 
to 20 mg/L for patients with an organism whose MIC is >1 mg/L [11]. Normal saline dummy infusions will 
be used to maintain the blind. 
Vancomycin dosing will be capped at 1750 mg per dose; in morbidly obese patients (above 100 kg of body 
weight), there is little additional increase in creatinine clearance at doses >1750 mg [12,13,14,15]. 
6. 
STUDY OBJECTIVES 
Primary Objective: 
The primary objective of this study is to demonstrate that iclaprim is non-inferior to vancomycin in 
achieving a ≥20% reduction in lesion size at 48 to 72 hours (ETP) compared to baseline in all randomized 
patients (ITT). 
Secondary Objectives: 
The secondary objectives of this study are to demonstrate non-inferiority of iclaprim compared to 
vancomycin in the ITT, mITT, mCE, PP, and mPP populations for the following: 
1. Resolution or near resolution of ABSSSI (clinical cure, defined by a ≥90% reduction in lesion size 
from the size at baseline, no increase in lesion size since ETP, and no requirement for additional 
antibiotics [except aztreonam and metronidazole] or unplanned significant surgical procedures 
after ETP other than bedside wound care) at Test of Cure (TOC) visit (7 to14 days after the end of 
treatment); 
2. Resolution or near resolution (≥90%) of ABSSSI at End of Therapy (EOT); 
3. Resolution or near resolution (≥90%) of ABSSSI at EOT and TOC among patients with severe 
infection at baseline defined by meeting one or more of the following criteria: 
a. 
fulfilled the published definition for systemic inflammatory response syndrome (SIRS) 
by having ≥2 of the following findings: body temperature >38°C or <36°C,  heart rate 
>90 bpm,  respiration rate >20 breaths/minute, and  WBC >12000/mm3 or <4000/mm3 
or >10% bands; 
b. Evaluated as having severe tenderness or severe erythema at the infection site; and 
c. 
Positive blood cultures at baseline. 
4. Time to resolution of systemic and local signs and symptoms of ABSSSI 
Additional secondary objectives are to: 
5. Assess microbiological outcome in the mITT, mCE, and mPP populations at EOT and TOC; 
6. Establish the PK profile for iclaprim using population pharmacokinetics; and 
Protocol Version (3 Dec 2015) 
Page 29 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
7. Establish the safety profile of iclaprim in patients with ABSSSI. 
7. 
INVESTIGATION PLAN 
7.1 
Overall Study Design and Plan Description 
This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to 
vancomycin. Patients will receive either iclaprim or vancomycin for 5 to 14 days, which comprises the 
range of total treatment duration. Patients will be evaluated daily up to ETP, then every 48 to 72 hours 
through the end of treatment. If the last dose of study drug falls on a day when an evaluation was not 
planned, an additional evaluation visit will need to be performed on that day (ie. All EOT evaluations 
should be performed on the last day [+2 days] of drug dose). Patients will also be evaluated at the TOC 
visit (7 to 14 days post-EOT), and will have a Late Follow-Up (LFU) phone call (28 to 32 days post-first 
dose) Note, however, that patients with high LFTs and unresolved AEs at TOC must be seen in person for 
an additional visit at LFU. The total duration of participation in the study for each patient is 29 to 33 days. 
After completing screening procedures, including obtaining cultures from a clinical specimen prior to 
antibacterial therapy, a total of 600 patients (300 per treatment group) will be randomized (1:1) to receive 
either: (1) iclaprim 80 mg every 12 hours or (2) vancomycin 15 mg/kg. The duration of treatment for both 
groups will be 5 days (minimum duration) to 14 days (maximum duration). Assignment to study treatment 
will be performed using a central randomization system. Approximately 80 active centers will be recruited. 
Figure 1 displays a diagram of the study design. 
The investigators, clinical study personnel, sponsor, and the patients will remain blinded with respect to the 
study drug treatment allocation. The unblinded pharmacist or his/her designee will be responsible for 
preparation of infusions. To account for the variable vancomycin dosing intervals, normal saline dummy 
infusions will be used to maintain the blind for patients who require a vancomycin dosing frequency other 
than Q12h. 
Concomitant antibiotics aztreonam and metronidazole used in compliance with their respective prescribing 
information are allowed at the discretion of the investigator during the study treatment phase. 
Systemic antibiotics (other than aztreonam and metronidazole) or topical antibiotics at the site of the 
ABSSSI under investigation, steroids >20 mg/day prednisolone or equivalent; and Type I A and 
Type III-antiarrhythmic drugs are prohibited. 
Regulatory guidances that have been taken into account while designing this protocol included: 
• 
Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. Center for 
Drug Evaluation and Research (CDER) Draft Guidance, October 2013. 
• 
Addendum to the guideline on the evaluation of medicinal products indicated for treatment of 
bacterial infections. (EMA/CHMP/351889/2013) EMEA, October 2013; 
• 
Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. 
(CPMP/EWP/558/95 rev 2) European Medicines Agency (EMEA), December 2011; 
• 
ICH EI4 Note for guidance on the clinical evaluation of QT/QTc interval prolongation and 
proarrhythmic potential for non-anti-arrhythmic drugs. (CHMP/ICH/2/04) EMEA, May 2005; and 
• 
Developing anti-microbial drugs - general considerations for clinical trials. CDER Draft Guidance, 
July 1998. 
 
Protocol Version (3 Dec 2015) 
Page 30 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
Figure 1: Study Design 
 
Protocol Version (3 Dec 2015) 
Page 31 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
7.2 
Study Endpoints 
7.2.1 
Efficacy Endpoints 
The primary efficacy endpoint is the proportion of randomized patients who achieve an early clinical 
response (defined as reduction in the lesion size ≥20% compared to baseline) at 48 to 72 hours (ETP) and 
will be evaluated among all randomized patients (ITT population). 
The secondary endpoints are: 
1. Resolution or near resolution of ABSSSI (ie, clinical cure, defined by a >90% reduction in lesion 
size from the size at baseline, no increase in lesion size since ETP, and no requirement for 
additional antibiotics [except aztreonam and metronidazole] or unplanned significant surgical 
procedures after ETP other than bedside wound care) at TOC for iclaprim (80 mg q12h) compared 
with vancomycin (weight-based dose) for ITT, mITT, mCE, PP, and mPP populations 
2. Resolution or near resolution (≥90%) of ABSSSI at EOT for ITT, mITT, mCE, PP, and mPP 
populations 
3. Resolution or near resolution (≥90%) of ABSSSI at EOT and TOC among patients with severe 
infection at baseline for ITT, mITT, mCE, PP, and mPP populations 
4. Time to resolution of signs and symptoms of ABSSSI from start of treatment for ITT, mITT, 
mCE, PP, and mPP populations 
5. Patient-level bacteriological response rate at EOT and TOC for mITT, mCE, and mPP populations 
6. Pathogen-level bacteriological response rate at EOT and TOC for mITT, mCE, and mPP 
populations 
7.2.2 
Safety Endpoints 
Safety endpoints are AEs, SAEs, ECG results, liver function tests, hematology, coagulation, serum 
chemistry, urinalysis (UA), vital signs, and physical examinations. 
7.3 
Selection of Study Population 
7.3.1 
Inclusion Criteria 
Patients will be considered for further screening procedures only if they meet all of the following criteria: 
1. 
At least 18 years of age  
2. 
Written informed consent to participate in the study before any study-specific screening 
procedures are performed. If any patient is unable to give consent, it may be obtained from an 
acceptable representative. 
3. 
A bacterial infection of the skin with a lesion size area of at least 75 cm2 (lesion size measured 
by the area of redness, edema, or induration) and clinical evidence of at least 1 of the following: 
a) Major cutaneous abscess,  
b) Cellulitis/erysipelas, and/or  
c) Wound infections (caused by external trauma [eg, needle sticks or insect bites]). 
Protocol Version (3 Dec 2015) 
Page 32 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
4. 
Presence of purulent or seropurulent drainage before or after surgical intervention of a wound 
within 24 hours of randomization (because surgical incision and drainage might influence 
treatment outcomes among patients with major cutaneous abscesses; note that patients with 
major cutaneous abscesses should not comprise >30% of the clinical trial population) OR 
At least 3 of the following signs and symptoms within 24 hours of randomization:  
a) Discharge,  
b) Erythema (extending at least 2 cm beyond a wound edge in one direction),  
c) Swelling and/or induration,  
d) Heat and/or localized warmth, and/or  
e) Pain and/or tenderness to palpation. 
5. 
At least 1 of the following conditions within 24 hours of randomization considered to be 
pathogen-related: 
a) Fever (>38°C/100.4°F orally, rectally, or tympanically),  
b) Enlarged and/or tender proximal lymphadenopathy and/or lymphangitis,  
c) Elevated total peripheral white blood cells (WBCs) >10,000/mm3,  
d) >10% immature neutrophils (bands), regardless of total peripheral WBC count, or 
e) A non-specific C-reactive protein greater than the upper limits of normal.  
6. 
Venous access available for IV dosing.  
7. 
Accessible infection site for culture. 
8. 
If female, must either: 
a) be post-menopausal for at least 1 year; or  
b) have had a hysterectomy or tubal ligation; or  
c) if of childbearing potential: 
i. 
have maintained her normal menstrual pattern for the 3 months prior to study entry, 
and have taken hormonal contraceptives for at least 3 months prior to study entry; 
or 
ii. 
agree to use two adequate methods of birth control defined as: intrauterine device 
plus a barrier method (diaphragm plus spermicide, condom used by partner, 
vasectomized partner, or contraceptive sponge) or use 2 adequate barrier methods 
(condom use by partner or vasectomized partner plus diaphragm and spermicide);  
or 
iii. 
must be using another medically acceptable method of contraception and agrees to 
Protocol Version (3 Dec 2015) 
Page 33 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
continue with the same method during the study; and 
d) have a negative serum pregnancy test (serum beta-human chorionic gonadotropin [hCG]) 
result immediately prior to randomization. If obtaining the serum pregnancy result would 
cause a delay in treatment, the patient can be entered on the basis of a negative urine 
pregnancy test result. The urine pregnancy test must be sensitive to at least 50 mU/mL of 
beta-hCG, pending results of the serum test. The patient must inform the investigator if she 
becomes pregnant, and study medication must be withdrawn. 
There are no male contraceptive requirements. 
7.3.2 
Exclusion Criteria 
Any of the following will exclude a patient from enrolling in this study: 
1. 
ABSSSI of the following categories: 
a) Severely impaired arterial blood supply such that amputation of the infected anatomical site 
is likely, 
b) Infected diabetic foot ulcers  
c) Infected decubitus ulcers,  
d) Infected human or animal bites (insect bites that cause an infection are permitted),  
e) Necrotizing fasciitis or gangrene,  
f) 
Uncomplicated skin or skin structure infection (eg, simple abscesses, folliculitis, impetigo, 
furunculosis, or superficial cellulitis),  
g) Recurrent cellulitis treated with oral suppressive therapy, 
h) Self-limiting infections such as isolated folliculitis or other infection that has a high surgical 
incision cure rate or furunculosis or carbunculosis that is not associated with a cellulitis at 
least 1 cm in radius,  
i) 
Skin and/or skin structure infection that can be treated by surgery alone,  
j) 
Infections associated with a prosthetic device (ie, suspected or confirmed prosthetic joint 
infection), and  
k) Suspected or confirmed osteomyelitis or septic arthritis 
2. 
Known or suspected concurrent infection or conditions requiring systemic anti-microbial 
treatment, prophylaxis, or suppression therapy;  
3. 
Known or suspected human immunodeficiency virus (HIV)-infected patients with a cluster of 
differentiation (CD4) count <200 cells/mm3 recorded in the last 30 to 60 days; 
4. 
Absolute neutrophil count (ANC) <500 cells/mm3;  
5. 
Organ transplant within the preceding 6 months;  
6. 
Received more than one dose of a short-acting (i.e., q12h dosing or less) systemic antibiotic(s) 
Protocol Version (3 Dec 2015) 
Page 34 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
active against Gram-positive pathogens (Appendix F) within the last 7 days, unless there is 
documented evidence of treatment failure OR demonstrated resistance of Gram-positive 
pathogens to the prior antibiotic therapy (antibiotics given for surgical prophylaxis are not 
included in this). Note that patients with prior short-acting systemic antibiotic(s) (i.e., q12h 
dosing or less) should not comprise >25% of the clinical trial population; 
7. 
ABSSSI suspected or documented as being exclusively due to Gram-negative or anaerobic 
organisms based on epidemiological grounds or on direct examination of a specimen with Gram 
stain (mixed ABSSSI in which both Gram-positive and Gram-negative pathogens are isolated 
may be enrolled if the clinician suspects that the predominant causative pathogen is a 
Gram-positive organism); 
8. 
ABSSSI known or suspected to be due to a fungal, parasitic or viral infection; 
9. 
Concomitant morbidity of such severity that the patient is likely to die or present with serious 
medical conditions within 30 days of study entry;  
10. 
Known or suspected local or systemic hypersensitivity to trimethoprim, iclaprim, vancomycin, or 
related compounds; 
11. 
Pregnant or lactating female;  
12. 
Severe hepatic disease (Child-Pugh Class C) or known aspartate aminotransferase (AST) or 
alanine transaminase (ALT) >5 times the upper limit of normal and/or bilirubin >2 times the 
upper limit of normal; 
13. 
Requirement for corticosteroids >20 mg/day prednisolone or equivalent, or received 
corticosteroids >20 mg per day prednisolone or equivalent in the past 3 days;  
14. 
Cardiovascular conditions and treatments: 
a) Patients known to have congenital or sporadic syndromes of QTcF prolongation;  
b) Type I A or III anti-arrhythmic drugs;  
c) Nonsustained ventricular tachycardia (NSVT) defined as >10 consecutive ventricular beats 
at a rate of >120 beats per minute (bpm) with a duration of <30 seconds,  
d) Bradycardia (<40 bpm), and  
e) QT/QTcF interval outside the normal range defined as: QTcF >500 msec. 
15. 
Clinically significant abnormal blood electrolyte levels, as defined below, that cannot be 
corrected prior to study inclusion: 
a) Potassium <3.0 mmol/L (after correction has been attempted), and/or  
b) Magnesium <0.5 mmol/L (1.2 mg/dL) (after correction has been attempted) 
16. 
Previous enrollment in Study ICL-23-ABSSSI1 or Study ICL-24-ABSSSI2;  
17. 
Receipt of any investigational agent or device within 30 days of study medication 
administration; or  
18. 
Patient unable or unwilling to adhere to the study-designated procedures and restrictions. 
Protocol Version (3 Dec 2015) 
Page 35 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
7.3.3 
Withdrawal of Patients 
7.3.3.1 
Replacement Procedures 
Patients withdrawn from the study or prematurely discontinued from study medication treatment will not be 
replaced. 
7.3.3.2 
Withdrawal from study medication and termination of study participation 
Reasons for withdrawal of study drug: 
• 
Death of patient; 
• 
Patient withdraws consent to participate in the study; and 
• 
At the request of the investigator or the sponsor: 
o 
General or specific changes in the patient's condition that render him or her unacceptable 
for further treatment in the judgment of the investigator; 
o 
Patient noncompliance, defined as refusal or inability to adhere to the prescribed dosing 
and follow-up regimen. 
Termination of study participation: 
Patients must be withdrawn from the study if they withdraw consent to participate. They are not required to 
state their reasons for withdrawing consent. 
Patients must have study treatment discontinued for any of the following reasons: 
• 
Infection-related reasons: 
o 
Baseline bacteriological cultures of acceptable specimen(s) demonstrate exclusively 
Gram-negative pathogens and/or fungi (patients with no growth in their baseline cultures 
may continue if they are improving clinically); 
o 
Worsening of clinical signs and symptoms of ABSSSI during study medication treatment 
such that additional or alternative systemic antibacterial therapy is warranted; 
o 
Treatment with a prohibited concomitant antibiotic (Section 7.4.4.2); 
o 
Treatment with antibiotics other than those specified in the protocol; 
o 
Development of a confirmed concomitant infection that is not an ABSSSI such that 
additional or alternative systemic antibacterial treatment is warranted; and 
o 
Diagnosis of osteomyelitis made while the patient is receiving study medication. 
o 
A baseline blood culture that is growing a Gram-negative organism. 
• 
Treatment-emergent cardiovascular abnormalities: 
o 
QTcF values that both exceed an absolute QTcF value of 520 msec and exceed the 
baseline QTcF value by >60 msec; 
Protocol Version (3 Dec 2015) 
Page 36 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
o 
Ventricular arrhythmia; and 
o 
Requirement for Type IA or III anti-arrhythmic drugs. 
• 
Treatment-emergent LFT abnormalities (see Section 7.6.2.6.4 for expected evaluations): 
o 
Patients who have confirmed AST or ALT elevations of > 5X ULN should be 
discontinued from study medication and followed through LFU for safety; and 
o 
Patients who have a bilirubin ≥ 2X ULN with an AST or ALT ≥ 3X ULN and with an 
alkaline phosphatase (ALP) < 2X ULN should be immediately discontinued from study 
medication and followed through LFU. 
• 
Treatment-emergent acute kidney injury: 
o 
Patients who have a confirmed increase in serum creatinine (SCr) of 0.5 mg/dL from 
baseline, if SCr was normal at baseline, or (2) a 50% increase in SCr from baseline, if the 
upper limit of SCr was not normal at baseline. This does not apply to patients on 
hemodialysis, continuous renal replacement therapy (e.g., CVVH, CVVHD), or 
peritoneal dialysis [12]. 
7.3.3.3 
Follow-up of Patients Prematurely Discontinued from the Study Treatment Regimen or 
Withdrawn from Study 
If a patient must be discontinued from the study treatment prior to the EOT evaluation, premature 
termination procedures should be performed at the time of withdrawal and appropriate standard of care 
therapy instituted. The reason for discontinuation, if known, and the antibacterial therapy must be recorded 
on the case report form (CRF). All patients will be requested to return for the TOC visit irrespective of 
whether randomized study treatment is completed. 
7.4 
Treatment of Patients 
7.4.1 
Treatments Administered 
7.4.1.1 
Investigational product, dosage and mode of administration 
Iclaprim will be administered at a dose of 80 mg in 500 mL normal saline, infused over 2 hours q12h for 5 
to 14 days. A window of +/- 2 hours is acceptable. 
Iclaprim must not be administered as a bolus injection, undiluted solution, intramuscular injection, or 
subcutaneous injection. 
For subjects with moderate hepatic impairment (Child-Pugh Class B [Appendix E]), iclaprim will be 
administered at a dose of 40 mg in 500 mL normal saline, infused over 2 hours q12h for 5 to 14 days. 
7.4.1.2 
Reference therapy, dosage, and mode of administration 
Vancomycin will be dosed as follows: 15 mg/kg body weight (to a maximum of 1750 mg; using actual 
body weight) in 500 mL normal saline infused over 2 hours for 5 to 14 days. Dosing interval will be every 
q12h, q24h, q48h, or based on daily levels based on creatinine clearance. Patients randomized to 
vancomycin who require dosing intervals of q24h, q48h, or dosed by daily level due to renal impairment 
will receive dummy infusions (normal saline) at 12 hour intervals when they are not to receive vancomycin. 
Patients who are on intermittent hemodialysis will be dosed after dialysis based on their pre-hemodialysis 
level. Patients who are on continuous renal replacement therapy will be dosed q24h. 
Protocol Version (3 Dec 2015) 
Page 37 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
Vancomycin dosing will be adjusted based on trough levels to maintain a trough of either 10 to 15 mg/L for 
patients with an organism whose MIC is ≤1 mg/L or 15 to 20 mg/L for patients with an organism whose 
MIC is >1 mg/L. Trough levels should be drawn at Dose 5 for patients with normal renal function. For 
patients with renal impairment (creatinine clearance < 75 mL/min), the following table should be used for 
the initial dosing interval: 
Table 2 
Vancomycin Dosing Intervals Based on Renal Clearance 
Creatinine Clearance (mL/min) 
Dosing Interval (hours) 
≥ 75 
Q12H 
50-74 
Q12H 
35-49 
Q24H 
25-34 
Q48H 
< 25 
Dose by daily level 
Intermittent Hemodialysis  
Dose after dialysis 
CRRT 
Q24H 
Abbreviations: CRRT = continuous renal replacement therapy; QnH=every n hours 
 
Patients with a creatinine clearance ≥25 mL/min should have their vancomycin level checked with the 5th 
dose due to difficulty interpreting levels checked prior to achieving steady state. 
For patients with a creatinine clearance < 25 mL/min, a daily level should be obtained and the unblinded 
team should monitor and re-dose the patient when that level is below 20 mg/L. 
See Appendix D for the vancomycin dosing nomogram. 
7.4.2 
Identity of Investigational Product 
Generic name: Iclaprim 
Trade name: Not applicable 
Formulation: Two 5 mL ampule containing sterile concentrate for IV infusion 
Concentration: 12.8 mg/mL iclaprim base (16.3 mg/mL iclaprim mesylate) 
Manufacturer: Wulfing GmbH, Germany 
7.4.2.1 
Packaging and Labeling 
Packaging and labeling will be performed by the sponsor in accordance with all local and federal legal and 
regulatory requirements. 
7.4.2.2 
Clinical Supplies Disclosure 
The Interactive Phone and Web Response System (IXRS) should be used to unblind patients and to unmask 
drug identity. Drug identification information is to be unmasked ONLY if necessary for the welfare of the 
patient. Every effort should be made not to unblind the patient unless necessary. Any unblinding that 
occurs at the site must be documented. 
7.4.2.3 
Storage and Stability 
Unopened ampoules of iclaprim should be stored at room temperature, below 25°C. Any unused contents 
of the opened ampoules must be discarded. The contents of the diluted solution for infusion may be stored 
Protocol Version (3 Dec 2015) 
Page 38 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
for up to 24 hours at room temperature. Until dispensed to the patients, the study medication will be stored 
in a securely locked area, accessible to authorized personnel only. 
Vancomycin or allowed concomitant antibiotics must be prepared and stored in accordance with the 
manufacturer's specifications, separately from iclaprim. 
7.4.2.4 
Study Drug Accountability, Reconciliation, and Return 
The sponsor will provide each investigator with sufficient amounts of the study medication. The 
investigator will confirm receipt of all batches of study medication in writing. 
The investigator will administer the study medication only to patients enrolled in this study and according 
to the procedures in this study protocol. Each patient will be given only the study medication carrying his 
or her randomization number. Each administration of study medication will be documented in the 
electronic case report form (eCRF). 
All supplies must be accounted for at the end of the study. The investigator’s unblinded designee must 
maintain accurate and adequate records, including dates; lot numbers; quantities received; individual usage, 
etc. The investigator’s designee must also return all unused supplies to the sponsor (or designee), noting the 
exact amount used in the study, regardless of whether the study was completed or terminated prematurely. 
At the time of return, the investigator’s unblinded designee must verify that all unused or partially used 
study medication supplies have been returned and that no remaining supplies are in the investigator's 
possession. 
7.4.3 
Method of Assigning Patients to Treatment Groups and Measures to Minimize/Avoid Bias 
7.4.3.1 
Randomization/Patient Identification 
Once a signed and dated consent form and the patient’s medical history have been obtained, the inclusion 
and exclusion criteria have been met, appropriate information has been obtained (including demographics, 
such as age and gender, as well as creatinine value), a complete physical examination has been completed 
(including weight), the biological samples have been collected, and ECGs have been obtained, the patient 
will be assigned a patient number and drug assignment via a centralized randomization system (IXRS). 
Randomization will occur in a 1:1 ratio into 1 of the 2 treatment groups: fixed-dose iclaprim or 
weight-based vancomycin. The IXRS will calculate the weight-based vancomycin dose (including CrCL 
considerations). 
As this is a double-blind study, all individuals except the unblinded pharmacist (and delegated unblinded 
staff) at the study site must remain blinded to the IV study therapy regimen. The unblinded pharmacist will 
access the IXRS and will receive open-labeled clinical supplies from Motif to prepare each dose of IV 
study therapy for each individual patient.  
 A single patient cannot be assigned more than 1 allocation number. 
7.4.3.2 
Blinding 
This is a double-blind study (operating under in-house blinding procedures) in which the patient enrolled, 
the study investigator, study center personnel, and the sponsor will be blinded to which clinical material is 
received until all patients have completed the study, the data have been screened for completeness and 
accuracy, the database has been locked, and protocol violators have been identified. There will be an 
unblinded pharmacist (and delegated unblinded staff) at each study center who will prepare and account for 
the infusion bags of active study therapy according to guidelines provided in the pharmacy manual. 
Vancomycin weight-based dosing levels, as well as adjustments made during the study as a result of trough 
monitoring, will only be known to the unblinded study team. The unblinded pharmacist and his/her 
delegated staff will not be involved in any management or evaluation of the safety and efficacy parameters 
Protocol Version (3 Dec 2015) 
Page 39 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
in the patient. All study personnel involved with patient eligibility and evaluation of safety and efficacy 
outcomes, including the study coordinator(s), investigator, or subinvestigator(s), must not have access to 
the treatment group assignment or the preparation of the infusion.  
Study blinding is employed to ensure the integrity of the data being collected. However, the safety of the 
patients participating in the study must not be compromised. If unblinding is urgently required to guide the 
immediate medical management of the patient, the investigator will be able to access the IXRS to 
determine the patient’s treatment group assignment. The IXRS unmasking feature is intended to be used 
only in situations in which emergency unblinding of the patient (eg, knowledge of the exact treatment 
group required for treatment of a serious adverse experience) is deemed medically necessary. If any patient 
is unblinded prior to the completion of the study (either accidental unblinding or emergency unblinding for 
a serious adverse experience), the investigator must promptly contact the appropriate sponsor representative 
to document the circumstances on the appropriate eCRF. 
Study medication accountability will be noted by the unblinded CRA during site visits and at study 
completion. 
7.4.4 
Prior and Concomitant Medications 
Any medication the patient takes other than study medications is considered a concomitant medication. All 
concomitant medications (except parenteral or enteral nutrition or IV solutions solely for the purpose of 
hydration or keeping the vein patent, and all nondrug therapy [surgeries, debridements, etc.]) must be 
recorded in the eCRF. The following information must be recorded in the eCRF for each concomitant 
medication: trade name, route of administration, dates of administration, dosage, and indication. 
At baseline, patients will be asked what medications they have taken during the previous 30 days. From 
first dose to TOC, patients will be asked what concomitant medications they are currently taking or changes 
since their previous study visit. 
7.4.4.1 
Permitted 
Aztreonam and metronidazole are allowed concomitant antibiotics at the discretion of the investigator. No 
synergism or antagonism has been observed with these antibiotics and iclaprim or vancomycin. They must 
be used in compliance with their respective package insert. For patients in whom Gram staining of 
culturable material or cultures indicates that Gram-negative coverage is required, and for patients in whom 
anaerobic pathogens are suspected or confirmed as pathogens at the infected site, aztreonam and 
metronidazole may be administered, respectively. Treatment with these agents should be continued for at 
least 5 days and should not be required for longer than the treatment duration of study medication. 
The use of aztreonam therapy was selected because it has activity against a wide spectrum of 
Gram-negative aerobic bacteria without cross-coverage of Gram-positive pathogens and provides, in 
combination with iclaprim or vancomycin, adequate empirical coverage for common aerobic 
Gram-positive, and Gram-negative pathogens associated with ABSSSI. Please refer to the country-specific 
package insert for recommendations about aztreonam dosing. 
Metronidazole was selected as a permitted concomitant antibiotic therapy because it has activity against 
anaerobic bacteria without cross-coverage of aerobic Gram-positive pathogens. The investigator has the 
discretion to determine if IV or p.o. metronidazole is administered. Please refer to the country-specific 
package insert for recommendations about metronidazole dosing. 
No other systemic antibiotics or topical antibiotics at the site of the ABSSSI under investigation may be 
used. 
In the event of suspected Clostridium dificile colitis, vancomycin may be administered orally. 
Protocol Version (3 Dec 2015) 
Page 40 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
Hormonal contraceptives for female patients are permitted. 
7.4.4.2 
Prohibited 
The following medications are prohibited: 
• 
Systemic antibiotics (other than aztreonam and metronidazole) or topical antibiotics at the site of 
the ABSSSI under investigation; 
• 
Steroids >20 mg/day prednisolone or equivalent; 
• 
Type IA and Type III anti-arrhythmic drugs; and 
• 
Local antiseptics. 
7.4.5 
Treatment Compliance 
Records of study medication used, dosages administered, and intervals between visits will be maintained 
during the study. Study medication accountability will be noted by the unblinded CRA during site visits 
and at study completion. 
7.5 
Study Procedures 
7.5.1 
Schedule of Study Procedures 
A schedule of procedures and assessments to take place during the study is shown in Table 3. 
Protocol Version (3 Dec 2015) 
Page 41 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
Table 3: Schedule of Study Procedures 
 
Procedure 
Baseline/ 
Screening/ 
Randomization 
Visit 1 
(up to 24 hours 
prior to first dose)1 
Daily until ETP 
Visit 2 
ETP 
(48 to 72 
hours post-
first dose) 
Visit 3 
Every 48 to 72 
hours until 
EOT 
Visit 4 
EOT/ 
Early Termination 
Visit 5 
(treatment duration: 
minimum 5 days, 
maximum 14 days) 
TOC 
7 to 14 days 
post-EOT 
Visit 6 
LFU 
28 to 32 days 
post-first dose 
Phone Call2 
Informed consent 
X 
 
 
 
 
 
 
Medical history 
X 
 
 
 
 
 
 
Prior medications (preceding 30 days) 
X 
 
 
 
 
 
 
Concomitant medications 
 
X 
X 
X 
X 
X 
 
Review of inclusion & exclusion criteria 
X 
 
 
 
 
 
 
Complete physical examination3
 
X 
 
 
 
 
 
 
Limited physical examination4 
 
X 
X 
X 
X 
X 
 
Assessment of signs & symptoms of ABSSSI with 
digital photography5 
X 
 
X 
 
X 
X 
 
Assessment of signs & symptoms of ABSSSI 
without digital photography5 
 
X 
 
X 
 
 
 
Evaluation of adverse events6 
X 
X 
X 
X 
X 
X 
X 
Significant procedures (incision & drainage, 
debridement, amputation, suture removal, etc.) 
 
X 
X 
X 
X 
X 
 
Creatinine clearance (estimated) 
X 
 
 
 
 
 
 
LFT safety 
X 
X 
X 
 
X 
X 
 
C-reactive protein 
X 
 
X 
 
X 
X 
 
Hematology7 
X 
 
X 
X 
X 
X 
 
Clinical chemistry7 
X 
 
X 
X 
X 
X 
 
Urinalysis7 
X 
 
X 
X 
X 
X 
 
Serum pregnancy test (females of 
childbearing potential)8 
X 
 
 
 
 
 
 
Blood cultures (aerobic/anaerobic) 
X9 
X10 
X11 
X11 
 
 
 
Study medication administration12 
 
X 
X 
X13 
X14 
 
 
Blood sample for PK analysis 
 
X15 
X16 
 
X16 
 
 
ECG (at each timepoint 3 ECGs at least 1 minute 
apart will be performed) 
X 
X17 
X18 
 
 
 
 
Infection site cultures19 
X 
 
X 
 
X 
X 
 
ASO antibody titers 
X 
 
 
 
 
X 
 
Draw trough levels20 
 
 
 
X21 
 
 
 
Central randomization 
X 
 
 
 
 
 
 
Clinical efficacy assessment 
 
 
 
 
X 
X 
 
Day 28 mortality 
 
 
 
 
 
 
X 
Protocol Version (3 Dec 2015) 
Page 42 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
Abbreviations: ASO = anti-streptolysin O; EOT = End of Therapy; ETP = Early Timepoint; LFT=liver function test; LFU = Late Follow-up; TOC = Test of Cure.  
1 Must be performed during the baseline visit and completed within 24 hours of study entry (first dose of study drug). 
2 Patients with high LFTs and unresolved AEs at TOC will be required to come in for an additional visit at LFU (for LFTs, blood samples will be obtained to document normalization). If duration of 
therapy is 14 days, LFU may overlap with TOC. In this case, all LFU evaluations may take place at the TOC visit. 
3 Complete physical examination, including vital signs (includes determination of body temperature), height, weight, and a review by body systems. 
4 Limited physical examination, including vital signs (includes determination of body temperature) and excluding weight and height. 
5 Eight signs (tenderness to palpitation, erythema, edema, purulent drainage/discharge, fluctuance, induration, ulceration, and necrotic tissue) and four symptoms (localized pain, swelling, chills, and 
fever) of infection will be assessed at each evaluation and graded on a scale of 0 to 3 (0=none, 1=mild, 2=moderate, or 3=severe). The extent of the infection (to include width, length, and depth and 
diagram of the infection site) will be determined via photography at baseline, ETP, EOT, and TOC only. Photography procedures outlined in Appendix B will be followed. Acetate based planimetric 
tracing will follow the procedures outlined in Appendix C. (Planimetry measurements are based upon automatic detection of pixels inside of the traced skin infection area. Pixels are converted to 
calibrated units based on the scanned resolution [eg, 300 DPI]. Skin infection measurements will be provided in cm2.). Patients who have a worsening of clinical signs and symptoms of ABSSSI 
during study medication treatment such that additional or alternative systemic antibacterial therapy is warranted must be withdrawn from study medication. 
6 All adverse events will be recorded throughout the study period, up to and including the LFU phone call. 
7 Hematology comprises a complete blood count (RBC count, WBC count with differential counts, platelet count, hemoglobin, and hematocrit), MCH, MCHC, MCV, and CRP. Clinical chemistry 
comprises creatinine, BUN, AST, ALT, alkaline phosphatase, total bilirubin, albumin, total protein, glucose, sodium, potassium, chloride, bicarbonate, LDH, GGT, and CPK. Urinalysis comprises 
determination of pH, specific gravity, presence of blood, glucose, protein, ketones, and bile, and microscopic examination of sediment. 
8 Serum pregnancy test must be obtained immediately prior to randomization. If obtaining the serum pregnancy result would cause a delay in treatment, the patient can be entered on the basis of a 
negative urine pregnancy test result. The urine pregnancy test must be sensitive to at least 50 mU/mL of beta-hCG, pending results of the serum test. The patient must inform the investigator if she 
becomes pregnant, and study medication must be withdrawn. 
9 Obtain two sets of blood cultures (aerobic and anaerobic) 10 minutes apart from two separate peripheral sites. 
10 If patient has a blood culture that grows a Gram-negative pathogen from Visit 1 blood cultures, the patient must be withdrawn from study medication and started on the appropriate antibiotics for 
complicated bacteremia. If patient has signs of bacteremia, obtain two sets of aerobic/anaerobic blood cultures 10 minutes apart that are collected at different sites. 
11 If patient has a blood culture that grows a Gram-negative pathogen from Visit 2 blood cultures, the patient must be withdrawn from study medication and started on the appropriate antibiotics for 
complicated bacteremia. If patient has a blood culture that grows a Gram-positive pathogen from Visit 1 and/or Visit 2 blood cultures, another 2 sets of blood cultures must be obtained at both Visit 3 
and Visit 4. If these are positive, the patient must be withdrawn from study medication and started on the appropriate antibiotics for complicated bacteremia. 
12 A window of +/- 2 hours is acceptable for infusion of study medication. For patients randomized to receive vancomycin, vancomycin dosing will be adjusted based on trough levels to maintain a 
trough of either 10 to 15 mg/L for patients with an organism whose MIC is ≤1 mg/L or 15 to 20 mg/L for patients with an organism whose MIC is >1 mg/L. Dose adjustments made due to trough 
monitoring will need to be performed in such a manner as to ensure that the blind is maintained. 
13 If the last dose of study drug falls on a day when an evaluation was not planned, an additional evaluation visit will need to be performed on that day (ie, all EOT evaluations should be performed on 
the last day [+2 days] of drug dose). 
14 If clinically indicated (ie, investigator may decide on a given day that a patient no longer needs treatment. In these cases, medication will not be administered, but all other EOT assessments must be 
performed.) 
15 On Day 1, before the start of first study medication infusion and within 5 to 15 minutes, 1 to 3 hours, and 5 to 7 (ensure last PK sample is taken prior to next dose) hours after the infusion. 
16 Before the start of study medication infusion at ETP and EOT, and within 5 to 15 minutes, l to 3 hours, and 5 to 7 hours (ensure last PK sample is taken prior to next dose) after the ETP and EOT 
infusions. 
17 On Day 1, before the start of first study medication infusion and within 10 minutes of the end of the first study medication infusion. If the median QTcF value is >500 msec and/or is >60 msec 
different from the predose baseline value, follow-up ECG tests should be performed every 1 to 2 hours until they are below these threshold values. 
18 At ETP, an ECG should be performed before the start of study medication infusion and within 10 minutes of the end of the study medication infusion. 
19 Prior to randomization, all patients (regardless of the disease type) should have appropriate cultures obtained. Deep culture samples, such as from a biopsy, needle aspiration, surgically obtained 
specimens, or punch biopsies of an area contiguous to the infected wound should be obtained. Swabs are not acceptable; cultures will be performed locally, where isolates will be retained for transport 
to a central microbiology laboratory for susceptibility testing according to CLSI-approved methodology. Note that only target pathogens will be sent to the central microbiology laboratory (therefore, 
contaminants/Gram-negative isolates [from mixed wound infections] in blood cultures do not need to be sent). If the patient is discontinued from the study due to treatment failure, a clinical specimen 
will be obtained at that time only. Additional clinical specimens will be obtained, if clinically feasible and if the patient has persistent clinical signs or symptoms, at ETP, EOT, and TOC. 
20 For vancomycin patients with a creatinine clearance < 25mL/min, a daily level should be obtained and the unblinded team should monitor and re-dose the patient when that level is below 20 mg/L. 
21 Vancomycin patients with a creatinine clearance ≥25 mL/min should have their vancomycin level checked with the 5th dose due to difficulty interpreting levels checked prior to achieving steady state. 
Protocol Version (3 Dec 2015) 
Page 43 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
7.5.2 
Screening Procedures 
7.5.2.1 
Baseline/screening/randomization (Visit 1) 
The following procedures will be performed during the baseline visit, within 24 hours of study entry (first 
dose of study drug): 
• 
Obtain informed consent; 
• 
Record medical history (pre-existing conditions); 
• 
Prior medications (within the preceding 30 days) 
• 
Verify inclusion and exclusion criteria; 
• 
Perform complete physical examination, including vital signs (includes determination of body 
temperature), height, weight, and a review by body systems; 
• 
Assess clinical signs and symptoms of ABSSSI; including photography (procedure outlined in 
Appendix B). Acetate based planimetric tracing will follow the procedures outlined in 
Appendix C. (Planimetry measurements are based upon automatic detection of pixels inside of the 
traced skin infection area. Pixels are converted to calibrated units based on the scanned resolution 
[eg, 300 DPI]. Skin infection measurements will be provided in cm2; 
• 
Assess AEs; 
• 
Estimate CrCL; 
• 
LFT safety assessment; 
• 
C-reactive protein (CRP) assessment; 
• 
Obtain blood and urine samples for clinical chemistry, hematology, and UA; 
• 
Serum pregnancy test must be obtained immediately prior to randomization. If obtaining the 
serum pregnancy result would cause a delay in treatment, the patient can be entered on the basis of 
a negative urine pregnancy test result. The urine pregnancy test must be sensitive to at least 50 
mU/mL of beta-hCG, pending results of the serum test. The patient must inform the investigator if 
she becomes pregnant, and study medication must be withdrawn; 
• 
Obtain two sets of blood cultures (aerobic and anaerobic) 10 minutes apart from two separate 
peripheral sites;  
• 
Perform and assess 12-lead ECG (3 ECGs at least 1 minute apart); 
• 
Obtain sample for culture from infection site. Deep culture samples, such as from a biopsy, needle 
aspiration, surgically obtained specimens, or punch biopsies of an area contiguous to the infected 
wound should be obtained. Swabs are not acceptable; cultures will be performed locally, where 
isolates will be retained for transport to a central microbiology laboratory for susceptibility testing 
according to CLSI-approved methodology; 
• 
Obtain anti-streptolysin O (ASO) antibody titers; and 
Protocol Version (3 Dec 2015) 
Page 44 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
• 
Contact the central randomization system to enroll the patient and receive blinded assignment of 
patient number and study arm allocation: 
o 
Contact the central randomization system to enroll the patient  
o 
Principal Investigator, Study Coordinator or designee may enter and randomize 
o 
Unblinded pharmacist or designee is the only individual who may access treatment 
assignment and prepare study infusions 
7.5.3 
Treatment Period Procedures 
A window of +/- 2 hours is acceptable for infusion of study medication. 
7.5.3.1 
Study treatment period from 5 to 14 days 
7.5.3.1.1 
Daily assessments until ETP (Visit 2) 
During the initial 48 to 72 hours of treatment, a V2 assessment will be performed daily which includes the 
following: 
• 
Record concomitant medications; 
• 
Perform limited physical exam, including vital signs (includes determination of body temperature) 
and excluding weight and height; 
• 
Assess clinical signs and symptoms of ABSSSI without digital photography. Patients who have a 
worsening of clinical signs and symptoms of ABSSSI during study medication treatment such that 
additional or alternative systemic antibacterial therapy is warranted must be withdrawn from study 
medication; 
• 
Assess AEs; 
• 
Record any significant procedures performed that require surgical intervention (incision and 
drainage, amputation, suture removal, etc. [debridement and incisions at bedside are permitted]); 
• 
LFT safety assessment; 
• 
If patient has a blood culture that grows a Gram-negative pathogen from Visit 1 blood cultures, the 
patient must be withdrawn from study medication and started on the appropriate antibiotics for 
complicated bacteremia. If patient has signs of bacteremia, obtain two sets of aerobic/anaerobic 
blood cultures 10 minutes apart that are collected at different sites; 
• 
Study medication administration 
• 
Blood samples for PK should be obtained on the first day of treatment before the start of first 
study medication infusion and 5 to 15 minutes, l to 3 hours, and 5 to 7 hours after the infusion; and 
• 
Perform and assess12-lead ECG (3 ECGs at least 1 minute apart) before the start of first study 
medication infusion and within 10 minutes of the end of the first study medication infusion on 
Day l. 
• 
For vancomycin patients with a creatinine clearance < 25mL/min, a daily trough level should be 
obtained and the unblinded team should monitor and re-dose the patient when that level is below 
Protocol Version (3 Dec 2015) 
Page 45 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
20 mg/L. 
7.5.3.1.2 
Early timepoint (Visit 3) 
Between 48 and 72 hours from first dose, an ETP visit should be performed and should include: 
• 
Record concomitant medications; 
• 
Perform limited physical exam, including vital signs (includes determination of body temperature) 
and excluding weight and height; 
• 
Assess clinical signs and symptoms of ABSSSI; including photography (procedure outlined in 
Appendix B). Acetate based planimetric tracing will follow the procedures outlined in 
Appendix C. (Planimetry measurements are based upon automatic detection of pixels inside of the 
traced skin infection area. Pixels are converted to calibrated units based on the scanned resolution 
[eg, 300 DPI]. Skin infection measurements will be provided in cm2.) Patients who have a 
worsening of clinical signs and symptoms of ABSSSI during study medication treatment such that 
additional or alternative systemic antibacterial therapy is warranted must be withdrawn from study 
medication; 
• 
Assess AEs; 
• 
Record any significant procedures performed that require surgical intervention (incision and 
drainage, amputation, suture removal, etc. [debridement and incisions at bedside are permitted]); 
• 
LFT safety assessment; 
• 
CRP assessment; 
• 
Obtain blood and urine samples for clinical chemistry, hematology, and UA; 
• 
If patient has a blood culture that grows a Gram-negative pathogen from Visit 2 blood cultures, the 
patient must be withdrawn from study medication and started on the appropriate antibiotics for 
complicated bacteremia. If patient has a blood culture that grows a Gram-positive pathogen from 
Visit 1 and/or Visit 2 blood cultures, another 2 sets of blood cultures must be obtained at both 
Visit 3 and Visit 4. If these are positive, the patient must be withdrawn from study medication and 
started on the appropriate antibiotics for complicated bacteremia;  
• 
Study medication administration; 
• 
PK blood sample (before the start of study medication infusion and 5 to 15 minutes, l to 3 hours, 
and 5 to 7 hours after the infusion); 
• 
Perform and assess 12-lead ECG (3 ECGs at least 1 minute apart) before the start of study 
medication infusion and within 10 minutes of the end of the study medication infusion; and 
• 
Obtain sample for culture from infection site (if clinically feasible and if the patient has persistent 
clinical signs or symptoms). 
7.5.3.1.3 
Assessments until EOT every 48 to 72 hours (Visit 4) 
During the patient’s remaining time on therapy, the following V4 assessments should take place every 48 to 
72 hours: 
Protocol Version (3 Dec 2015) 
Page 46 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
• 
Record concomitant medications; 
• 
Perform limited physical exam, including vital signs (includes determination of body temperature) 
and excluding weight and height; 
• 
Assess clinical signs and symptoms of ABSSSI without digital photography. Patients who have a 
worsening of clinical signs and symptoms of ABSSSI during study medication treatment such that 
additional or alternative systemic antibacterial therapy is warranted must be withdrawn from study 
medication; 
• 
Assess AEs; 
• 
Record any significant procedures performed that require surgical intervention (incision and 
drainage, amputation, suture removal, etc. [debridement and incisions at bedside are permitted]); 
• 
Obtain blood and urine samples for clinical chemistry, hematology, and UA; 
• 
If patient has a blood culture that grows a Gram-positive pathogen from Visit 1 and/or Visit 2 
blood cultures, another 2 sets of blood cultures must be obtained at both Visit 3 and Visit 4. If 
these are positive, the patient must be withdrawn from study medication and started on the 
appropriate antibiotics for complicated bacteremia; and 
• 
Study medication administration. If the last dose of study drug falls on a day when an evaluation 
was not planned, an additional evaluation visit will need to be performed on that day (ie. All EOT 
evaluations should be performed on the last day [+2 days] of drug dose). 
• 
Vancomycin patients with a creatinine clearance ≥25 mL/min should have their vancomycin level 
checked with the 5th dose due to difficulty interpreting levels checked prior to achieving steady 
state. 
7.5.3.2 
End of Therapy/Early Termination (Visit 5) 
The following procedures will be performed on the last day of therapy (duration of therapy: minimum 
5 days, maximum 14 days): 
• 
Record concomitant medications; 
• 
Perform limited physical examination, including vital signs (includes determination of body 
temperature) and excluding weight and height; 
• 
Assess clinical signs and symptoms of ABSSSI; including photography (procedure outlined in 
Appendix B). Acetate based planimetric tracing will follow the procedures outlined in 
Appendix C. (Planimetry measurements are based upon automatic detection of pixels inside of the 
traced skin infection area. Pixels are converted to calibrated units based on the scanned resolution 
[eg, 300 DPI]. Skin infection measurements will be provided in cm2.); 
• 
Assess AEs; 
• 
Record any significant procedures performed that require surgical intervention (incision and 
drainage, amputation, suture removal, etc. [debridement and incisions at bedside are permitted]); 
• 
LFT safety assessment 
• 
CRP assessment; 
Protocol Version (3 Dec 2015) 
Page 47 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
• 
Obtain blood and urine samples for clinical chemistry, hematology, and UA; 
• 
Study medication administration if clinically indicated (ie, investigator may decide on a given day 
that a patient no longer needs treatment. In these cases, medication will not be administered, but 
all other EOT assessments must be performed.); 
• 
PK blood sample (before the start of study medication infusion and 5 to 15 minutes, l to 3 hours, 
and 5 to 7 hours after the infusion); 
• 
Obtain sample for culture from infection site (if clinically feasible and if the patient has persistent 
clinical signs or symptoms); and 
• 
Perform clinical efficacy assessment. 
7.5.3.3 
Test of Cure (Visit 6) 
The following procedures will be performed at the TOC visit, 7 to 14 days post-EOT: 
• 
Record concomitant medications; 
• 
Perform limited physical examination, including vital signs (includes determination of body 
temperature) and excluding weight and height; 
• 
Assess clinical signs and symptoms of ABSSSI; including photography (procedure outlined in 
Appendix B). Acetate based planimetric tracing will follow the procedures outlined in 
Appendix C. (Planimetry measurements are based upon automatic detection of pixels inside of the 
traced skin infection area. Pixels are converted to calibrated units based on the scanned resolution 
[eg, 300 DPI]. Skin infection measurements will be provided in cm2.); 
• 
Assess AEs; 
• 
Record any significant procedures performed that require surgical intervention (incision and 
drainage, amputation, suture removal, etc. [debridement and incisions at bedside are permitted]); 
• 
LFT safety assessment;  
• 
CRP assessment; 
• 
Obtain blood and urine samples for clinical chemistry, hematology, and UA; 
• 
Obtain sample for culture from infection site (if clinically feasible and if the patient has persistent 
clinical signs or symptoms); 
• 
Obtain ASO antibody titers; and 
• 
Perform clinical efficacy assessment. 
7.5.3.4 
Late Follow-Up (phone call) 
Late follow-up will be performed via a telephone call to the patient 28 to 32 days post-first dose. 
• 
Assess AEs; and 
• 
Documentation of Day 28 mortality. 
Protocol Version (3 Dec 2015) 
Page 48 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
Patients with high liver function tests and unresolved AEs at TOC will be required to come in for an 
additional visit at LFU. Blood samples will be obtained to document normalization. 
If duration of therapy is 14 days, LFU may overlap with TOC. In this case, all LFU evaluations may take 
place at the TOC visit. 
7.5.4 
Procedures for Premature Discontinuation from the Study Treatment Regimen 
All patients who discontinue early from the study medication must have an Early Termination Assessment. 
This assessment should take place as soon as possible after the patient stops taking study medication. The 
observations and procedures scheduled for EOT should be performed at the Early Termination Assessment. 
7.6 
Efficacy and Safety Variables 
7.6.1 
Efficacy Assessments 
Table 4 displays a summary of all assessments. 
Protocol Version (3 Dec 2015) 
Page 49 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
Table 4: Summary of Assessments 
Population 
Definition 
Analyses 
ITT 
All randomized patients 
Primary efficacy analysis: Patients with early clinical 
response at ETP 
 
Secondary efficacy analyses: 
• 
Resolution or near resolution of ABSSSI at 
TOC 
• 
Resolution or near resolution of ABSSSI at 
EOT 
• 
Resolution or near resolution of ABSSSI at 
EOT and TOC among patients with severe 
infection at baseline 
• 
Time to resolution of signs and symptoms of 
ABSSSI 
mITT 
ITT 
with 
causative 
Gram-
positive organism at baseline 
Secondary efficacy analyses: 
• 
Supportive analysis of primary efficacy 
endpoint 
• 
Resolution or near resolution of ABSSSI at 
TOC 
• 
Resolution or near resolution of ABSSSI at 
EOT 
• 
Resolution or near resolution of ABSSSI at 
EOT and TOC among patients with severe 
infection at baseline 
• 
Time to resolution of signs and symptoms of 
ABSSSI 
• 
Pathogen-level bacteriological response rate 
at EOT and TOC 
• 
Patient-level bacteriological response rate at 
EOT and TOC 
mCE 
All patients excluded from the 
PP population only because they 
have 
received 
prohibited 
concomitant 
or 
preceding 
antibiotic therapy active against 
Gram-positive pathogens 
 
Secondary efficacy analyses: 
• 
Supportive analysis of primary efficacy 
endpoint 
• 
Resolution or near resolution of ABSSSI at 
TOC 
• 
Resolution or near resolution of ABSSSI at 
EOT 
• 
Resolution or near resolution of ABSSSI at 
EOT and TOC among patients with severe 
infection at baseline 
• 
Time to resolution of signs and symptoms of 
ABSSSI 
• 
Pathogen-level bacteriological response rate 
at EOT and TOC 
• 
Patient-level bacteriological response rate at 
EOT and TOC 
PP 
ITT with ≥80% of planned doses 
+ provide adequate data for 
assessment 
Secondary efficacy analyses: 
• 
Supportive analysis of primary efficacy 
endpoint 
• 
Resolution or near resolution of ABSSSI at 
TOC 
• 
Resolution or near resolution of ABSSSI at 
EOT 
Protocol Version (3 Dec 2015) 
Page 50 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
• 
Resolution or near resolution of ABSSSI at 
EOT and TOC among patients with severe 
infection at baseline 
• 
Time to resolution of signs and symptoms of 
ABSSSI 
mPP 
mITT with ≥80% of planned 
doses + provide adequate data 
for assessment 
Secondary efficacy analyses: 
• 
Supportive analysis of primary efficacy 
endpoint 
• 
Resolution or near resolution of ABSSSI at 
TOC 
• 
Resolution or near resolution of ABSSSI at 
EOT 
• 
Resolution or near resolution of ABSSSI at 
EOT and TOC among patients with severe 
infection at baseline 
• 
Time to resolution of signs and symptoms of 
ABSSSI 
• 
Pathogen-level bacteriological response rate 
at EOT and TOC 
• 
Patient-level bacteriological response rate at 
EOT and TOC 
Safety 
All patients who received study 
drug 
All safety analyses 
Abbreviations: ABSSSI = acute bacterial skin and skin structure infection; EOT = End of Therapy; 
ETP = Early Timepoint; ITT = Intent-to-treat; mCE = modified clinically evaluable; mITT = 
Microbiological intent-to-treat; PP = Per-protocol population; mPP = Per-protocol microbiologically 
evaluable population; TOC = Test of Cure. 
7.6.1.1 
Primary Efficacy Assessments 
The primary efficacy endpoint will be the proportion of randomized patients who achieve an early clinical 
response (defined as reduction in the lesion size ≥20% compared to baseline) at 48 to 72 hours (ETP) as 
measured by planimetric tracing (See Appendix C). 
7.6.1.2 
Secondary Efficacy Assessments 
The secondary endpoints are resolution or near resolution of ABSSSI (ie, clinical cure) at TOC for iclaprim 
compared with vancomycin, resolution or near resolution (≥90%) of ABSSSI at EOT, resolution or near 
resolution (≥90%) of ABSSSI at EOT and TOC among patients with severe infection at baseline, time to 
resolution of signs and symptoms of ABSSSI, by-patient bacteriological response rate at EOT and TOC, 
and by-pathogen bacteriological response rate at EOT and TOC. 
7.6.1.2.1 
Clinical Assessment 
The primary endpoint for clinical response (defined as the reduction in lesion size ≥20% compared to 
baseline) will be evaluated in all randomized patients at ETP (48 to 72 hours post-first dose). Patients who 
have died or who received rescue antibacterial therapy prior to that time will be included as treatment 
failures. In addition, clinical outcome will be evaluated by the investigator at EOT and TOC (7 to 14 days 
post-EOT). The assessments of clinical outcome will be categorized as cure, failure, or indeterminate 
defined as follows: 
• 
Cure: defined by a ≥90% reduction in lesion size from baseline, no increase in lesion size since 
ETP, and no requirement for additional antibiotics (except aztreonam and metronidazole) or 
unplanned significant surgical procedures;  
Protocol Version (3 Dec 2015) 
Page 51 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
• 
Failure: reduction in lesion size that is <20% for ETP and <90% for EOT and TOC compared to 
baseline, death related to the infection, persisting or recurrent infection, need for unplanned 
surgical procedure, or administration of rescue antibiotic therapy for the index infection or 
recurrence of index infection; or  
• 
Indeterminate: data inadequate for assessment of efficacy (there are no post-baseline local or 
systemic signs and symptoms data available to make this assessment [eg, patient lost to follow up] 
after <2 days of treatment or <4 doses and no EOT evaluation), lost to follow-up prior to ETP, 
withdrawal of consent, receipt of effective antibiotic therapy for a cause other than the index 
infection, or death not attributed to the index ABSSSI or complication of ABSSSI. 
7.6.1.2.2 
Clinical Signs and Symptoms of Infection 
Eight signs (tenderness to palpitation, erythema, edema, purulent drainage/discharge, fluctuance, 
induration, ulceration, and necrotic tissue) and 4 symptoms (localized pain, swelling, chills, and fever) of 
infection will be assessed at each evaluation and graded on a scale of 0 to 3 (0=none, 1=mild, 2=moderate, 
or 3=severe). 
7.6.1.2.3 
Microbiology Assessment 
An adequate clinical specimen for microbiologic evaluation (eg, pus from a wound or abscess, an aspirate 
or skin biopsy specimen from the leading edge of cellulitis) will be obtained at baseline prior to 
randomization. Additional clinical specimens will be obtained, if clinically feasible and if the patient has 
persistent clinical signs or symptoms, at ETP, EOT, and TOC. If the patient is discontinued from the study 
due to treatment failure, a clinical specimen will be obtained at that time. Specimens will be evaluated by 
the local microbiology laboratory; in addition, isolates will be subcultured and sent to a central 
microbiology laboratory for confirmation of pathogen identity and MICs 
Two sets of blood samples for aerobic/anaerobic cultures 10 minutes apart from different sites peripherally 
will be obtained within 24 hours prior to the first dose of study drug. If patient has a blood culture that 
grows a Gram-negative pathogen from Visit 1 blood cultures, the patient must be withdrawn from study 
medication and started on the appropriate antibiotics for complicated bacteremia. If patient has signs of 
bacteremia at any Visit, 2 sets of aerobic/anaerobic blood cultures that are collected at different sites should 
be obtained 10 minutes apart. If patient has a blood culture that grows a Gram-negative pathogen from 
Visit 2 blood cultures, the patient must be withdrawn from study medication and started on the appropriate 
antibiotics for complicated bacteremia. If patient has a blood culture that grows a Gram-positive pathogen 
from Visit 1 and/or Visit 2 blood cultures, another 2 sets of blood cultures must be obtained at both Visit 3 
and Visit 4. If these are positive, the patient must be withdrawn from study medication and started on the 
appropriate antibiotics for complicated bacteremia. Blood cultures from intravascular devices are not 
permitted. Any potential pathogen will be subcultured and the isolates shipped to the central laboratory. 
The data generated by the central laboratory will be used for the primary analysis. Anti-streptolysin O titers 
will also be taken within 24 hours of the start of treatment. 
Microbiological response will be assessed at the patient level and at the microbiological level on the basis 
of results of the cultures, the susceptibilities of identified organisms, and the clinical outcome of the patient. 
In patients with a Gram-positive pathogen isolated at baseline, microbiological response by patient will be 
determined at ETP, EOT, and TOC visits and categorized as eradication, presumed eradication (no material 
available for culture in clinically cured patients), persistence, presumed persistence (no material available 
for culture in patients who had clinical failure), indeterminate (those patients with clinical outcome of 
indeterminate), superinfection (ie, the emergence of a new isolate documented at the site of infection with 
worsening signs and symptoms of infection–identified after completion of therapy), or recurrent infection 
(pathogen that is different from baseline pathogen[s] is isolated). 
The protocol for shipment of isolates from the local laboratory to the central laboratory, and details of the 
environmental conditions under which specimens and isolates will be stored, can be found in the 
Protocol Version (3 Dec 2015) 
Page 52 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
Laboratory Manual. 
7.6.1.2.3.1 
By-Pathogen Bacteriological Response 
For each assessment (ETP, EOT, and TOC), the by-pathogen bacteriological response for each causative 
organism identified at baseline will be defined as follows: 
• 
Eradication: baseline causative organism cannot be isolated from any culture(s) at the assessment. 
• 
Presumed eradication: The patient is a clinical cure at the assessment, and there is no appropriate 
material for culture from the original site of infection. 
• 
Persistence: The baseline causative pathogen (based on susceptibility profile or molecular typing) 
is isolated at the assessment. 
• 
Presumed persistence: The patient is a clinical failure at the assessment, and no appropriate 
material is available for culture from the original site of ABSSSI. 
• 
Indeterminate: Clinical response was Indeterminate at the assessment and no appropriate material 
is available for culture from the original site of ABSSSI. 
• 
Superinfection: A pathogen is isolated at the assessment that is different from the baseline 
causative pathogen. 
• 
Recurrent infection: A pathogen is isolated only after the EOT visit that is different from the 
baseline pathogen(s). 
7.6.1.2.3.2 
By-Patient Bacteriological Response 
The by-patient bacteriological response will be determined according to the following definitions: 
• 
Eradication: All baseline Gram-positive causative organism(s) have a response of Eradication. 
• 
Presumed eradication: All baseline Gram-positive causative organism(s) have a response of 
Presumed Eradication or a combination of responses of Eradication and Presumed Eradication. 
• 
Persistence: All or some baseline Gram-positive causative organism(s) have a response of 
Persistence or a combination of responses of Persistence and Presumed Persistence. 
• 
Presumed persistence: All or some baseline Gram-positive causative organism(s) have a response 
of Presumed Persistence. 
• 
Indeterminate: All baseline causative organism(s) have a response of Indeterminate. 
• 
Superinfection: Any patient classified as a clinical failure who has a pathogen isolated during 
therapy that is different from the baseline causative pathogen. 
• 
Recurrent infection: Any patient classified as a clinical failure who has a pathogen isolated after 
the EOT visit only, that is different from the baseline pathogen(s). 
7.6.2 
Safety Assessments 
All patients who receive any study drug will be evaluated for safety on the basis of medical history and 
physical examinations, reports of clinical AEs, routine electrocardiography, and clinically significant 
Protocol Version (3 Dec 2015) 
Page 53 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
findings from routine liver function tests, serum chemistry, hematology, coagulation, and UA tests. All 
adverse events will be recorded throughout the study period, up to and including the LFU phone call. While 
blinded to treatment assignment, the investigator will categorize the severity of each AE and the potential 
for relationship to study drug. Serious AEs include those that were life threatening, led to prolongation of 
the existing hospitalization, a congenital anomaly/birth defect, or caused persistent or significant disability, 
incapacity, or death. Treatment-emergent AEs (TEAEs) will be defined as those that start or worsen in 
severity during or after the first dose of study drug administration through end of study. 
The guidance for grading the severity of adverse events can be found in Appendix G. 
7.6.2.1 
Adverse Events 
7.6.2.1.1 
Definitions 
The term "adverse event," as used by the sponsor, is synonymous with the term "adverse experience," 
which is used by the FDA. 
An AE is any untoward, undesired, unplanned clinical event in the form of signs, symptoms, disease, or 
laboratory or physiological observations occurring in a human being participating in a clinical study with a 
sponsor test article, regardless of causal relationship. This includes the following: 
• Any clinically significant worsening of a pre-existing condition. 
• Note: Emergence of a new pathogen associated with a clinical event during therapy at a site 
other than the initial site of infection will be considered to be an AE. 
• Any recurrence of a pre-existing condition. 
• An AE occurring from overdose of a sponsor study drug whether accidental or intentional (ie, a 
dose higher than that prescribed by a health care professional for clinical reasons). 
• An AE occurring from abuse of a sponsor study drug (ie, use for nonclinical reasons). 
• An AE that has been associated with the discontinuation of the use of a sponsor study drug. 
 
A procedure is not an AE, but the reason for a procedure may be an AE. 
A pre-existing condition is a clinical condition (including a condition being treated) that is diagnosed 
before the patient signs the ICF. Pre-existing conditions will be recorded on the Medical History/Current 
Medical Conditions page of the eCRF. 
The questions concerning whether the condition existed before the start of the active phase of the study and 
whether it has increased in severity and/or frequency will be used to determine whether an event is a 
TEAE. An AE is considered to be treatment emergent if (1) it is not present when the active phase of the 
study begins and is not a chronic condition that is part of the patient’s medical history, or (2) it is present at 
the start of the active phase of the study or as part of the patient’s medical history, but the severity or 
frequency increases during the active phase. The active phase of the study begins at the time of the first 
dose of the study drug. The active phase of the study ends at the last follow-up visit. 
Abnormal laboratory values or test results constitute AEs only if they induce clinical signs or symptoms or 
require therapy, and are recorded on the AE page of the eCRF under the signs, symptoms, or diagnosis 
associated with them. 
7.6.2.1.2 
Reporting of Adverse Events 
All AEs, including intercurrent illnesses, must be documented. Volunteered, observed, and elicited AEs 
will be recorded in the eCRF. This includes AEs the patient reports spontaneously, those the investigator 
observes, and those the patient reports in response to open-ended questions. 
Protocol Version (3 Dec 2015) 
Page 54 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
At each visit the investigator, or delegate, will determine whether or not any AEs have occurred. The 
patient will be questioned in a general way and no specific symptoms will be suggested. The patient will be 
asked an open-ended question such as, "How have you been feeling since your last study assessment/visit?" 
All AEs, regardless of relationship to study medication, must be recorded in the patient’s medical records 
and on the AE page(s) of the eCRF. If known, the diagnosis should be recorded, and the individual signs 
and symptoms should be listed. All AE entries should contain the date of onset; time of onset (if known); a 
brief description of the event; duration of event; severity; treatment required; relationship to study 
medication; action taken with regard to study medication; outcome; date and time of resolution (if 
applicable); and whether the event is classified as serious by the investigator. Each AE will be assessed by 
the investigator with regard to seriousness, severity, and relationship to study medication. 
Adverse event reporting begins from the time of informed consent and ends at LFU. 
7.6.2.1.3 
Assessment of Severity 
The severity of each AE must be assessed by the investigator and recorded in the eCRF as mild, moderate, 
or severe defined as the following: 
• 
Mild:  An AE that does not interfere with usual activities. 
• 
Moderate:  An AE that interferes with usual activities. 
• 
Severe:  An AE that is intense or debilitating and interferes with usual activities. 
7.6.2.1.4 
Relationship to Study Treatment 
The relationship of each AE to study medication must be assessed and recorded by the investigator as not 
related, probably not related, probably related, and related. 
• 
Not related:  Clinical event with an incompatible time relationship to drug administration, and 
that could be explained by underlying disease or other drugs or chemicals or is incontrovertibly 
not related to the study drug. 
• 
Probably not related:  Clinical event whose time relationship to drug administration makes a 
causal connection improbable, but that could plausibly be explained by underlying disease or other 
drugs or chemicals. 
• 
Probably related:  Clinical event with a reasonable time relationship to study drug 
administration, but that could also be explained by concurrent disease or other drugs or chemicals. 
• 
Related:  Clinical event with plausible time relationship to study drug administration, and that 
cannot be explained by concurrent disease or other drugs or chemicals. 
7.6.2.1.5 
Follow-up of Adverse Events 
Patients with high LFTs and unresolved AEs at TOC must be seen in person for an additional visit at LFU. 
The investigator must continue to follow all non-serious AEs (and SAEs) until they resolve or until the 
investigator assesses them as chronic or stable. This follow-up may extend after the end of the study. 
7.6.2.2 
Serious Adverse Events 
Each AE must be assessed and recorded in the eCRF as serious or not serious. Serious AEs must be 
reported as described in Section 7.6.2.2.2. International Conference on Harmonisation Guidelines and the 
Code of Federal Regulations (CFR; 21 CFR 312.32, revised as of 01 April 2014) define an SAE as any 
adverse drug experience occurring at any dose that results in any of the following outcomes: 
• 
Death; 
• 
A life-threatening adverse event; 
Protocol Version (3 Dec 2015) 
Page 55 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
• 
Inpatient hospitalization or prolongation of existing hospitalization; 
• 
A persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions; or 
• 
A congenital anomaly/birth defect. 
Important medical events that may not result in death, be life-threatening, or require hospitalization may be 
considered serious when, based upon appropriate medical judgment, they may jeopardize the patient and 
may require medical or surgical intervention to prevent one of the outcomes listed in the above definition. 
Examples of such medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, 
or the development of drug dependency or drug abuse. 
Events not considered to be SAEs are: 
1. Clinical failure, which is the primary study endpoint/variable; 
2. Routine treatment or monitoring of the studied indication not associated with any deterioration in 
condition; 
3. Elective or preplanned treatment for a pre-existing condition that did not worsen; and 
4. Treatment on an emergency, outpatient basis for an event not fulfilling any of the definitions of 
serious given above and not resulting in hospital admission. 
7.6.2.2.1 
Review of Serious Adverse Events 
The investigator and the sponsor (or designee) will review each SAE report and evaluate the relationship of 
the SAE to study treatment. Based on the investigator's and sponsor's assessment of the SAE, a decision 
will be made concerning the need for further action. The primary consideration governing further action is 
whether new findings affect the safety of patients participating in the clinical study. If the discovery of a 
new SAE related to the study medication raises concern over the safety of continued administration of the 
study medication to patients, the sponsor will take immediate steps to notify the US FDA/other regulatory 
authorities and all investigators participating in clinical studies of the study medication. 
Further action that may be required includes the following: 
• 
Modification of the protocol; 
• 
Discontinuation or suspension of the study; 
• 
Modification of the existing consent form and informing current study participants of new 
findings; 
• 
Addition of any newly identified study medication-related AEs to the list of expected AEs. 
7.6.2.2.2 
Reporting Serious Adverse Events 
All SAEs, occurring after the signing of the ICF until LFU, and regardless of study drug relationship, must 
be reported by telephone to Covance within 24 hours of obtaining knowledge of the event. The caller’s 
name and telephone number, as well as the name of the drug and study, should be recorded. 
SAEs in North America - Covance Pharmacovigilance & Drug Safety Services (PV&DSS) 
Protocol Version (3 Dec 2015) 
Page 56 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
 
Telephone number – +1 888-724-4908 
Fax number - +1 888-887-8097 
 
SAEs in Asian-Pacific - Covance PV&DSS 
 
Telephone number – +61 2 8879 2000 
 
Fax number - +61 2 9888 8322 
 
SAEs in Europe & Middle East/Africa - Covance PV&DSS 
 
Telephone number – +44 1628 548000 
 
Fax number - +44 1628 540028 
 
SAEs in Latin America - Covance PV&DSS 
 
Telephone number – +55 11 3750-3900 
 
Fax numbers – Columbia – 01800 518 1218 
 
 
           Chile – 1230-020-5597 
 
The site must also complete the Clinical Safety Event Report (CSER) Form and fax to Covance PV&DSS.  
The CSER Form will collect data surrounding the event, eg, the nature of the symptom(s), time of onset in 
relation to initiation of therapy, duration, intensity, and whether or not therapy was interrupted or 
discontinued. The investigator’s assessment of the probable cause of the event will also be included. In 
addition, relevant medical history, concomitant medications, laboratory and diagnostic tests reports, and 
procedures as well as all pertinent medical information related to the event will also be collected. 
Covance PV&DSS will forward SAE queries directly to the investigator requesting incomplete or missing 
information. It is the investigator’s responsibility to be diligent in providing this information back to 
Covance PV&DSS as soon as it is available. 
If event qualifies for expedited reporting (serious, related, or unexpected events), the CRO will submit a 
report to the FDA by Day 15. If the event is also fatal or life-threatening, the FDA will be notified by Day 7 
via phone, fax, or email (note that the date of first receipt is considered to be Day 0).  Expected safety 
reports will also be distributed to the investigators by Day 15. 
Investigators will be notified by the CRO of all SAEs that require prompt submission to their IRB/IEC. 
Investigators should provide written documentation of IRB/IEC notification for each report to the CRO. 
The CRO will ensure that all SAEs are reported to the appropriate regulatory authorities. For sites using the 
central IRB, the CRO will submit reports to the central IRB on behalf of those sites. 
7.6.2.2.3 
Follow-up of Serious Adverse Events 
The investigator must continue to follow all SAEs (and non-serious AEs) until they resolve or until the 
investigator assesses them as chronic or stable. This follow-up may extend after the end of the study. 
7.6.2.3 
Pregnancy 
Pregnancy (of a female patient, or of a woman impregnated by a male patient during the study), although 
not itself an SAE, should be reported on a Clinical Pregnancy Report Form and be followed up to 
determine the outcome, including spontaneous or voluntary termination, details of birth, and the presence 
or absence of any birth defects or congenital abnormalities. Pregnancy follow-up should be done until the 
infant is at least 6 months of age. 
Protocol Version (3 Dec 2015) 
Page 57 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
7.6.2.4 
Protocol Deviations due to an Emergency or Adverse Event 
Departures from the protocol may occur in the event of an emergency. In such cases, the investigator or 
other physician in attendance must contact the CRO Medical Monitor as soon as possible to discuss the 
circumstances of the emergency. All protocol deviations and the reasons for such deviations must be 
reported accordingly. 
7.6.2.5 
Safety Laboratory Determinations 
Investigative sites will use local laboratory results to confirm patient eligibility (inclusion/exclusion 
criteria). A central laboratory will receive samples for all safety laboratory evaluations as described in 
Table 3. 
Procedures for the collection, preparation, and transportation of samples to the central laboratory for 
evaluation are detailed in the Laboratory Manual. 
Although the results of these analyses will be provided to the respective investigators on a regular basis, 
investigators should use their local laboratories to generate data necessary for the routine management of 
the patient's medical conditions, since central laboratory results will not be available in a timely manner for 
patient management. 
Clinical hematology and chemistry tests and UA will be performed on certain study days as shown in the 
Schedule of Study Procedures (Table 3). In addition, a serum or urine pregnancy test will be performed 
immediately prior to randomization for female patients of childbearing potential. (Patients who are 
pregnant will be excluded or withdrawn from the study. Patients who become pregnant during the study 
must inform the investigator and be withdrawn from study medication.) 
Clinical hematology tests will include hematocrit, hemoglobin, red blood cell (RBC) count, WBC count, 
platelet count, and WBC differential including neutrophils, lymphocytes, monocytes, eosinophils, 
basophils, MCH, MCHC, MCV, and CRP. 
Clinical chemistry tests will include creatinine, blood urea nitrogen (BUN), AST, ALT, ALP, gamma 
glutamyl transferase, lactate dehydrogenase, creatine phosphokinase, total bilirubin, albumin, total protein, 
glucose, sodium, potassium, chloride, and bicarbonate. 
Urinalysis will include determination of pH, specific gravity, presence of blood, glucose, protein, ketones, 
and bile, and microscopic examination of sediment. 
7.6.2.6 
Vital Signs, Physical Examination, and Other Safety Evaluations 
7.6.2.6.1 
Vital Signs 
Systolic and diastolic blood pressure, heart rate, and respiration rate will be assessed on each study visit. 
7.6.2.6.2 
Physical Examination 
A complete physical examination, including vital signs (includes determination of body temperature), 
height, weight, and a review by body systems, will be conducted at baseline. 
Limited physical examinations, including vital signs (includes determination of body temperature) and 
excluding weight and height, will be conducted at all post-baseline visits. 
Protocol Version (3 Dec 2015) 
Page 58 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
7.6.2.6.3 
Electrocardiogram 
Twelve-lead ECGs will be performed at screening, Day 1, and at ETP. On Day 1 and at ETP, the triplicate 
ECGs will be taken prior to study medication administration and within 10 minutes of the end of the first 
study medication dose. In addition, a 12-lead ECG will be performed at ETP within 10 minutes after the 
end of infusion, as specified in the Schedule of Study Procedures (Table 3). 
If the median QTcF value is >500 msec and/or is >60 msec different from the predose baseline value, 
follow-up ECG tests should be performed every 1 to 2 hours until they are below these threshold values. 
Fredericia’s formula is as follows: 
QTcF = QT / RR1/3 
All ECG recordings will be taken as triplicates at least 1 minute apart and the median QTcF value will be 
evaluated at the respective study site for exclusion criterion 15 (Section 7.3.2), for compliance with study 
protocol-defined procedures (see above) and safety. 
Furthermore, all ECG tests will also be transmitted to, and electronically stored at, a central center 
specialized in the standardized evaluation of ECG tests. Procedures for performing ECG tests and 
subsequent transmission to and interpretation by the central ECG laboratory are detailed in the ECG 
Manual. 
7.6.2.6.4 
Liver Function Tests 
Liver function tests will be taken at screening, and patients with severe hepatic disease (Child-Pugh 
Class C) or known AST or ALT >5 times the upper limit of normal and/or bilirubin >2 times the upper 
limit of normal will be excluded from the study. During the course of the study, liver function tests will 
also be taken at V2 visits, ETP, EOT, and TOC. Patients with high liver function tests at TOC will be 
required to come in for an additional visit at LFU. Blood samples will be obtained to document 
normalization. 
For patients who meet 1 of the 2 LFT discontinuation criteria (Section 7.3.3.2), an appropriate evaluation of 
causes for the liver enzyme abnormalities should be initiated and the LFTs should be followed every 48-72 
hours until normalization or stability. The following evaluations should be considered: 
• 
History, including alcohol and other drugs of abuse; 
• 
Clinical symptoms – RUQ pain, nausea etc.; 
• 
Viral hepatitis serologies; 
• 
Autoimmune hepatitis serologies; 
• 
Concomitant medication review to eliminate possible heptatotoxic medications where possible; 
• 
Ethanol and acetaminophen/paracetamol levels; and 
• 
Abdominal ultrasound. 
7.6.2.7 
Reporting Safety Information 
The investigator must promptly report to his or her IRB/IEC/ REB all unanticipated problems involving 
risks to patients. This includes death from any cause and all SAEs associated, or possibly associated, with 
the use of the study medication. 
Protocol Version (3 Dec 2015) 
Page 59 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
7.7 
Pharmacokinetic Analysis 
Pharmacokinetic samples will be obtained from patients on 3 occasions: following the first dose of study 
medication, at ETP, and at EOT. After the study is complete, the database locked, and the data unblinded, 
patients randomized to iclaprim will have their samples assayed. 
7.7.1 
Collection and Handling of Samples 
Pharmacokinetic blood samples (5 mL) for determination of iclaprim concentrations will be collected on 
Day 1, ETP and EOT at the following timepoints: before study medication infusion, and within 5 to 15 
minutes, 1 to 3 hours, and 5 to 7 hours after the end of study medication infusion (see Table 3). Per patient, 
a total of 12 samples, for a total of 60 mL blood, will be obtained for PK analysis. All samples will be 
labeled to indicate the clinical study number, patient number, actual relative time after study medication 
administration, and sampling number. Processing, storage, and shipping instructions are provided in the 
pharmacy manual. Plasma concentrations of iclaprim will be measured by a validated liquid 
chromatography tandem mass spectrometric detection assay [16]. 
7.8 
Data Handling and Record Keeping 
7.8.1 
Data Quality Assurance 
Before study initiation, at a site initiation visit, or at an investigator's meeting, a sponsor representative will 
review the protocol and CRFs with the investigators and their staff. During the study, the CRA will visit the 
site regularly to check the completeness of patient records, the accuracy of entries in the CRFs, the 
adherence to the protocol and to GCP, the progress of enrollment, and also to ensure that study medication 
is being stored, dispensed, and accounted for according to specifications. Key study personnel should be 
available to assist the monitor during these visits. 
Subsequently, information entered into the database is systematically checked by Data Management staff, 
using error messages printed from validation programs and database listings. Obvious errors, eg, simple 
spelling errors, will be corrected by Data Management personnel. Other errors or omissions will be entered 
on Data Query Forms, which will be returned to the investigational site for resolution. A copy of the signed 
Data Query Form is to be kept with the CRFs, and, once the original is received at the sponsor (or 
designee), the resolutions will be entered into the database. Quality control audits of all key safety and 
efficacy data in the database will be made after entering data from each visit. 
When the database has been declared to be complete and accurate, the database will be locked and 
unblinded. Any changes to the database after that time can only be made by joint written agreement among 
the Clinical Study Leader, the Study Statistician, and the Data Manager. 
Further details are defined in the separate guidelines for data entry and data management personnel. 
7.8.2 
Case Report Forms and Source Documentations 
Investigators must enter the information required by the protocol onto the CRFs in accordance with 
procedures described in the pharmacy manual. 
The investigator must complete the CRFs and transmit the data as instructed by the sponsor (or designee) 
and must store a copy of the source documents with other study documents, eg, the protocol, the 
investigators' brochure, and any protocol amendments, in a secure place. All entries to the CRFs must be 
made as described in the CRF Completion Guideline or as instructed by the sponsor (or designee) at study 
initiation. 
Patient data collected within the eCRFs during the study will be documented in an anonymous fashion and 
the patient will only be identified by the patient number, and by his/her birth date if also required. If, as an 
Protocol Version (3 Dec 2015) 
Page 60 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
exception, it is necessary for safety or regulatory reasons to identify the patient, both the sponsor (or 
designee) and the investigator are bound to keep this information confidential. 
The investigator must maintain source documents for each patient in the study, consisting of all 
demographic and medical information, including laboratory data, ECG tests, etc., and keep a copy of the 
signed ICF. All information on CRFs must be traceable to these source documents kept in the patient's file. 
7.8.3 
Direct Access to Source Data 
The investigator must give the monitor access to relevant hospital or clinical records to confirm their 
consistency with the CRF entries. No information in these records about the identity of the patients will 
leave the study site. Sponsor monitoring standards require full verification for the presence of informed 
consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and the recording of 
primary efficacy and safety variables. Additional checks of the consistency of the source data with the 
CRFs are performed according to the study-specific monitoring plan. 
The FDA or other regulatory authority, the IRB/IEC/REB, and/or the sponsor's Clinical Quality Assurance 
Group (or designate) may wish to perform source data checks and/or on-site audit inspections. Investigators 
and their institutions will provide direct access to source data and documents to these authorities. The 
investigator assures the sponsor of the necessary support at all times. 
7.8.4 
Archiving Study Records 
Essential documents, as listed below, must be retained by the investigator for as long as needed to comply 
with national and international regulations (generally 2 years after discontinuing clinical development or 
after the last marketing approval). Motif Biosciences will notify the investigator(s)/institution(s) when the 
study-related records are no longer required. The investigator agrees to adhere to the document retention 
procedures by signing the protocol. Essential documents include: 
1. IRB/IEC/REB approvals for the study protocol and all amendments; 
2. All source documents and laboratory records; 
3. eCRF copies; 
4. Patients' ICFs (with study number and title of study); 
5. FDA Form 1572 (as required); and 
6. Any other pertinent study document. 
7.9 
Statistical Methods 
The primary efficacy endpoint will be the proportion of patients who achieve an early clinical response 
(defined as reduction in the lesion size ≥20% compared to baseline) at 48 to 72 hours (ETP) and will be 
evaluated among all randomized patients (ITT population). 
In general, statistical tests will be two-sided, and at the level of significance alpha = 0.05. The NI 
assessment will be made with a one-sided test at significance level of 0.025. Confidence intervals will be 
calculated at a 95% confidence level. 
Continuous data will be summarized by treatment group using the number of patients in the analysis 
population (N), mean, standard deviation (SD), median and range and categorical data will be summarized 
by treatment group using N and percentage. 
Protocol Version (3 Dec 2015) 
Page 61 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
7.9.1 
Determination of Sample Size  
Using Farrington and Manning’s method for non-inferiority (NI) testing with a 1 sided alpha of 0.025, 
assuming a 75% early clinical response rate in each group and a 10% non-inferiority bound delta, a sample 
size of 295 ITT patients per treatment group is required for 80% power. In addition, using similar methods 
of NI testing with a 1-sided alpha of 0.025, assuming a 90% early clinical response rate at TOC in each 
group and a 10% NI bound delta, a sample size of 300 patients in the ITT population per treatment group is 
required for 82% power. If the initial endpoint of clinical response at ETP does not achieve statistical 
significance, no further statistical testing will be done. 
A total of 600 patients will be randomized (approximately 300 per treatment group will be randomized). 
7.9.2 
Patient Populations Analyzed 
Intent-to-treat (ITT) population — All randomized patients (primary population for efficacy analyses). 
Patients will be analyzed in treatment group to which they were randomized. 
 
Microbiological intent-to-treat (mITT) population — All randomized patients who have a Gram-positive 
baseline bacterial pathogen identified as the cause of ABSSSI. 
 
Modified clinically evaluable (mCE) population consists of all patients excluded from the PP population 
only because they have received prohibited concomitant or preceding antibiotic therapy active against 
Gram-positive pathogens. 
 
PP population — ITT patients who receive at least 80% of their planned doses and provide adequate data 
for assessment for each of the following timepoints: ETP, EOT, and TOC. This excludes patients with 
Gram-negative bloodstream infections who were discontinued in order to treat the Gram-negative 
pathogen. 
 
PP microbiologically evaluable population (mPP) — mITT patients who receive at least 80% of their 
planned doses and provide adequate data for assessment for each of the following timepoints: ETP, EOT, 
and TOC. 
 
Safety population — All patients who receive any study drug during the trial (primary population for safety 
analyses). Patients will be analyzed according to the treatment they received. 
7.9.3 
Efficacy Analysis 
7.9.3.1 
Primary Efficacy Outcome Measures 
The primary efficacy endpoint is the proportion of randomized patients who achieve an early clinical 
response (defined as reduction in the lesion size ≥20% compared to baseline) at 48 to 72 hours (ETP) and 
will be evaluated among all randomized patients (ITT population). The primary efficacy analysis will be 
the NI of iclaprim (group 1) to vancomycin (group 2) for the proportion of patients with a ≥20% reduction 
in lesion size at ETP compared to baseline. Let P1 be the proportion for iclaprim and P2 be the proportion 
for vancomycin. Equivalently, if the lower bound of the two-sided 95% CI for P1 – P2 is greater than -
0.100 based on the Z test with unpooled variance estimate, NI will be concluded. 
 
7.9.3.2 
Secondary Efficacy Outcome Measures 
The primary NI efficacy analysis will be repeated in the mITT, mCE, the Per Protocol, and the mPP 
populations as secondary outcomes. 
 
 
Protocol Version (3 Dec 2015) 
Page 62 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
The secondary endpoints are: 
1. Resolution or near resolution of ABSSSI (ie, clinical cure, defined by a >90% reduction in lesion 
size from the size at baseline, no increase in lesion size since ETP, and no requirement for 
additional antibiotics [except aztreonam and metronidazole] or unplanned significant surgical 
procedures after ETP other than bedside wound care) at TOC for iclaprim (80 mg q12h) compared 
with vancomycin (weight-based dose) for ITT, mITT, mCE, PP, and mPP populations 
2. Resolution or near resolution (≥90%) of ABSSSI at EOT for ITT, mITT, mCE, PP, and mPP 
populations 
3. Resolution or near resolution (≥90%) of ABSSSI at EOT and TOC among patients with severe 
infection at baseline for ITT, mITT, mCE, PP, and mPP populations 
4. Time to resolution of signs and symptoms of ABSSSI from start of treatment for ITT, mITT, 
mCE, PP, and mPP populations 
5. Patient-level bacteriological response rate at EOT and TOC for mITT, mCE, and mPP populations 
6. Pathogen-level bacteriological response rate at EOT and TOC for mITT, mCE, and mPP 
populations 
7.9.4 
Safety Analysis 
All patients who received any amount of iclaprim or vancomycin during the trial will be evaluated for 
safety.  
Safety evaluation include incidence of TEAEs, laboratory test results (including liver function tests), vital 
signs, ECG results, and physical examination findings. All summaries of safety data will be based on the 
safety population (all treated patients). No formal statistical analysis of the safety data will be performed. 
Summary tables will be provided for all AEs by treatment group. The incidence of AEs, related AEs, SAEs, 
and AEs leading to discontinuation of the study treatment will be presented by Medical Dictionary for 
Regulatory Activities system organ class (SOC) and preferred term. In addition, the incidence of AEs by 
severity will be presented by SOC and preferred term.  
The AE summary tables will include counts of patients. Therefore, if a patient experiences more than one 
episode of a particular AE, the patient will be counted only once for that event. If a patient has more than 
one AE that is coded to the same preferred term, the patient will be counted only once for that preferred 
term. Similarly, if a patient has more than one AE within a SOC, the patient will be counted only once in 
that SOC. 
Laboratory test variables will be summarized by treatment group and visit using descriptive statistics 
(number of patients, mean, SD, minimum, maximum, as well as mean change from baseline, SD for mean 
and standard error for mean change, minimum, median, maximum, and number and percent of patients 
within specified categories). Shift tables (ie, cross-tabulations of below the lower limit of the normal range, 
within the limits of the normal range and above the upper limit of the normal range at baseline versus 
scheduled visits) will be presented by laboratory test. Laboratory tests with categorical results that cannot 
be analyzed by change from baseline or shift table analysis will not be included in these summaries, but 
will be listed. Data obtained from laboratory tests not required by the protocol will not be summarized, but 
will be listed.  
Descriptive statistics of vital signs and ECG results at each visit will be presented by treatment group. 
Physical examination findings will be listed for each patient. 
Protocol Version (3 Dec 2015) 
Page 63 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
7.9.5 
Population Pharmacokinetics 
Iclaprim plasma concentrations will be used to determine population PK parameters, including Cmax, AUC 
to infinity (AUC0-∞), clearance, and volume of distribution. Interindividual variability (IIV) will be 
determined for PK parameters, as well as residual variability. The potential influence of clinical 
characteristics (age, size, sex, hepatic function, renal function, concomitant medications, etc.) on PK 
parameters will be evaluated. Further details will be detailed in a separate population PK analysis plan. 
7.9.6 
Interim Analysis 
When 75% of the randomized patients have undergone the 48- to 72-hour (ETP) response assessment, the 
sponsor will do a blinded interim analysis to estimate the percentage of patients in the study who classify as 
having a reduction in the lesion size ≥20% compared to baseline at the 48- to 72-hour visit. Based on the 
observed overall percentage, the sponsor may increase the total sample size to attempt to ensure that an 
adequate number of ITT patients are included in the study. Since the review is blinded and the efficacy 
analyses will not be reviewed by treatment group, no adjustment of p-values is required. Nevertheless, the 
sponsor will take steps to minimize the distribution of results to avoid introducing any bias. 
Protocol Version (3 Dec 2015) 
Page 64 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
8. 
RISKS AND BENEFITS 
The combined data set from the Phase 3 studies indicated that iclaprim has similar efficacy in the treatment 
of patients with cSSSI when compared with linezolid. Both iclaprim and linezolid were associated with 
high clinical cure and bacteriological response rates. 
Iclaprim was well tolerated. Results from the Phase 3 clinical studies indicated that administration of 
iclaprim led to a mean increase of the QTc interval of about 5 to 6 msec more than linezolid, whereas the 
latter is considered as having no QTc prolonging effect. 
The Phase 2 study indicated that iclaprim has similar efficacy in the treatment of patients with cSSSI when 
compared with vancomycin. The two iclaprim (0.8 and 1.6 mg base per kg body weight) and vancomycin 
study arms were associated with high clinical cure and bacteriological response rates. 
Both doses of iclaprim were well tolerated; however, AEs and shifts from normal baseline in laboratory 
parameters were recorded somewhat more frequently in the iclaprim 1.6 mg/kg group. 
Phase 1 studies to examine the effect of iclaprim on QTc interval have indicated that doses up to 1.6 mg/kg 
b.i.d. are considered safe for clinical use. 
Iclaprim has the potential to be a new antibacterial agent active against Gram-positive drug-resistant 
strains, with a good safety profile, and therefore should be further studied in larger patient populations. 
Protocol Version (3 Dec 2015) 
Page 65 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
9. 
INVESTIGATORS REGULATORY OBLIGATIONS 
9.1 
Prestudy Documentation 
The investigator must provide the sponsor with the following documents BEFORE enrolling any patients: 
1. 
Completed and signed Statement of Investigator, Form FDA 1572 (21 CFR 312.53[c]). 
2. 
All applicable country-specific regulatory forms. 
3. 
Current signed and dated curricula vitae for the investigator, subinvestigators, and all key 
personnel listed on the clinical study information form. 
4. 
Copy of the IRB/IEC/REB approval letter for the protocol and informed consent. Written 
assurance of continuing approval (at least annually) as well as a copy of the annual progress 
report submitted to the IRB/IEC/REB must also be provided to the sponsor. Any changes in this 
study or unanticipated problems involving risks to the patients must be reported promptly to the 
IRB/IEC/REB. An investigator must not make any changes in the study without IRB/IEC/REB 
and sponsor approval except when necessary to eliminate apparent immediate hazards to the 
patients. All protocol amendments must be submitted to the IRB/IEC/REB and approved. 
5. 
Copy of the IRB/IEC/REB-approved informed consent form (ICF) to be used. 
6. 
When applicable, a list of the IRB/IEC/REB members and their qualifications, and a description 
of the committee’s working procedure. 
7. 
Copy of the protocol signature page signed by the investigator. 
8. 
Fully executed clinical study agreement (CSA). 
9. 
A written document containing the name, location, certification number, and date of certification 
of the laboratory to be used for laboratory assays and those of other facilities conducting tests. 
This document should be returned along with the Statement of Investigator form. The sponsor 
must be notified if the laboratory is changed or if any additional laboratory is to be used. 
9.2 
Electronic Data Capture 
1. 
All data will be entered into an electronic data capture (EDC) system or eCRF. 
2. 
Sponsor designees will review the supporting source documentation against the data entered into 
the eCRFs to verify the accuracy of the data. The designee will ensure that corrections are made 
to the eCRFs and that queries are resolved in a timely manner by the study staff. 
3. 
The eCRFs and other pertinent electronic records will be transmitted to the sponsor periodically 
during and/or at completion or termination of the study. 
4. 
The investigator also must submit all incomplete EDC records that document patient experience 
with the study drug, including retrievable data on patients who withdraw before completion of 
the study. 
Results of central safety laboratory results will be transmitted monthly to the EDC vendor. At the 
conclusion of the study all data will be delivered to the sponsor. 
9.3 
Adverse Event Reporting 
The investigator agrees to report all AEs to the sponsor as described in the Adverse Events section 
(Section 7.6.2.1.2). Furthermore, the investigator is responsible for ensuring that any subinvestigator 
promptly brings AEs to the attention of the investigator. If applicable, the investigator also is responsible 
for informing the participating IRB/IEC/REB of any SAEs. 
9.4 
Review of Source Records 
The investigator agrees that qualified representatives of the sponsor and regulatory agencies will have the 
right, both during and after this study, to conduct inspections and to audit and review medical records 
pertinent to the clinical study as permitted by the regulations. Patients will not be identified by name on any 
of the study documents or samples retained by the sponsor for their analysis, and confidentiality of 
Protocol Version (3 Dec 2015) 
Page 66 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
information in medical records will be preserved. The confidentiality of the patient will be maintained 
unless disclosure is required by regulations. Accordingly, the following statement (or similar statement) 
will be included in the informed consent document:  
“Representatives of regulatory agencies, IRBs/IECs, the sponsor, and your personal 
physician may review your medical records and all information related to this study as 
permitted by law.” 
9.5 
Monitoring of the Study 
A Study Monitor from Covance Late Stage Development Services will be responsible for monitoring this 
clinical trial. The Study Monitor will monitor the study conduct, proper eCRFs completion, and source 
documentation completion and retention, and accurate study drug accountability. To this end, the Study 
Monitor will visit the study site at suitable intervals and be in frequent contact through verbal and written 
communication. It is essential that the Study Monitor have access to all documents (related to the study and 
the individual participants) at any time these are requested. In turn, the Study Monitor will adhere to all 
requirements for patient confidentiality as outlined in the ICF. The investigator and investigator’s staff will 
be expected to cooperate with the Study Monitor, to be available during a portion of the monitoring visit to 
answer questions, and to provide any missing information. 
9.6 
Protocol Amendments 
There will be no alterations in the protocol without agreement between the sponsor and the investigator. 
There will be no alterations in the protocol affecting patient safety without the express written approval of 
the sponsor, investigator, and the IRB/IEC/REB. 
A protocol change intended to eliminate an apparent immediate hazard to patients may be implemented 
immediately, but the change must then be documented in an amendment, reported to the IRB/IEC/REB 
within 5 working days, and submitted to the appropriate regulatory agency in the required time frame. 
9.7 
Investigator Meeting 
Prior to the start of the clinical study, the representative(s) of the sponsor will meet with the investigator(s) 
and appropriate clinical staff to familiarize the investigator and clinical staff with the materials necessary 
for conducting the clinical study. 
9.8 
Change in Investigator 
If any investigator retires, relocates, or otherwise withdraws from conducting a study, the responsibility for 
maintaining records may be transferred to the sponsor, IRB/IEC/REB, or another investigator. The sponsor 
must be notified of and agree to the change. Regulatory agencies will be notified with the appropriate 
documentation. An updated Form FDA 1572 will be filed with the sponsor for any changes in the study 
personnel reported in the current Form FDA 1572. 
9.9 
Termination of the Study 
If the investigator or the CRO Medical Monitor becomes aware of conditions or events that suggest a 
possible hazard to patients if the study continues, he or she must notify the sponsor (or designee) 
immediately. The sponsor and Medical Monitor will consult to determine whether termination of the study 
is necessary. The study may also be terminated early at the sponsor's discretion in the absence of such a 
finding. Conditions that may warrant termination include, but are not limited to: 
• 
The discovery of an unexpected, significant, or unacceptable risk to the patients enrolled in the 
study. 
• 
Failure of the investigator to enter patients at an acceptable rate. 
• 
Insufficient adherence to protocol requirements. 
Protocol Version (3 Dec 2015) 
Page 67 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
• 
A decision on the part of the sponsor to suspend or discontinue development of iclaprim. 
In the case of study termination, all efforts should be made to conduct an Early Termination Assessment 
and follow-up of AEs as described in Section 7.5.4. 
9.10 
Final Study Report 
A clinical study report will be written to describe the results of this clinical trial. Before any data from this 
study are published on the initiative of investigator, a manuscript will be sent to the sponsor for review and 
approval at least 30 days prior to submission to the publisher. The sponsor holds all publication rights to the 
data obtained from this study. 
9.11 
Confidentiality 
All unpublished information that the sponsor gives to the investigator shall be kept confidential and shall 
not be published or disclosed to a third party without the prior written consent of the sponsor. 
When the sponsor generates reports for presentations to regulatory agencies, one or more of the 
investigators who has/have contributed significantly to the study will be asked to endorse the final report. 
The endorsement is required by some regulatory agencies. 
The investigator shall not make a patent application based on the results of this study and shall not assist 
any third party in making such an application without the written authorization of the sponsor unless 
otherwise specified in the CSA. 
9.12 
Records Retention 
All primary data, or copies thereof (eg, laboratory records, eCRFs, data sheets, correspondence, 
photographs, and computer records), which are a result of the original observations and activities of the 
study and are necessary for the reconstruction and evaluation of any study report, will be retained in the 
Covance archives. 
The results from screening and data collected during the study will be recorded in the eCRFs and/or source 
documents, as appropriate, for each patient. To maintain confidentiality, the patients will be identified by 
numbers and/or initials on the eCRFs.  
The completed, signed eCRFs will be transferred to the sponsor or designee. The signature of the 
investigator (including electronic signature, as appropriate) will designate the investigator’s review of the 
eCRFs. All source documents, records, and reports will be retained by the Covance Late Stage 
Development Services in accordance with 21 CFR 312.62(c). 
9.13 
Publications 
If on completion of the study the data warrant publication, the investigator may publish the results in 
recognized (refereed) scientific journals patient to the provisions of the CSA. Unless otherwise specified in 
the CSA, the following process shall occur: 
The institution and investigator shall not publish or present data from an individual study center until the 
complete multicenter study has been presented in full or for 2 years after the termination of the multicenter 
study, whichever occurs first. Subsequent publications must refer to the multicenter findings. Thereafter, if 
the investigator expects to participate in the publication of data generated from this site, the institution and 
investigator shall submit reports, abstracts, manuscripts and/or other presentation materials to the sponsor 
for review before submission for publication or presentation. The sponsor shall have 60 days to respond 
with any requested revisions, including without limitation, the deletion of confidential information. The 
investigator shall act in good faith upon requested revisions, except the investigator shall delete any 
confidential information from such proposed publications. The investigator shall delay submission of such 
Protocol Version (3 Dec 2015) 
Page 68 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
publication or presentation materials for up to an additional 90 days in order to have a patent application(s) 
filed. 
9.14 
Patient Injury 
In general, if a patient is injured as a direct result of the study drug, the sponsor will pay for reasonable and 
necessary medical treatment for the injury, to the extent the expenses are not covered by the patient’s 
medical insurance, a government program, or other responsible third party. If laws or regulations of the 
locality in which the trial is taking place require additional payment of expenses, the sponsor shall comply 
with such law or regulation. Where applicable, the sponsor has taken specific national insurance. 
Protocol Version (3 Dec 2015) 
Page 69 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
10. 
REFERENCES 
1. Oberg KC, Bauman JL. QT interval prolongation and torsades de pointes due to erythromycin 
lactobionate. Pharmacother. 1995;15(6):687-92. 
2. van Haarst AD, van't Klooster GA, van Gerven JM, et al. The influence of cisapride and 
clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther.1998;64(5):542-6. 
3. Henry DC, Moller DJ Jr, Adelglass J, et al. Comparison of sparfloxacin and clarithromycin in the 
treatment of acute bacterial maxillary sinusitis. Sparfloxacin Multicenter AMS Study Group. Clin 
Ther. 1999;21(2):340-52. 
4. Ramirez J, Unowsky J, Talbot GH, Zhang H, Townsend L. Sparfloxacin versus clarithromycin in 
the treatment of community-acquired pneumonia. Clin Ther. 1999;21(1):103-17. 
5. Avelox FDA Application No 21-277. 
Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. Effect of a New 
Antibacterial, Telavancin, on Cardiac Repolarization (QTc Interval Duration) in Heathy Subjects. 
J Clin Pharmacol. 2004;44(7):689-95. 
Food and Drug Administration. FDA Briefing Document Cardiovascular and Renal Drug Products 
Advisory Committee; May 29, 2003, NDA 21 -287 (alfuzosin) and NDA 21-400 (vardenafil). 
page 19, table I 7. 
6. Food and Drug Administration. Guidance for Industry: Acute Bacterial Skin and Skin Structure 
Infections: Developing Drugs for Treatment. October 2013. 
7. Open label, parallel, single dose study to investigate the pharmacokinetics of iclaprim in subjects 
with hepatic or renal dysfunction and in obese subjects. Study Iclaprim-HKI-004. Harrison 
Clinical Research GmbH, Munich, Germany. 05 February 2007. 
8. UK SmPC: Summary of product characteristics. Revised 2012. 
9. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management 
of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin 
Infect Dis. 2014;59(2):147-59. 
10. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary 
of consensus recommendations from the infectious diseases Society of America, the American 
Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin 
Infect Dis. 2009;49(3):325-7. 
11. Devabhakthuni S. Antibiotic Pharmacokinetic Monitoring. American Society of Health-System 
Pharmacists, New Practitioners Forum. 
http://www.ashp.org/DocLibrary/MemberCenter/NPF/2011Pearls/Antibiotic-Pharmacokinetic-
Monitoring.aspx. Updated May 2011. Accessed August 6, 2015. 
12. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult 
patients: a consensus review of the American Society of Health-System Pharmacists, the 
Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J 
Health Syst Pharm. 2009;66(1):82–98. 
13. Young JF, Luecke RH, Pearce BA, et al. Human organ/tissue growth algorithms that include 
obese individuals and black/white population organ weight similarities from autopsy data. J 
Protocol Version (3 Dec 2015) 
Page 70 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
Toxicol Environ Health. 2009;Part A 72:527–40. 
14. Pai M. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chron 
Kid Dis. 2010;17(5):e53–e62. 
15. Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int. 
2010;77(9):760–4. 
16. Sweeney MT, Zurenko GE. In vitro activities of linezolid combined with other antimicrobial 
agents against Staphylococci, Enterococci, Pneumococci, and selected Gram-negative organisms. 
Antimicrob Agents Chemother. 2003;47(6):1902-6. 
17. Hsu CY, Bates DW, Kuperman GJ, Curhan G. Relationship between hematocrit and renal function 
in men and women. Kidney Int. 2001;59(2):725-31. 
18. Ridge KL, Van Damia JM. PIC Question of the Week: 10/06/08. Duquesne University, Mylan 
School of Pharmacy. 
http://www.duq.edu/Documents/pharmacy/aboutus/publications/pic/08/childPughScore.pdf. 
Published October 6, 2008. Accessed August 6, 2015. 
19. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular 
carcinoma. Nat Clin Pract Oncol. 2007;4(7):424-32. 
20. Adult Antimicrobial Dosing, Non-dialysis. Infectious Diseases Management Program at 
University of California San Francisco. http://idmp.ucsf.edu/adult-antimicrobial-dosing-non-
dialysis. Accessed November 25, 2015. 
21. Dosage Guidelines for Commonly Used Antibiotics in Adults. Institut national d’excellence en 
santé et en services sociaux. https://www.inesss.qc.ca/fileadmin/doc/CDM/UsageOptimal/Guides-
serieI/CdM-Antibio1-DosageGuidelines-Adults-en.pdf. Published October 2009. Accessed 
November 25, 2015. 
22. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. National 
Institutes of Health. 
http://www.niaid.nih.gov/labsandresources/resources/daidsclinrsrch/documents/daidsaegradingtabl
e.pdf. Published December 2004. Accessed August 6, 2015. 
 
 
Protocol Version (3 Dec 2015) 
Page 71 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
11. 
APPENDICES 
APPENDIX A – CLINICAL LABORATORY EVALUATIONS 
The following clinical laboratory evaluations will be performed:  
 
Chemistry [Fasted] (Chem-20): 
Hematology (CBC): 
Albumin 
Hematocrit 
ALP 
Hemoglobin 
ALT 
MCH 
AST 
MCHC 
BUN 
MCV 
Chloride 
Platelet count  
Creatinine 
Red blood cell count 
GGT 
White blood cell count 
Glucose 
White blood cell differential 
LDH 
(% & ABS): 
Potassium 
Basophils 
Sodium 
Eosinophils 
Total Bilirubin 
Lymphocytes 
Total CO2 (measured as bicarbonate) 
Monocytes 
Total Protein 
Neutrophils 
CPK 
CRP 
 
 
Complete Urinalysis (UA): 
For females of childbearing potential: 
pH and specific gravity 
Serum Pregnancy Test  
Glucose 
Urine Pregnancy Test (alternative until serum 
pregnancy test results are verified) 
Ketones  
 
Occult blood  
 
Protein  
 
Microscopic examination of sediment 
(including RBCs and WBCs) 
 
Bilirubin/urobilinogen  
 
 
 
Protocol Version (3 Dec 2015) 
Page 72 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
APPENDIX B – DIGITAL PHOTOGRAPHIC PROCEDURES 
 
SERIAL PHOTOGRAPHIC DOCUMENTATION OF INFECTION SITES 
Locations: 
 
ID card and color card: 
 
 
 
 
2 each 
 
Anatomical view of the infection site(s): 
 
 
2 each 
Equipment: 
 
 
Canon EOS D-SLR w/ Ranging Lights 
 
Color Card/Patient ID Holder 
 
Standardized Background Material 
Procedures:  
In these clinical photographs, for the duration of the study, the only variable allowed to change is the skin 
condition itself. Therefore, anything extraneous to the condition (clothing, jewelry, bandages, etc.) is to be 
eliminated from the photographic field from the entry visit through the final visit. The necessity of good 
photos (taken at baseline, ETP, EOT, and TOC) should be stressed to the patients to ensure their 
cooperation. Lighting, framing, exposure and reproduction ratios must be held constant. In the end, the 
pictures should read like a time-lapse movie. 
1. The supplied equipment is to be used exclusively for this study. No modification, adjustments, or 
repairs of the camera equipment is to be undertaken without the expressed instruction of Canfield 
Scientific, Inc. 
2. The supplied standardized background material is to be used. Folded or wrinkled material is not 
allowed. 
3. Magnification: the ranging lights on the macro ring flash are set to predefined distance to ensure 
consistency of reproduction ratio. Once the two lights converge as one, the target image is at the 
correct distance. If there is any doubt as to the correctness of photographic technique, a re-shoot is 
encouraged at that time. 
4. Each photographic session includes an exposure series of: 
a. 
Patient ID, which will include the following legible information in black indelible ink. 
(2 exposures) 
 
 
 
Protocol No. 
 
 
 
Image Date 
 
 
 
Center Number 
 
 
 
Visit Name 
 
 
 
Patient Initials 
Protocol Version (3 Dec 2015) 
Page 73 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
 
 
 
Patient ID Number 
 
 
 
Photographer’s Initials 
 
 
 
Color Card 
b. Anatomical view of the patient’s infection site (2 exposures) 
5. A secure, validated, and compliant web server set up at Canfield is used for secure transfer of 
study images by study sites. Images are to be transferred the day recorded. Remote access to all 
images by the Sponsor is also provided. Only approved individuals by Sponsor have access to the 
website.  
Canfield is to provide each study site with the necessary hardware, consumables and instructions 
to acquire consistent serial imaging. Technical support is available as needed. 
6. All supplied photographic equipment and photographic originals remain the property of the 
Sponsor. Any questions or problems regarding the photographic portion of this protocol are to be 
forwarded to the Project Manager at Canfield Scientific. 
 
 
Canfield Scientific, Inc. 
 
 
253 Passaic Avenue 
 
 
Fairfield, NJ 07004 
 
 
Toll Free: +1 800 815-4375 
 
 
Telephone: +1 973 276-0300 
 
 
Facsimile: +1 973 276-0333 
 
 
 
Protocol Version (3 Dec 2015) 
Page 74 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
APPENDIX C – TRACING & PLANIMETRY PROCEDURES 
 
The following procedures are to be followed to ensure accurate area measurements are achieved at each 
visit during the study. 
 
Standard Supplies 
 
Tracing Media:  
Sterilized double layer clear plastic acetate tracing film with cardboard backer 
Tracing Pens: 
   
Itoya FinePoint, permanent ink, 0.5mm 
Tracing Envelope: 
Preprinted protective envelope for shipping 
 
1. Tracings of ABSSSI site are conducted at: baseline, ETP, EOT, and TOC. 
2. All required patient demographic information is to be recorded on tracing film header. Both films 
are to be peeled away from the cardboard backer and placed face-up over the patient’s infection 
site. Tracing of the infection site is to be accomplished with the supplied Itoya tracing pen using a 
continuous stroke. 
3. The traced edge must be dark and continuous with no broken ink line. 
4. The following ABSSSI demarcations are made: 
a. 
Erythema (red pen) 
b. Induration (green pen) 
c. 
Wound (black pen), if necessary 
5. The top film is to be peeled from the bottom film and placed back onto the cardboard backer. The 
bottom film that came into contact with the infection site is to be discarded as biomedical waste at 
the study site. 
6. The top film containing the actual tracing and header information is to be attached to the “waxy” 
side of the cardboard backer.  
7. The tracing is scanned on a supplied flatbed scanner and the scan uploaded to Canfield’s secure 
website for instant image analysis.  
8. The Canfield planimetry application automatically detects the outlines of each of the colored 
demarcations contained on the tracing, and measures each demarcation for area (cm2).  
9. A QC technician performs quality control of the detection and data generated. 
 
 
 
Protocol Version (3 Dec 2015) 
Page 75 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
APPENDIX D – VANCOMYCIN DOSING NOMOGRAM 
Both iclaprim and vancomycin will be diluted in 500 mL of normal saline and infused over 2 hours. Dosing 
interval for iclaprim will be q12h. Dosing interval for vancomycin will be every q12h, q24h, q48h, or dosed 
by daily level based on creatinine clearance. Patients randomized to vancomycin who require dosing 
intervals of q24h, q48h, or dosed by daily level due to renal impairment will receive dummy infusions 
(normal saline) at 12 hour intervals when they are not to receive vancomycin. 
 
Intervals based on renal clearance [11]: 
 
Creatinine Clearance (mL/min) 
Dosing Interval (hours) 
≥ 75 
Q12H 
50-74 
Q12H 
35-49 
Q24H 
25-34 
Q48H 
< 25 
Dose by daily level 
Intermittent Hemodialysis  
Dose after dialysis 
CRRT 
Q24H 
Abbreviations: CRRT = continuous renal replacement therapy; QnH=every n hours 
 
Cockcroft -Gault equation based on actual body weight [17]: 
 
 
 
Protocol Version (3 Dec 2015) 
Page 76 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
 
 
 
Protocol Version (3 Dec 2015) 
Page 77 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
APPENDIX E – CHILD-PUGH SCORING SYSTEM 
Child-Pugh Scoring System [18, 19]: 
 
Severity Score 
Clinical Marker 
1 point 
2 points 
3 points 
Bilirubin (mg/dL) 
1-2 
2.1-3 
≥3.1 
Albumin (g/dL) 
≥3.5 
2.8-3.4 
≤2.7 
Prothrombin Time Or 
INR 
1-4 
<1.7 
4.1-6 
1.7-2.3 
≥6.1 
>2.3 
Ascites 
None 
Mild 
Moderate 
Encephalopathy 
None 
1 or 2 
3 or 4 
Grade A = 5 to 6 points 
Grade B = 7 to 9 points 
Grade C = 10 to 15 points 
 
 
Protocol Version (3 Dec 2015) 
Page 78 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
APPENDIX F – SHORT-ACTING SYSTEMIC ANTIBIOTICS ACTIVE 
AGAINST GRAM-POSITIVE PATHOGENS 
 
A short acting systemic antibiotic is defined as an antibiotic dosed q12h or less. 
 
The following is a list of short-acting systemic antibiotics active against Gram-positive pathogens [20,21]: 
 
• 
Amoxicillin 
• 
Amoxicillin-clavulanate potassium 
• 
Ampicillin 
• 
Ampicillin/sulbactam 
• 
Cefadroxil 
• 
Ceftaroline 
• 
Cefazolin 
• 
Cefepime 
• 
Cefprozil 
• 
Ceftazidime 
• 
Cefuroxime axetil 
• 
Cephalexin 
• 
Ciprofloxacin 
• 
Clarithromycin 
• 
Clindamycin 
• 
Doxycycline 
• 
Linezolid 
• 
Meropenem 
• 
Minocycline 
• 
Nafcillin 
• 
Norfloxacin 
• 
Ofloxacin 
• 
Penicillin  
• 
Piperacillin/ tazobactam 
• 
Trimethorpim-sulfamethoxazole 
• 
Trimethoprim 
 
Protocol Version (3 Dec 2015) 
Page 79 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
APPENDIX G – TABLE FOR GRADING THE SEVERITY OF LABORATORY ADVERSE EVENTS 
Table for Grading the Severity of Laboratory Adverse Events [22]: 
PARAMETER 
GRADE 1 
GRADE 2 
GRADE 3 
GRADE 4 
MILD 
MODERATE 
SEVERE 
POTENTIALLY 
LIFE-THREATENING 
HEMATOLOGY 
Standard International Units are listed in italics 
 
Absolute CD4+ count 
300 – 400/mm3 
200 – 299/mm3 
100 – 199/mm3 
< 100/mm3 
(HIV NEGATIVE ONLY) 
300 – 400/µL 
200 – 299/µL 
100 – 199/µL 
< 100/µL 
Absolute lymphocyte 
600 – 650/mm3 
500 – 599/mm3 
350 – 499/mm3 
< 350/mm3 
count 
0.600 x 109 – 
0.500 x 109 – 
0.350 x 109 – 
< 0.350 x 109/L 
(HIV NEGATIVE ONLY) 
0.650 x 109/L 
0.599 x 109/L 
0.499 x 109/L 
 
Absolute neutrophil count (ANC) 
1,000 – 1,300/mm3 
750 – 999/mm3 
500 – 749/mm3 
< 500/mm3 
1.000 x 109 – 
0.750 x 109 – 
0.500 x 109 – 
< 0.500 x 109/L 
1.300 x 109/L 
0.999 x 109/L 
0.749 x 109/L 
Fibrinogen, decreased 
100 – 200 mg/dL 
75 – 99 mg/dL 
50 – 74 mg/dL 
< 50 mg/dL 
1.00 – 2.00 g/L 
0.75 – 0.99 g/L 
0.50 – 0.74 g/L 
< 0.50 g/L 
OR 
OR 
OR 
OR 
0.75 – 0.99 x LLN 
0.50 – 0.74 x LLN 
0.25 – 0.49 x LLN 
< 0.25 x LLN 
OR 
Associated with gross 
bleeding 
Hemoglobin (Hgb) 
(HIV POSITIVE 
8.5 – 10.0 g/dL 
7.5 – 8.4 g/dL 
6.50 – 7.4 g/dL 
< 6.5 g/dL 
ONLY) 
1.32 – 1.55 mmol/L 
1.16 – 1.31 mmol/L 
1.01 – 1.15 mmol/L 
< 1.01 mmol/L 
(HIV NEGATIVE 
10.0 – 10.9 g/dL 
9.0 – 9.9 g/dL 
7.0 – 8.9 g/dL 
< 7.0 g/dL 
ONLY) 
1.55 – 1.69 mmol/L 
1.40 – 1.54 mmol/L 
1.09 – 1.39 mmol/L 
< 1.09 mmol/L 
 
OR 
OR 
OR 
 
Any decrease 
Any decrease 
Any decrease 
2.5 – 3.4 g/dL 
3.5 – 4.4 g/dL 
≥ 4.5 g/dL 
0.39 – 0.53 mmol/L 
0.54 – 0.68 mmol/L 
 0.69 mmol/L 
 
 
Protocol Version (3 Dec 2015) 
Page 80 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
PARAMETER 
GRADE 1 
GRADE 2 
GRADE 3 
GRADE 4 
MILD 
MODERATE 
SEVERE 
POTENTIALLY 
LIFE-THREATENING 
International Normalized 
1.1 – 1.5 x ULN 
1.6 – 2.0 x ULN 
2.1 
– 3.0 x ULN 
> 3.0 x ULN 
Ratio of prothrombin time 
(INR) 
Methemoglobin 
5.0 – 10.0% 
10.1 – 15.0% 
15.1 – 20.0% 
> 20.0% 
Prothrombin Time (PT) 
1.1 – 1.25 x ULN 
1.26 – 1.50 x ULN 
1.51 – 3.00 x ULN 
> 3.00 x ULN 
Partial Thromboplastin 
1.1 – 1.66 x ULN 
1.67 – 2.33 x ULN 
2.34 – 3.00 x ULN 
> 3.00 x ULN 
Time (PTT) 
Platelets, decreased 
100,000 – 
50,000 – 
25,000 – 
< 25,000/mm3 
124,999/mm3 
99,999/mm3 
49,999/mm3 
< 25.000 x 109/L 
100.000 x 109 – 
50.000 x 109 – 
25.000 x 109 – 
124.999 x 109/L 
99.999 x 109/L 
49.999 x 109/L 
WBC, decreased 
2,000 – 2,500/mm3 
1,500 – 1,999/mm3 
1,000 – 1,499/mm3 
< 1,000/mm3 
2.000 x 109 – 
1.500 x 109 – 
1.000 x 109 – 
< 1.000 x 109/L 
2.500 x 109/L 
1.999 x 109/L 
1.499 x 109/L 
CHEMISTRIES 
Standard International Units are listed in italics 
Acidosis 
NA 
pH < normal, but ≥ 7.3 
pH < 7.3 without life- 
pH < 7.3 with life- 
threatening 
threatening 
consequences 
consequences 
Albumin, serum, low 
3.0 g/dL – < LLN 
2.0 – 2.9 g/dL 
< 2.0 g/dL 
NA 
30 g/L – < LLN 
20 – 29 g/L 
< 20 g/L 
Alkaline Phosphatase 
1.25 – 2.5 x ULN† 
2.6 – 5.0 x ULN† 
5.1 – 10.0 x ULN† 
> 10.0 x ULN† 
Alkalosis 
NA 
pH > normal, but ≤ 7.5 
pH > 7.5 without life- 
pH > 7.5 with life- 
threatening 
threatening 
consequences 
consequences 
ALT (SGPT) 
1.25 – 2.5 x ULN 
2.6 – 5.0 x ULN 
5.1 – 10.0 x ULN 
> 10.0 x ULN 
AST (SGOT) 
1.25 – 2.5 x ULN 
2.6 – 5.0 x ULN 
5.1 – 10.0 x ULN 
> 10.0 x ULN 
 
 
Protocol Version (3 Dec 2015) 
Page 81 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
PARAMETER 
GRADE 1 
GRADE 2 
GRADE 3 
GRADE 4 
MILD 
MODERATE 
SEVERE 
POTENTIALLY 
LIFE-THREATENING 
Bicarbonate, serum, low 
16.0 mEq/L – < LLN 
11.0 – 15.9 mEq/L 
8.0 – 10.9 mEq/L 
< 8.0 mEq/L 
 
16.0 mmol/L – < LLN 
11.0 – 15.9 mmol/L 
8.0 – 10.9 mmol/L 
< 8.0 mmol/L 
 
Bilirubin (Total) 
1.1 – 1.5 x ULN 
1.6 – 2.5 x ULN 
2.6 – 5.0 x ULN 
> 5.0 x ULN 
Calcium, serum, high (corrected for 
albumin) 
10.6 – 11.5 mg/dL 
11.6 – 12.5 mg/dL 
12.6 – 13.5 mg/dL 
> 13.5 mg/dL 
 
2.65 – 2.88 mmol/L 
2.89 – 3.13 mmol/L 
3.14 – 3.38 mmol/L 
> 3.38 mmol/L 
Calcium, serum, low (corrected for 
albumin) 
7.8 – 8.4 mg/dL 
7.0 – 7.7 mg/dL 
6.1 – 6.9 mg/dL 
> 6.1 mg/dL 
 
1.95 – 2.10 mmol/L 
1.75 – 1.94 mmol/L 
1.53 – 1.74 mmol/L 
> 1.53 mmol/L 
Cardiac troponin I (cTnI) 
NA 
NA 
NA 
Levels consistent with 
myocardial infarction 
or unstable angina as 
defined by the 
manufacturer 
Cardiac troponin T (cTnT) 
NA 
NA 
NA 
≥ 0.20 ng/mL 
OR 
Levels consistent with 
myocardial infarction 
or unstable angina as 
defined by the 
manufacturer 
Cholesterol (fasting) 
200 – 239 mg/dL 
240 – 300 mg/dL 
> 300 mg/dL 
NA 
 
5.18 – 6.19 mmol/L 
6.20 – 7.77 mmol/L 
> 7.77 mmol/L 
Creatine Kinase 
3.0 – 5.9 x ULN† 
6.0 – 9.9 x ULN† 
10.0 – 19.9 x ULN† 
≥ 20.0 x ULN† 
Creatinine 
1.1 – 1.3 x ULN† 
1.4 – 1.8 x ULN† 
1.9 – 3.4 x ULN† 
≥ 3.5 x ULN† 
Glucose, serum, high 
Nonfasting 
116 – 160 mg/dL 
161 – 250 mg/dL 
251 – 500 mg/dL 
> 500 mg/dL 
 
6.44 – 8.88 mmol/L 
8.89 – 13.88 mmol/L 
13.89 – 27.75 mmol/L 
> 27.75 mmol/L 
 
Fasting 
110 – 125 mg/dL 
126 – 250 mg/dL 
251 – 500 mg/dL 
> 500 mg/dL 
 
6.11 – 6.94 mmol/L 
6.95 – 13.88 mmol/L 
13.89 – 27.75 mmol/L 
> 27.75 mmol/L 
 
Protocol Version (3 Dec 2015) 
Page 82 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
PARAMETER 
GRADE 1 
GRADE 2 
GRADE 3 
GRADE 4 
MILD 
MODERATE 
SEVERE 
POTENTIALLY 
LIFE-THREATENING 
Glucose, serum, low 
55 – 64 mg/dL 
40 – 54 mg/dL 
30 – 39 mg/dL 
< 30 mg/dL 
 
3.05 – 3.55 mmol/L 
2.22 – 3.06 mmol/L 
1.67 – 2.23 mmol/L 
< 1.67 mmol/L 
Lactate 
< 2.0 x ULN without 
≥ 2.0 x ULN without 
Increased lactate with 
Increased lactate with 
acidosis 
acidosis 
pH < 7.3 without life- 
pH < 7.3 with life- 
threatening 
threatening 
consequences 
consequences 
LDL cholesterol (fasting) 
130 – 159 mg/dL 
160 – 190 mg/dL 
≥ 190 mg/dL 
NA 
 
3.37 – 4.12 mmol/L 
4.13 – 4.90 mmol/L 
 4.91 mmol/L 
 
Lipase 
1.1 – 1.5 x ULN 
1.6 – 3.0 x ULN 
3.1 – 5.0 x ULN 
> 5.0 x ULN 
Magnesium, serum, low 
1.2 – 1.4 mEq/L 
0.9 – 1.1 mEq/L 
0.6 – 0.8 mEq/L 
< 0.60 mEq/L 
0.60 – 0.70 mmol/L 
0.45 – 0.59 mmol/L 
0.30 – 0.44 mmol/L 
< 0.30 mmol/L 
Pancreatic amylase 
1.1 – 1.5 x ULN 
1.6 – 2.0 x ULN 
2.1 – 5.0 x ULN 
> 5.0 x ULN 
Phosphate, serum, low 
2.5 mg/dL – < LLN 
2.0 – 2.4 mg/dL 
1.0 – 1.9 mg/dL 
< 1.00 mg/dL 
 
0.81 mmol/L – < LLN 
0.65 – 0.80 mmol/L 
0.32 – 0.64 mmol/L 
< 0.32 mmol/L 
Potassium, serum, high 
5.6 – 6.0 mEq/L 
6.1 – 6.5 mEq/L 
6.6 – 7.0 mEq/L 
> 7.0 mEq/L 
5.6 – 6.0 mmol/L 
6.1 – 6.5 mmol/L 
6.6 – 7.0 mmol/L 
> 7.0 mmol/L 
Potassium, serum, low 
3.0 – 3.4 mEq/L 
2.5 – 2.9 mEq/L 
2.0 – 2.4 mEq/L 
< 2.0 mEq/L 
3.0 – 3.4 mmol/L 
2.5 – 2.9 mmol/L 
2.0 – 2.4 mmol/L 
< 2.0 mmol/L 
Sodium, serum, high 
146 – 150 mEq/L 
151 – 154 mEq/L 
155 – 159 mEq/L 
≥ 160 mEq/L 
146 – 150 mmol/L 
151 – 154 mmol/L 
155 – 159 mmol/L 
 160 mmol/L 
Sodium, serum, low 
130 – 135 mEq/L 
125 – 129 mEq/L 
121 – 124 mEq/L 
≤ 120 mEq/L 
130 – 135 mmol/L 
125 – 129 mmol/L 
121 – 124 mmol/L 
 120 mmol/L 
Triglycerides (fasting) 
NA 
500 – 750 mg/dL 
751 – 1,200 mg/dL 
> 1,200 mg/dL 
5.65 – 8.48 mmol/L 
8.49 – 13.56 mmol/L 
> 13.56 mmol/L 
Uric acid 
7.5 – 10.0 mg/dL 
10.1 – 12.0 mg/dL 
12.1 – 15.0 mg/dL 
> 15.0 mg/dL 
0.45 – 0.59 mmol/L 
0.60 – 0.71 mmol/L 
0.72 – 0.89 mmol/L 
> 0.89 mmol/L 
 
 
Protocol Version (3 Dec 2015) 
Page 83 of 84 
CONFIDENTIAL 
 


Motif BioSciences 
Clinical Protocol 
Protocol/Amendment No.: 
Iclaprim 
ICL-23-ABSSSI1-01 
 
PARAMETER 
GRADE 1 
GRADE 2 
GRADE 3 
GRADE 4 
MILD 
MODERATE 
SEVERE 
POTENTIALLY 
LIFE-THREATENING 
URINALYSIS 
Standard International Units are listed in italics 
Hematuria (microscopic) 
6 – 10 RBC/HPF 
> 10 RBC/HPF 
Gross, with or without 
Transfusion indicated 
 
clots OR with RBC 
 
casts 
 
Proteinuria, random 
1 + 
2 – 3 + 
4 + 
NA 
collection 
 
Proteinuria, 24 hour collection 
200 – 999 mg/24 h 
1,000 – 1,999 mg/24 h 
2,000 – 3,500 mg/24 h 
> 3,500 mg/24 h 
0.200 – 0.999 g/d 
1.000 – 1.999 g/d 
2.000 – 3.500 g/d 
> 3.500 g/d 
† Use age and sex appropriate values (e.g., bilirubin). 
 
Protocol Version (3 Dec 2015) 
Page 84 of 84 
CONFIDENTIAL 
 

SAP_001.pdf: 
COVANCE INC. CONFIDENTIAL 
Page 1 of 33 
ST-AD-008 version 03
Motif BioSciences 
Protocol No.: ICL-23-ABSSSI1 
A Phase 3, randomized double-blind, multicenter study to evaluate the safety and efficacy of 
intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure 
infections suspected or confirmed to be due to Gram-positive pathogens. (REVIVE-1) 
Covance Study ID: 000000145416 
STATISTICAL ANALYSIS PLAN 
Final Amendment 2.0 
Date of Issue: 23 March 2017 
Author: Alyssa Liu 
Motif BioSciences 
Covance Clinical Development Services 
125 Park Avenue, 25th Floor, Suite 2622
New York, NY 10017 
206 Carnegie Center 
Princeton, NJ 08540 




Statistical Analysis Plan 
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
Covance Study ID: 000000145416 
COVANCE INC. CONFIDENTIAL 
Page 3 of 33 
ST-AD-008 version 02
VERSION HISTORY 
Version Number Version Date 
Summary and rational of change(s) 
Final 1.0 
17-Aug-2016 
Amendment 1.0 
12-Jan-2017 
Section 2.3 (Sample Size and Power) 
• Revised power assumption related to TOC visit.
Section 3.2 (Secondary Efficacy Endpoints) 
• The order of PP population and mCE population was changed.
•Two definitions of “Persistent Infection” and “Recurrent
Infection” were added when defining clinical failure. 
Section 5 (Analysis Population) 
• The order of PP population and mCE population was changed.
Section 6.2 (Handling of Dropouts or Missing Data) 
• Added mITT efficacy analyses for primary endpoint, while
patients who do not have an adequate assessment at the
appropriate visit assumed as non-responders.
Section 7.2 (Patient Disposition and Data Sets Analysed) 
• The order of PP population and mCE population was changed.
Section 7.4 (Demographics and Other Baseline Characteristics) 
• The order of PP population and mCE population was changed.
• Added two demographic variables, diabetes (present or absent)
and geographic region (US vs ex-US).
Section 7.7 (Measurements of Treatment Compliance and Exposure) 
• Clarify the treatment is started in the AM and completed in the
PM when patients are administered with iclaprim q12h for 5 to
14 days.
Section 7.8.2.2 (Time to Resolution of Signs and Symptoms of 
ABSSSI) 
• The order of PP population and mCE population was changed.
Section 7.8.3 (Exploratory Analysis) 
• For primary endpoint, added exploratory analysis for ITT
population with ≥50%, ≥75%, and ≥90% reduction in lesion size 
at ETP compared from baseline. 
• For the secondary endpoint of resolution or near resolution of
ABSSSI at EOT and TOC, added exploratory analysis for ITT
population with at least 50% and at least 75% reduction in lesion
size at both EOT and TOC compared from baseline.
• If it is concluded that Iclaprim is non-inferior to Vancomycin
(i.e., the lower bound of two-sided 95% confidence interval of
group difference in early clinical response is greater than -0.1), it
may be concluded that Iclaprim is superior to Vancomycin if the
entire 95% confidence interval is >0. Superiority may also be


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 4 of 33 
ST-AD-008 version 02 
Version Number Version Date 
Summary and rational of change(s) 
concluded for resolution of ABSSSI at TOC in a similar manner. 
Section 7.8.4 (Subgroup Analysis) 
• Added two demographic variables for subgroup analysis: 
diabetes (present or absent) and geographic region (US vs ex-
US). 
Section 7.9.1 (Adverse Events) 
• Added another summary of TEAEs by diabetes (present or 
absent). 
• Added the definition of SAE. 
Section 7.9.2 (Laboratory Evaluations) 
• Parameter of CRP was updated from category of haematology to 
chemistry. 
Section 7.10 (Interim Analysis) 
• Clarified analysis for the primary endpoint under blinded interim 
data was using at least 20% reduction in lesion size at ETP when 
compared to baseline visit. 
Section 7.10.2 (Laboratory Evaluations) 
• Add another kind of shift table between baseline and post-
baseline change, only applied for liver enzyme and renal function 
tests. 
Amendment 1.0 
15–Feb-2017 
Table 1 Summary of Assessments was deleted.  Same information is 
given in the text and it is a copy from protocol. 
 
 
Section 4 (Pharmacokinetics/ Pharmacodynamics Variables) 
 Deleted “After the study is complete, the database locked, and 
the data unblinded, patients randomized to iclaprim will have 
their samples assayed.” 
 
 
Section 5 (Analysis Population) 
 Added details to Per Protocol population definition. 
 Table 1 reformatted to separate protocol deviation types that 
would exclude a patient from some visits and visits from 
deviation types that excludes a patient from all visits. 
 Deleted Type I A and Type III antiarrhythmic drugs from list 
of prohibited medications that would exclude a patient from 
per protocol analysis. 
 Added mITT subpopulation, strep-enriched mITT for 
exploratory analysis. 
 Added PP population for EMA analysis. 
 
 
Section 5.6.1 Important Protocol Deviations Leading to Exclusion 
from the mPP Analysis. 
 This section was deleted because it provides some 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 5 of 33 
ST-AD-008 version 02 
Version Number Version Date 
Summary and rational of change(s) 
information as in PP population. 
 
 
Section 6.1 (Time Points and Visit Widows) 
 Baseline for microbiology analysis was added. 
 
 
7.4 (Demographic and Other Baseline Characteristics) 
 Blood culture at baseline was defined; Geographic region 
subgroups were revised;  
 Geographic region subgroups were revised 
 
 
7.9.2 (Secondary Efficacy Analysis) 
 Added S. pyogenes-enriched mITT population and PP 
population for EMA to repeat the primary efficacy analysis.  
 
 
7.9.2.1 (Resolution or Near Resolution of ABSSSI) 
 Added S. pyogenes-enriched mITT at TOC to the analysis 
 
 
7.9.2.2 (Signs and Symptoms of ABSSSI) 
 Descriptive summary statistics for signs and symptoms will 
be limited to baseline display only. 
 
 
7.9.2.3 (Bacteriological response) 
 By-pathogen and by-patient bacteriological outcome section 
were moved from Section 3 to this section. 
 Added more description of analyses.  
 Added summary of MIC frequency and interpretation. 
 
 
7.10.1  (Adverse Events) 
 Treatment-emergent adverse event definition was clarified. 
Amendment 2.0 
10–Mar-2017 6.1 
(Time Points and Visit Windows) 
 Added definition of baseline for microbiology data. 
 
 
6.2 
(Handling of Dropouts or Missing Data) 
 Deleted general principle for imputing dates and clarified the 
imputing details refer to mockup. 
 
 
7.6 
(Prior and Concomitant Medications) 
 Added the definition of prior medication. 
 
 
7.9.2.2  (Signs and Symptoms of ABSSSI) 
 Clarified patients are free of specific signs or symptoms at 
baseline should be out of that time-to-event analysis. 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 6 of 33 
ST-AD-008 version 02 
Version Number Version Date 
Summary and rational of change(s) 
 
 
7.9.3  (Exploratory Analysis) 
 Revised the definition for one exploratory analysis and added 
another exploratory analysis. 
 
 
7.10.1  (Adverse Events) 
 Treatment-emergent adverse event definition was clarified. 
 
 
 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 7 of 33 
ST-AD-008 version 02 
TABLE OF CONTENTS 
APPROVALS ............................................................................................................................................... 2 
VERSION HISTORY .................................................................................................................................. 3 
GLOSSARY OF ABBREVIATIONS ......................................................................................................... 9 
1 SOURCE DOCUMENTS .................................................................................................................... 11 
2 PROTOCOL DETAILS ...................................................................................................................... 11 
2.1 Study Objectives .......................................................................................................................... 11 
2.2 Overall Study Design .................................................................................................................. 11 
2.3 Sample Size and Power ............................................................................................................... 12 
3 EFFICACY AND SAFETY VARIABLES ........................................................................................ 14 
3.1 Primary Efficacy Endpoint ........................................................................................................ 14 
3.2 Secondary Efficacy Endpoints ................................................................................................... 14 
3.3 Safety Variables ........................................................................................................................... 15 
4 PHARMACOKINETIC/PHARMACODYNAMIC VARIABLES ................................................. 15 
5 ANALYSIS POPULATIONS .............................................................................................................. 15 
5.1 Safety Population ........................................................................................................................ 15 
5.2 Intent-to-treat (ITT) population ................................................................................................ 15 
5.3 Microbiological intent-to-treat (mITT) population ................................................................. 15 
5.4 Per Protocol (PP) Population ..................................................................................................... 16 
5.4.1 Important Protocol Deviations Leading to Exclusion from the PP Analysis .................... 16 
5.5 Modified clinically evaluable (mCE) population ...................................................................... 18 
5.6 PP microbiological evaluable (mPP) population ...................................................................... 18 
5.7 S. pyogenes-enriched mITT  (S. pyogenes mITT) population ................................................. 18 
5.8 PP population for EMA sensitivity analysis ............................................................................. 18 
6 DATA HANDLING ............................................................................................................................. 18 
6.1 Time Points and Visit Windows ................................................................................................. 18 
6.2 Handling of Dropouts or Missing Data ..................................................................................... 19 
7 STATISTICAL METHODS ............................................................................................................... 19 
7.1 General Principles ....................................................................................................................... 19 
7.2 Patient Disposition and Data Sets Analyzed ............................................................................. 20 
7.3 Protocol Deviations ..................................................................................................................... 20 
7.4 Demographics and Other Baseline Characteristics ................................................................. 20 
7.5 Medical History ........................................................................................................................... 21 
7.6 Prior and Concomitant Medications ......................................................................................... 21 
7.7 Significant Procedures ................................................................................................................ 22 
7.8 Measurements of Treatment Compliance and Exposure ........................................................ 22 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 8 of 33 
ST-AD-008 version 02 
7.9 Efficacy ......................................................................................................................................... 22 
7.9.1 Primary Efficacy Analysis ................................................................................................ 22 
7.9.2 Secondary Efficacy Analysis ............................................................................................ 22 
7.9.3 Exploratory Analysis ......................................................................................................... 24 
7.9.4 Subgroup Analysis ............................................................................................................ 25 
7.10 Safety ............................................................................................................................................ 26 
7.10.1 Adverse Events.................................................................................................................. 26 
7.10.2 Laboratory Evaluations ..................................................................................................... 27 
7.10.3 Vital Signs ......................................................................................................................... 28 
7.10.4 Electrocardiograms ........................................................................................................... 28 
7.10.5 Physical Examination ........................................................................................................ 29 
7.11 Interim Analysis .......................................................................................................................... 29 
8 REFERENCES ..................................................................................................................................... 29 
9 APPENDICES ...................................................................................................................................... 30 
Appendix A – Prohibited Medicines ................................................................................................... 30 
Appendix B – Schedule of Events ....................................................................................................... 31 
Appendix C – Table, Figure and Listing Shells ................................................................................. 33 
 
TABLES: 
Table 1: Important Protocol Deviations Leading to Exclusion from the PP population ............................. 17 
Table 2: Laboratory Evaluations .................................................................................................................. 27 
 
FIGURES: 
Figure 1: Study Design ................................................................................................................................ 13 
 
 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 9 of 33 
ST-AD-008 version 02 
GLOSSARY OF ABBREVIATIONS 
Abbreviation 
Term 
ABSSSI 
acute bacterial skin and skin structure infection  
AE 
adverse event 
ALP 
alkaline phosphatase  
ALT 
alanine aminotransferase  
ASO 
anti-streptolysin O 
AST 
aspartate aminotransferase  
ATC 
Anatomical Therapeutic Chemical  
BMI 
Body Mass Index  
BUN 
blood urea nitrogen  
CBC 
complete blood count  
CCLS 
Covance Central Laboratory Services 
CI 
confidence interval  
CO2 
carbon dioxide  
CPK 
creatine phosphokinase  
CrCL 
creatinine clearance 
CRF 
case report form 
CRP 
C-reactive protein  
CTMS 
Clinical Trial Management System 
CV 
Conventional units for laboratory results 
ECG 
Electrocardiogram  
eCRF 
electronic case report form  
EOT 
End of Therapy  
EMA 
European Medicines Agency 
ETP 
early timepoint  
GGT 
gamma glutamyl transferase  
hCG 
beta-human chorionic gonadotropin 
ITT 
intent-to-treat  
IXRS 
Interactive Phone and Web Response System 
LDH 
lactate dehydrogenase  
LFT 
Liver Function Test  
LFU 
Late Follow-Up  
MCH 
mean corpuscular hemoglobin  
MCHC 
mean corpuscular hemoglobin concentration  
MCV 
mean corpuscular volume  
MedDRA 
Medical Dictionary for Regulatory Activities  
MIC 
minimum inhibitory concentration 
MRSA 
Methicillin-resistant Staphylococcus aureus 
MSSA 
Methicillin-sensitive Staphylococcus aureus 
mCE 
Modified clinically evaluable population  
mITT 
microbiological intent-to-treat  
mPP 
Per-protocol microbiologically evaluable population  
N 
analysis population 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 10 of 33 
ST-AD-008 version 02 
Abbreviation 
Term 
NI 
non-inferiority  
PK 
pharmacokinetic 
PP 
Per-protocol population 
PT 
Preferred Term  
Q12h 
every 12 hours  
QTc 
QT interval corrected for heart rate  
QTcB 
QTc corrected according to Bazett  
QTcF 
QTc corrected according to Fridericia  
RBC 
red blood cell  
SAE 
serious adverse event  
SCr 
serum creatinine  
SD 
standard deviation 
SI Units 
International System of Units 
SOC 
system organ class (MedDRA classification)  
TEAE 
treatment-emergent adverse event 
TFLs 
Tables, Figures and Listings  
TOC 
Test of Cure  
UA 
Urinalysis  
WBC 
white blood cells  
 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 11 of 33 
ST-AD-008 version 02 
1 
SOURCE DOCUMENTS 
The Statistical Analysis Plan (SAP) was written based on the following documentation: 
Document 
Date 
Version 
Protocol 
21 Oct 2015 
Final 1.0 
Protocol Amendment 1 
3 Dec 2015 
Amendment 1.0 
eCRF 
3 Feb 2016 
Production 3.0 
2 
PROTOCOL DETAILS 
2.1 Study Objectives 
Primary Objective: 
The primary objective of this study is to demonstrate that iclaprim is non-inferior to vancomycin in 
achieving a ≥20% reduction in lesion size at 48 to 72 hours (early timepoint, ETP) compared to baseline 
in all randomized patients (intent-to-treat, ITT). 
Secondary Objectives: 
The secondary objectives of this study are to demonstrate non-inferiority of iclaprim compared to 
vancomycin in the ITT, microbiological ITT (mITT), modified clinically evaluable (mCE), per protocol 
(PP), and microbiological PP (mPP) populations for the following: 
1. Resolution or near resolution of acute bacterial skin and skin structure infection (ABSSSI) 
(clinical cure, defined by a ≥90% reduction in lesion size from the size at baseline, no increase in 
lesion size since ETP, and no requirement for additional antibiotics [except aztreonam and 
metronidazole] or unplanned significant surgical procedures after ETP other than bedside wound 
care) at Test of Cure (TOC) visit (7 to14 days after the end of treatment); 
2. Resolution or near resolution (≥90%) of ABSSSI at End of Therapy (EOT); 
3. Resolution or near resolution (≥90%) of ABSSSI at EOT and TOC among patients with severe 
infection at baseline defined by meeting one or more of the following criteria: 
a. fulfilled the published definition for systemic inflammatory response syndrome (SIRS) by 
having ≥2 of the following findings: body temperature >38°C or <36°C, heart rate 
>90 bpm, respiration rate >20 breaths/minute, and WBC >12000/mm3 or <4000/mm3 or 
>10% bands; 
b. Evaluated as having severe tenderness or severe erythema at the infection site; or 
c. Positive blood cultures at baseline. 
4. Time to resolution of systemic and local signs and symptoms of ABSSSI. 
Additional secondary objectives are to: 
5. Assess microbiological outcome in the mITT, mCE, and mPP populations at EOT and TOC; 
6. Establish the pharmacokinetic (PK) profile for iclaprim using population pharmacokinetics; and 
7. Establish the safety profile of iclaprim in patients with ABSSSI. 
2.2 Overall Study Design 
This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to 
vancomycin. Patients will receive either iclaprim or vancomycin for 5 to 14 days, which comprises the 
range of total treatment duration. Patients will be evaluated daily up to ETP, then every 48 to 72 hours 
through the end of treatment. If the last dose of study drug falls on a day when an evaluation was not 
planned, an additional evaluation visit will need to be performed on that day (i.e. All EOT evaluations 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 12 of 33 
ST-AD-008 version 02 
should be performed on the last day [+2 days] of drug dose). Patients will also be evaluated at the TOC 
visit (7 to 14 days post-EOT) for both efficacy and safety, and will have a Late Follow-Up (LFU) phone 
call (28 to 32 days post-first dose) for safety only. Note, however, that patients with high liver function 
tests (LFTs) and unresolved adverse events (AEs) at TOC must be seen in person for an additional visit at 
LFU. The total duration of participation in the study for each patient is 29 to 33 days. 
After completing screening procedures, including obtaining cultures from a clinical specimen prior to 
antibacterial therapy, a total of 600 patients (300 per treatment group) will be randomized (1:1) to receive 
either: (1) iclaprim 80 mg every 12 hours or (2) vancomycin 15 mg/kg. The duration of treatment for both 
groups will be 5 days (minimum duration) to 14 days (maximum duration). Assignment to study drug will 
be performed using a central randomization system. Approximately 80 active centers will be recruited. 
Figure 1 displays a diagram of the study design. 
The investigators, clinical study personnel, sponsor, and the patients will remain blinded with respect to 
the study drug treatment allocation. The unblinded pharmacist or his/her designee will be responsible for 
preparation of infusions. To account for the variable vancomycin dosing intervals, normal saline dummy 
infusions will be used to maintain the blind for patients who require a vancomycin dosing frequency other 
than every 12 hours (Q12h). 
Concomitant antibiotics aztreonam and metronidazole used in compliance with their respective 
prescribing information are allowed at the discretion of the investigator during the study drug phase. 
Systemic antibiotics (other than aztreonam and metronidazole) or topical antibiotics at the site of the 
ABSSSI under investigation, steroids >20 mg/day prednisolone or equivalent; and Type I A and 
Type III-antiarrhythmic drugs are prohibited. 
2.3 Sample Size and Power 
For non-inferiority (NI) testing with a 1-sided alpha of 0.025, assuming a 75% early clinical response rate 
in each group and a 10% NI bound delta, a sample size of 295 ITT patients per treatment group is 
required for 80% power. In addition, using similar methods of NI testing with a 1-sided alpha of 0.025, 
assuming a 90% clinical response rate at TOC in vancomycin and iclaprim group and a 10% NI bound 
delta, a sample size of 300 patients in the ITT population per treatment group is required for 98% power.  
A total of 600 patients (approximately 300 per treatment group) will be randomized (1:1) for this study. 
 


Statistical Analysis Plan  
Version: Amendment 2.0 
 Date of Issue: 16 Feb 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
 Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 13 of 33 
ST-AD-008 version 02 
 
Figure 1: Study Design 
 
 
 
 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 14 of 33 
ST-AD-008 version 02 
3 
EFFICACY AND SAFETY VARIABLES 
3.1  Primary Efficacy Endpoint 
The primary efficacy endpoint is the proportion of randomized patients who achieve an early clinical 
response (defined as reduction in the lesion size ≥20% compared to baseline) at 48 to 72 hours (ETP) and 
will be evaluated in ITT population.   
3.2 Secondary Efficacy Endpoints 
 
The primary efficacy endpoint will be repeated in mITT, PP, mCE and mPP populations. 
 
The secondary endpoints are: 
1. Resolution or near resolution of ABSSSI (i.e., clinical cure, defined by a >90% reduction in lesion 
size from the size at baseline, no increase in lesion size since ETP, and no requirement for 
additional antibiotics [except aztreonam and metronidazole] or unplanned significant surgical 
procedures after ETP other than bedside wound care) at TOC for iclaprim (80 mg q12h) compared 
with vancomycin (weight-based dose) for ITT, mITT, PP, mCE, and mPP populations 
2. Resolution or near resolution (≥90%) of ABSSSI at EOT for ITT, mITT, PP, mCE, and mPP 
populations 
3. Resolution or near resolution (≥90%) of ABSSSI at EOT and TOC among patients with severe 
infection at baseline for ITT, mITT, mCE, PP, and mPP populations 
4. Time to resolution of signs and symptoms of ABSSSI from start of treatment for ITT, mITT, PP, 
mCE, and mPP populations 
5. Patient-level bacteriological response rate at EOT and TOC for mITT, mCE, and mPP populations 
6. Pathogen-level bacteriological response rate at EOT and TOC for mITT, mCE, and mPP 
populations 
The clinical outcome will be evaluated at EOT and TOC (7 to 14 days post-EOT) programmatically for 
ITT, PP and mPP populations, and categorized as cure, failure, or indeterminate defined as follows: 
 Cure: defined by a ≥90% reduction in lesion size from baseline, no increase in lesion size since 
ETP, and no requirement for additional antibiotics (except aztreonam and metronidazole) or 
unplanned significant surgical procedures;  
 Failure: reduction in lesion size that is <20% for ETP and <90% for EOT and TOC compared to 
baseline, death related to the infection, persisting or recurrent infection, need for unplanned 
surgical procedure, or administration of rescue antibiotic therapy for the index infection before or 
at assessed visits or recurrence of index infection;  
 Indeterminate: data inadequate for assessment of efficacy (there are no post-baseline local or 
systemic signs and symptoms data available to make this assessment [e.g., patient lost to follow 
up] after <2 days of treatment or <4 doses and no EOT evaluation), lost to follow-up prior to ETP, 
withdrawal of consent, receipt of effective antibiotic therapy for a cause other than the index 
infection before assessed visits, or death not attributed to the index ABSSSI or complication of 
ABSSSI. 
  
Noted: If a patient starts an antibiotic for an infection other than the primary ABSSSI at EOT visit 
date, they will still be included as “Clinical Cure” or “Clinical Failure” dependent on the size of 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 15 of 33 
ST-AD-008 version 02 
the lesion at EOT. The same rule will be applied to the evaluation of clinical outcome at TOC 
visit. 
The definition of “Persistent Infection” and “Recurrent infection” when defining Clinical Failure are 
listed as follows:  
1. Persistent Infection: If a patient has <90% reduction in lesion size at EOT compared to baseline, this 
represents “Persistent Infection” at EOT. The same rule applies when evaluating clinical failure at TOC 
visit. 
2. Recurrent Infection: If a patient has Clinical Cure (≥90% reduction in lesion size from baseline) at EOT 
visit, and becomes Clinical Failure (<90% reduction in lesion size from baseline) at TOC visit, this 
represents “Recurrent infection”. It means the lesion size becomes larger than EOT at TOC visit.  
3.3 Safety Variables 
Safety endpoints are AEs, serious adverse events (SAEs), electrocardiogram (ECG) results, liver function 
tests, hematology, coagulation, serum chemistry including creatinine and creatinine clearance, urinalysis 
(UA), vital signs, and physical examinations. 
4 
PHARMACOKINETIC/PHARMACODYNAMIC VARIABLES 
Pharmacokinetic samples will be obtained from patients on 3 occasions: following the first dose of study 
medication, at ETP, and at EOT.  
Iclaprim plasma concentrations will be used to determine population PK parameters with a non-linear 
mixed effect model. The potential influence of clinical characteristics (age, size, sex, hepatic function, 
renal function, concomitant medications, etc.) on PK parameters will be evaluated. Further details will be 
provided in a separate population PK analysis plan. 
5 
ANALYSIS POPULATIONS 
The ITT population will be the primary population for analysis of primary endpoint. Microbiological 
response will be evaluated for mITT, mCE and mPP populations. All other efficacy analyses will be 
performed for each of the ITT, mITT, PP, mCE and mPP populations. All safety analysis will be 
performed in the Safety population. Enrolled patients are those who signed the inform consent form. 
5.1 Safety Population 
All patients who receive any study drug during the trial will be included in the Safety population. It is the 
primary population for safety analyses. Patients will be analyzed according to the treatment they receive. 
5.2 Intent-to-treat (ITT) population 
All randomized patients will be included in the ITT population. It is the primary population for efficacy 
analyses. Patients will be analyzed in the treatment group to which they are randomized. 
5.3 Microbiological intent-to-treat (mITT) population 
All randomized patients who have a Gram-positive baseline bacteria pathogen identified as the cause of 
ABSSSI will be included in mITT population.  
A Gram-positive bacteria pathogen is identified as the cause of ABSSSI if the Gram-positive pathogen is 
identified from the lesion sample, and is subsequently confirmed by Covance Central Laboratory Services 
(CCLS).    


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 16 of 33 
ST-AD-008 version 02 
5.4 Per Protocol (PP) Population 
The PP population will consist of all patients in the ITT population who receive at least 80% of their 
planned doses and provide adequate data for assessment for each of the following time points: ETP, EOT, 
and TOC. This population excludes patients with Gram-negative bloodstream infections at baseline who 
are discontinued in order to treat the Gram-negative pathogen.  
The data are considered adequate for inclusion in the PP population when the assessment of lesion size 
and clinical signs and symptoms are both performed at corresponding time point. To be included in the PP 
population, a patient must not have important protocol deviations.   
5.4.1 Important Protocol Deviations Leading to Exclusion from the PP Analysis 
Only those important protocol deviations considered to have a major effect on efficacy will lead to 
complete exclusion of the patient from the PP population. For the purposes of this study, the following 
criteria (Table 1) have been identified as important protocol deviations leading to exclusion from the PP 
population as it is considered that the occurrences of any of these criteria might have an important 
influence on the primary efficacy endpoint.  
The majority of the important protocol deviations leading to exclusion from the PP population will be 
determined programmatically from the data. Those criteria which require clinical or medical monitoring 
interpretation will be reviewed prior to database lock, following discussion with the medical monitor and 
Sponsor. 
 
 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 17 of 33 
ST-AD-008 version 02 
Table 1: Important Protocol Deviations Leading to Exclusion from the PP population 
Type 
Important Protocol Deviations 
Leading to Exclusion from the PP 
population 
Method of Identification 
Discontinuation of 
study drug 
Patients with Gram-negative 
bloodstream infections who are 
discontinued in order to treat the Gram-
negative pathogen. 
Programmatic check on blood culture results and 
patient disposition status. 
Manual review will be performed for identifying 
patients who discontinue the study drug. 
Noncompliance  
Received less than 80% of the planned 
study drug.  
Programmatic check based on the exposure and 
drug accountability data.  
Manual review will be performed for identifying 
patients who miss the study drug. 
Errors in 
Treatment 
Allocation 
Patients that receive a wrong treatment at 
1 or more study visits due to packaging 
or dispensing errors 
Programmatic check based on unblinded IXRS 
database after the study is unblinded. The check 
will be done by comparing the package number 
that IXRS had assigned to the patient against the 
package number actually used. 
Clinical Trial 
Management 
System (CTMS) 
Covance Clinical will provide the list of 
protocol deviations based on the clinical 
monitoring 
Manual review: This list will be reviewed and the 
important protocol deviations that will lead to 
exclusion from the PP population will be 
identified. 
Type 
Important Protocol Deviations 
Leading to Exclusion at Affected 
Visits 
Method of Identification 
Missing the 
required clinical 
evaluation 
No adequate data at ETP, EOT and TOC 
Programmatic check the missing assessment of 
lesion size, and the signs and symptoms at time 
points ETP, EOT and TOC 
Prohibited 
medications 
Systemic antibiotics (other than 
aztreonam and metronidazole) or topical 
antibiotics at the site of the ABSSSI 
under investigation, and steroids >20 
mg/day prednisolone or equivalent (See 
Appendix A). 
Manual 
review: 
List 
of 
preceding 
and 
concomitant medications will be reviewed by the 
study 
physician 
for 
potential 
prohibited 
medications occurring during the study up to and 
including TOC. 
 
 
All important protocol deviations leading to exclusion from the PP population occurring during the study 
will be reviewed and approved by the Sponsor prior to database lock and unblinding. Should additional 
important protocol deviations leading to exclusion from the PP population, not anticipated at the time of 
preparing this SAP, be identified during the study (and prior to unblinding), they will be documented in a 
SAP amendment and included in all relevant protocol deviation reviews and approvals. 
If a patient is one or more visits, the rule to determine if they are included in Per-protocol population for 
different time-point is summarized in the table below. For overall analysis, such as demographic 
summary, patients are included in the overall Per-protocol population if they are included in PP analysis 
at any visit. 
   
 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 18 of 33 
ST-AD-008 version 02 
ETP visit 
EOT visit 
TOC visit 
Per-protocol Assessment  
Missing 
Missing 
or 
not missing 
Missing or 
not missing 
Patient is excluded from all visits even if EOT or 
TOC are not missing because lesion size 
difference from ETP cannot be determined. 
Not missing 
Missing 
Missing 
Evaluable at ETP only.  
Not missing 
Missing 
Not missing 
Evaluable at ETP and TOC, excluded from EOT.  
Not missing 
Not missing 
Missing 
Evaluable at ETP and EOT, excluded from TOC.  
Missing 
Missing 
Missing 
Non-evaluable at all visits 
 
When analyzing efficacy endpoints, the following two rules will be applied to determine the clinical 
outcome for Per-protocol analysis: 
1. If a rescue antibiotic is taken at a visit for clinical failure in ITT analysis, then the patient is still 
included for Per-protocol analysis at that timepoint and the outcome of failure is carried forward to 
subsequent visits and the patient is included at each of those visits for PP population. 
2 If antibiotic is taken for a cause other than the index infection before assessed visits, the clinical 
outcome for this patient is Indeterminate for ITT population; however, this patient is excluded from PP 
population at that visit and subsequent visits.  
 
5.5 Modified clinically evaluable (mCE) population 
The mCE population will consist of all patients excluded from the PP population only because they have 
received prohibited concomitant or preceding antibiotics therapy active against Gram-positive pathogens. 
5.6 PP microbiological evaluable (mPP) population  
All mITT patients who receive at least 80% of their planned doses and provide adequate data for 
assessment for each of the following time points: ETP, EOT, and TOC. 
5.7 S. pyogenes-enriched mITT (S. pyogenes mITT) population  
S. pyogenes mITT include all mITT patients and patients who have infection site culture negative and 
ASO titer positive for S. pyogenes at baseline or TOC. 
5.8 PP population for EMA sensitivity analysis  
All PP patients without excluding any results at visits because of missing results at ETP.  
6 
DATA HANDLING 
6.1 Time Points and Visit Windows 
All analyses will use the nominal study visit as defined in the Study Schedule and eCRF. The study visit 
designations throughout tables and listings are listed as Baseline, Visit 2 (0-24 HRS), VISIT 2 (25-48 
HRS), VISIT 2 (49-72 HRS), ETP, EOT, TOC, every 48 to 72 hours until EOT for Visit 4 and LFU. For 
microbiology data, baseline is defined within ±24 hours for first study treatment. 
 
 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 19 of 33 
ST-AD-008 version 02 
Study Visit in Protocol 
Visit designations in tables and listings 
Baseline/Screening/Visit 1 or Visit 2 (0-24 HRS) 
Baseline 
Visit 1 
Visit 1 
Daily until ETP for Visit 2 
Visit 2.1, Visit 2.2 and Visit 2.3 
ETP for Visit 3 
ETP 
Every 48 to 72 hours until EOT for Visit 4 
Visit 4.1, Visit 4.2, Visit 4.3 and Visit 4.4  
EOT for Visit 5 
EOT 
TOC for Visit 6 
TOC 
LFU phone call 
LFU 
6.2 Handling of Dropouts or Missing Data 
For all ITT and mITT efficacy analyses, including the analysis of the primary endpoint, patients who do 
not have an adequate assessment at the appropriate visit will be assumed to be non-responders. 
The safety evaluations will be performed on observed data only. Missing data will not be imputed for 
safety analyses except following rules to determine onset or stop dates of AEs or concomitant medications 
(see Section 1.4 in Appendix C – Table, Figure and Listing Shells for more details).  
The imputed dates will not be listed. Study day relative to the first dose of treatment associated with 
missing or partial dates will not be displayed in AE listings. 
The imputed dates of a medication will only be used to determine whether that medication will be 
classified as prior medication or concomitant medication. 
7 
STATISTICAL METHODS 
7.1 General Principles 
All data processing, summarization and analyses will be performed using Hosted SAS Environment / 
Version 9.3 (or later) of the SAS (SAS Institute, Cary, NC) statistical software package. 
Unless specified otherwise, data will be displayed using the following treatment group labels, in the order 
presented: 
 Iclaprim 
 Vancomycin 
 Total (if applicable)  
All data collected will be presented in listings by treatment group, country, center, patient, and visit 
(where applicable), unless otherwise specified.  
Data will be presented in summary tables by treatment group, assessment and visit (where applicable). 
The category “Missing” will be presented if the number missing is greater than zero for at least one 
treatment group. 
Descriptive summary statistics for continuous variables will include the number of observations (N), 
mean, standard deviation (SD), median and range.  


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 20 of 33 
ST-AD-008 version 02 
Descriptive summary statistics for categorical variables will include frequency counts and percentages. 
Unless stated otherwise in the table shells, the denominator for percentage calculations will be the number 
of patients in the analysis population. 
Dates will be displayed as DDMMMYYYY. 
All significance tests will use a significance level of 5% for two-sided tests and a significance level of 
2.5% for one-sided tests. 
7.2 Patient Disposition and Data Sets Analyzed 
Patient disposition will be listed and summarized by treatment group and overall, and will include the 
number and percentage of patients: 
 enrolled; 
 randomized (ITT population); 
 treated (Safety populations); 
 other study populations (mITT, PP, mCE, mPP, S. pyogenes mITT, safety). 
In addition, the number and percentage of patients who complete the study, who discontinue from study 
early, including a breakdown of the primary reasons for discontinuation, will be presented for ITT and 
Safety populations. The number and percentage of patients who complete the treatment will be analyzed 
in a similar manner. 
A summary of patient enrollment by country and center will also be provided by treatment group and 
overall for the ITT population.  
The number of patients who complete study or complete each visit of ETP, TOC and TOC will be 
analyzed by treatment groups and study populations. 
7.3 Protocol Deviations 
All important protocol deviations leading to exclusion from the PP population (see Section 5.4.1) will be 
listed and summarized by treatment group for the ITT and mITT populations. 
The deviations will be identified before data are unblinded. 
7.4 Demographics and Other Baseline Characteristics 
Demographic and baseline characteristics will be listed and summarized by treatment group and overall 
for ITT, mITT, PP, mCE, mPP and safety populations. Standard descriptive statistics will be presented for 
the continuous variables of: 
 age (years) calculated as (calendar months between date of informed consent and date of birth – 
I(day of informed consent < day of birth))/12, where I is the indicator function. Months between 
dates in the same month will be 0. Age will be reported as whole years; 
 weight (kg); 
 height (cm); 
 body mass index (BMI; kg/m2) calculated as (weight/height2) where weight is in kilograms and 
height is in meters;  
 lesion size (cm2) 
The total counts and percentages of patients will be presented for the categorical variables of: 
 age group (grouped as 18-39 years, 40-64 years, and 65 years and older); 
 sex; 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 21 of 33 
ST-AD-008 version 02 
 race; 
 ethnicity; 
 creatinine clearance (CrCL) in mL/min (grouped as 90, 60-89, 30-59, 15-29, and <15 or 
hemodialysis); 
 lesion type (major cutaneous abscess, cellulitis/erysipelas, and wound infection); 
 Receipt of prior antibiotics (obtained from IXRS as Yes, No); 
 Blood culture at baseline (positive, if anaerobic or aerobic blood culture has pathogen; negative, 
if culture taken and organism isolated but there is no pathogen or no organism was isolated) 
 Gram-positive vs Gram-negative pathogen (mixed); 
 Methicillin-resistant Staphylococcus aureus (MRSA) vs Methicillin-sensitive Staphylococcus 
aureus (MSSA); 
 multiple pathogens vs single pathogen; 
 Streptococcus pyogenes determined from ASO and either blood or infection site culture results 
from baseline (ASO positive only (> 330 IU/mL), culture positive only, ASO positive and 
culture positive, ASO negative (<= 330 IU/mL) and culture negative).   
 severe infection (yes vs no), defined in Section 2.1 
 diabetes (yes – if patient have medical history for diabetes, or baseline glucose > 200 mg/dL, or 
concomitant medications of either insulin or oral hypoglycemic; or no – no medical history for 
diabetes, baseline glucose <= 200 mg/dL, no concomitant medications of either insulin or oral 
hypoglycemic.) 
 geographic region (US, Europe, Latin America). 
 
Other baseline measurements, such as type of culture specimen / culture result, lesion type, blood culture 
by visit, baseline pathogens, vital signs, ECG, and laboratory evaluations, will be summarized by 
treatment group with the post-baseline measurements. 
7.5 
Medical History 
Medical history will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) Version 
18.1 (or a later version if updated during the study). All medical history will be listed, and the number and 
percentage of patients with any medical history will be summarized for ITT population by system organ 
class (SOC) and preferred term (PT) for each treatment group and overall.   
7.6 Prior and Concomitant Medications 
Medications received prior to or concomitantly with treatment will be coded by Covance using the WHO 
Drug Dictionary, Version WHODRUG Enhanced 201509, DDEB2 (or a later version if updated during 
the study), Anatomical Therapeutic Chemical (ATC) Classification codes.  
Prior medications are those taken prior to the first dose date of treatment and within the preceding 30 days 
of the Informed Consent.  
Concomitant medications are those with a start date on or after the first dose date of treatment, or those 
with a start date before the first dose date of treatment and a stop date on or after the first dose date of 
treatment, or with a start date before the first dose date of treatment and are reported as ongoing. 
If a medication cannot be classified as “prior” or “concomitant” after applying imputation rules for 
missing/incomplete dates, it will be classified as concomitant. 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 22 of 33 
ST-AD-008 version 02 
The number and percentage of patients using each medication will be displayed together with the number 
and percentage of patients using at least one medication within each therapeutic class (ATC-Level 2), 
chemical subgroup (ATC-Level 4), and generic term. 
Separate summaries will be presented for prior medications, concomitant medication excluding 
antibiotics, and concomitant antibiotic medications for ITT population.  A patient listing of all prior and 
concomitant medications will be provided for ITT population. 
7.7 
Significant Procedures 
The number and percentage of patients receiving any significant procedures, such as debridement or 
incision and drainage will be displayed by study visits and treatment groups for ITT population. 
7.8 
Measurements of Treatment Compliance and Exposure 
Percentage compliance is calculated as: 
 
100 * actual number of doses received / planned number of doses.  
For example, patients are administered iclaprim q12h for 5 to 14 days, so the planned number of doses is 
2 times the number of days in treatment period if the treatment is started in the AM.  If a patient was 
treated for <5 days, the planned number of dosing days will be considered as 5 days.  If a patient was 
treated for > 5 days, the planned number of dosing days is the actual number of days dosed.  Missed doses 
will not be included in the actual number of doses for the compliance calculation. 
The number and percentage of compliant patients will be presented for the Safety population, where 
compliant is defined as percentage compliance greater ≥ 80.0%. The category of percentage compliance < 
80.0% will also be presented. The treatment compliance will be tabulated with three categories with 
number and percentage of patients: <80%, 80% to 100%, >100%. 
The total treatment duration is defined as: Date of last dose – Date of first dose + 1 if treatment is started 
in the AM and completed in the PM. Treatment duration (days) will be summarized using descriptive 
statistics (n, mean, SD, median, minimum, and maximum) by treatment group for the Safety population. 
7.9 
Efficacy 
7.9.1 Primary Efficacy Analysis 
The primary efficacy analysis will be the NI (at significance level 0.025) of iclaprim (group 1) to 
vancomycin (group 2) for the proportion of ITT patients with a ≥20% reduction in lesion size at ETP 
compared to baseline. The NI bound will be 10%. Let P1 be the proportion for iclaprim and P2 be the 
proportion for vancomycin. Equivalently, if the lower bound of the two-sided 95% confidence interval 
(CI) for P1 – P2 is greater than -0.100 based on the Z test with unpooled variance estimate, NI will be 
concluded. 
 
7.9.2 Secondary Efficacy Analysis 
The primary NI efficacy analysis will be repeated in the mITT, mCE, PP, mPP populations, S. pyogenes 
enriched mITT population and PP population for EMA.   
The secondary endpoints are resolution or near resolution of ABSSSI (i.e., clinical cure) at TOC for 
iclaprim compared with vancomycin, resolution or near resolution (≥90%) of ABSSSI at EOT, resolution 
or near resolution (≥90%) of ABSSSI at EOT and TOC among patients with severe infection at baseline, 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 23 of 33 
ST-AD-008 version 02 
time to resolution of signs and symptoms of ABSSSI, by-patient bacteriological response rate at EOT and 
TOC, and by-pathogen bacteriological response rate at EOT and TOC. 
7.9.2.1 Resolution or Near Resolution of ABSSSI 
For resolution or near resolution of ABSSSI at TOC, the NI test described in Section 7.9.1 will be used to 
demonstrate the non-inferiority of iclaprim to vancomycin in the ITT population EMA primary endpoint. 
The same NI test will be repeated for mITT, mCE, PP, mPP and S. pyogenes enriched mITT population at 
TOC. All above tests will then be repeated for resolution or near resolution of ABSSSI at EOT.  
The NI test will be performed for resolution or near resolution of ABSSSI at TOC as well as EOT among 
patients with severe infection at baseline in ITT population, and repeated for mITT, PP populations.  
A summary of clinical outcome, including the number and percent of patients with cure, failure and 
indeterminate outcomes at EOT and at TOC will be produced for the ITT, mITT, PP, and mPP. 
7.9.2.2 Signs and Symptoms of ABSSSI 
Baseline signs (tender to palpitations, erythema, edema, purulent drainage/discharge, fluctuance, 
induration, ulceration, and necrotic tissue) and baseline symptoms (localized pain, swelling, chills, and 
fever) will be summarized using descriptive statistics.  
Time (in days) to resolution of each of the signs and symptoms of ABSSSI is defined as: first date with no 
specified sign/symptom of ABSSSI recorded on eCRF post treatment – date of first dose + 1. For patients 
who are not free of the specified sign/ symptom until the end of study, the last day recorded available 
sign/symptom on eCRF will be used as the censoring day. For patients free of any specific signs or 
symptoms at baseline (i.e. “none” of results for sign/symptom), please exclude these patients when 
analyzing time to resolution of that specific sign or symptom. 
For each of the signs and symptoms, the hazard ratio of iclaprim vs vancomycin will be estimated in a 
Cox proportional hazard model for time to resolution of the specified sign/symptom, with the treatment 
group as the only covariate. The Kaplan-Meier (KM) method will be applied to estimate the distribution 
of the resolution time of each signs or symptom for each treatment group. The 95% CI of the hazard ratio 
will also be reported. This Cox regression will be performed in the ITT, mITT, PP populations.  
7.9.2.3 Bacteriological response 
Bacteriological response will be assessed at the patient level and at the microbiological level on the basis 
of results of the cultures, the susceptibilities of identified organisms, and the clinical outcome of the 
patient for the mITT, mCE and mPP populations. 
For each assessment (ETP, EOT, and TOC), the by-pathogen bacteriological response for each causative 
organism identified at baseline will be defined as follows: 
 Eradication: baseline causative organism cannot be isolated from any culture(s) at the assessment. 
 Presumed eradication: The patient is a clinical cure at the assessment, and there is no appropriate 
material for culture from the original site of infection. 
 Persistence: The baseline causative pathogen (based on susceptibility profile or molecular typing) is 
isolated at the assessment. 
 Presumed persistence: The patient is a clinical failure at the assessment, and no appropriate material 
is available for culture from the original site of ABSSSI. 
 Indeterminate: Clinical response was Indeterminate at the assessment and no appropriate material is 
available for culture from the original site of ABSSSI. 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 24 of 33 
ST-AD-008 version 02 
 Superinfection: A pathogen is isolated at the assessment that is different from the baseline causative 
pathogen. 
 Recurrent infection: A pathogen is isolated only after the EOT visit that is different from the 
baseline pathogen(s). 
By-pathogen bacteriological response categories will be summarized in a frequency table for each 
causative baseline pathogen per treatment group.  
The by-patient bacteriological response will be determined according to the following definitions: 
 Eradication: All baseline Gram-positive causative organism(s) have a response of Eradication. 
 Presumed eradication: All baseline Gram-positive causative organism(s) have a response of 
Presumed Eradication or a combination of responses of Eradication and Presumed Eradication. 
 Persistence: All or some baseline Gram-positive causative organism(s) have a response of 
Persistence or a combination of responses of Persistence and Presumed Persistence. 
 Presumed persistence: All or some baseline Gram-positive causative organism(s) have a response of 
Presumed Persistence. 
 Indeterminate: All baseline causative organism(s) have a response of Indeterminate. 
 Superinfection: Any patient classified as a clinical failure who has a pathogen isolated during 
therapy that is different from the baseline causative pathogen. 
 Recurrent infection: Any patient classified as a clinical failure who has a pathogen isolated after the 
EOT visit only, that is different from the baseline pathogen(s). 
The by-patient bacteriological response will be determined by ordering the pathogen outcome for the 
patient by medical importance: persistence, presumed persistence, superinfection, recurrent infection, 
presumed eradication, and eradication.  Patient bacteriological outcome is determined by the pathogen 
outcome of higher importance. For the combined rate of eradication or presumed eradication, 95% CI will 
be calculated per treatment group and for the difference as specified for the primary endpoint analysis, 
and number and percentages for all underlying by-patient bacteriological response categories will be 
tabulated. 
Minimum inhibitory concentrations (MIC) will be summarized using EUCAST and CSLI methods for 
vancomycin and iclaprim antibiotics. The number and corresponding percentage for interpretation of the 
MIC result will be summarized for three categories: susceptible, Intermediate or resistance. 
 
7.9.3 Exploratory Analysis 
 Mortality rate within 28 days of first dose of treatment will be summarized overall and by treatment 
group for the ITT population.   
 For early clinical response of ABSSSI, the NI test described for the primary endpoint analysis will 
be used to evaluate the proportion of ITT patients with a ≥50%, ≥75%, and ≥90% reduction in lesion 
size at ETP compared to baseline. 
 For improvement of ABSSSI at EOT and TOC, the NI test described for the primary endpoint 
analysis will be used to evaluate the proportion of ITT patients with a ≥50% and ≥75% reduction in 
lesion size at EOT and TOC.  
 In addition, sensitivity analyses for resolution or near resolution of ABSSSI will be evaluated as 
follows:  


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 25 of 33 
ST-AD-008 version 02 
(1) Resolution and near resolution of ABSSSI excluding the criteria for lesion size reduction, but 
including the following considerations: Resolution or near resolution of ABSSSI (no requirement 
for additional antibiotics (except aztreonam and metronidazole), no death related to the infection, 
and no unplanned surgical procedure) for the ITT population at EOT and TOC. 
(2) Resolution and near resolution of ABSSSI excluding the criteria for lesion size reduction at ETP, 
but including the following considerations: 
- Cure: defined by a ≥90% reduction in lesion size from baseline and no requirement for additional 
antibiotics (except aztreonam and metronidazole) or unplanned significant surgical;  
- Failure: reduction in lesion size that is <90% for EOT and TOC compared to baseline, death 
related to the infection, persisting or recurrent infection, need for unplanned surgical procedure, or 
administration of rescue antibiotic therapy for the index infection before or at assessed visits or 
recurrence of index infection. 
 If it is concluded that Iclaprim is non-inferior to Vancomycin (i.e., the lower bound of two-sided 95% 
confidence interval of group difference in early clinical response is greater than -0.1), it may be 
concluded that Iclaprim is superior to Vancomycin if the entire 95% confidence interval is >0. 
Superiority may also be concluded for resolution of ABSSSI at TOC in a similar manner. 
7.9.4 Subgroup Analysis 
The primary endpoint, the proportion of patients with a ≥20% reduction in lesion size at ETP compared to 
baseline and the key secondary endpoint, proportion of patients with a clinical cure at TOC, will be 
presented for ITT and PP populations.  
 age group (grouped as 18-39 years, 40-64 years, and 65 years and older); 
 sex; 
 race (white vs non-white); 
 creatinine clearance (CrCL) in mL/min (grouped as 90, 60-89, 30-59, 15-29, and <15 or 
hemodialysis); 
 blood culture at baseline (positive, if anaerobic or aerobic blood culture has pathogen; negative, 
if culture taken and organism isolated but there is no pathogen or no organism was isolated) 
 MRSA vs MSSA; 
 multiple pathogens vs single pathogen; 
 Streptococcus pyogenes determined from ASO and either blood or infection site culture results 
from baseline (ASO positive only, culture positive only, ASO positive and culture positive, ASO 
negative and culture negative).   
 diabetes (yes – if patient have medical history for diabetes, or baseline glucose > 200 mg/dL, or 
concomitant medications of either insulin or oral hypoglycemic; or no – no medical history for 
diabetes, baseline glucose <= 200 mg/dL, no concomitant medications of either insulin or oral 
hypoglycemic.) 
 geographic region (US, Europe and Latin America). 
 
The difference in the proportions of the two treatment groups and 95% CI will be calculated for each 
subgroup, and forest plots will be used to display these intervals graphically. 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 26 of 33 
ST-AD-008 version 02 
7.10 Safety 
7.10.1 Adverse Events 
All adverse events (AEs) recorded on the eCRF will be coded using the MedDRA dictionary Version 18.1 
(or a later version if updated during the study) and classified as either pre-treatment AEs or treatment – 
emergent AEs (TEAEs) as follows: 
 Pre-treatment AEs are events that start prior to the date of first dose of treatment. 
 TEAEs are events with start date on or after the date of first dose of treatment (using dates and 
times as recorded on the medication administration log) through TOC visit, or events with start 
date prior to the date of first dose of treatment whose severity worsens on or after the date of 
first dose of treatment. SAEs will be reported through end of study as TEAE. 
If any incomplete date/time of AE onset or start of first infusion is not sufficient to exclude that the AE is 
treatment emergent, then the AE will be considered to be a TEAE. 
All AE data will be listed by treatment group with Pre-treatment AEs and TEAEs presented separately.  
Treatment-emergent status will be flagged in the listing. In addition, corresponding listings of SAEs, AEs 
leading to discontinuation of treatment and AEs resulting in death will be produced. 
The severity of all AEs is recorded as mild, moderate, or severe.  If severity is missing for a TEAE, it will 
be considered severe only in the overall category in the summary tables.  
The relationship between an AE and treatment is assessed as related, probably related, probably not 
related, or not related. A drug-related AE is an AE considered by the investigator as related or probably 
related to the study drugs, or with unknown/missing relationship to treatment.   
Each AE must be assessed and recorded in the eCRF as serious or not serious. Serious AEs must be 
reported as described in the protocol  
An overview table will summarize the number and percentage of patients with at least one of the 
following TEAEs for Safety population, where patients with more than one TEAE in a particular category 
are counted only once in that category: 
 
any TEAE;  
 
any TEAE by severity (mild, moderate, severe); 
 
drug-related TEAEs;  
 
TEAEs leading to discontinuation of the study drug; 
 
SAEs;  
 
drug-related SAEs;  
 
SAEs leading to death. 
The number and percentage of patients reporting each TEAE, including TEAE by age (<65 and ≥65), 
TEAEs by CrCL (≥90, 60-89, 30-59, 15, 29, and < 15 or hemodialysis), TEAEs by diabetes (present or 
absent), TEAEs leading to discontinuation, SAEs, drug related SAEs, and SAEs leading to death, will be 
summarized for each treatment group and overall, by SOC (sorted alphabetically) and PT (sorted by 
descending overall total) for Safety population. The analogous summaries will also be given for study 
drug related TEAEs, all TEAEs by severity and for all SAEs. TEAEs with missing severity will not be 
included in the counts of patients within a SOC or PT. For counting the number of events, the same rule 
for multiple events in one category will be applied as specified above. There will also be summaries of the 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 27 of 33 
ST-AD-008 version 02 
most common TEAEs (>5%) and SAEs (>5%) by PT in descending order of frequency in the iclaprim 
group. 
No statistical comparisons of AEs, deaths, AE leading to discontinuation, or SAEs between treatment 
groups will be performed. 
7.10.2 Laboratory Evaluations 
Data for the following hematology, blood chemistry, and urinalysis analytes received from central 
laboratory as well as LFT results (Table 2) recorded in the eCRF will be listed (see Appendix B for the 
scheduled data collection) and summarized by treatment group and visit. Data received from local 
laboratories will be listed with the original units. If data for any additional analytes are also received then 
these will be listed only. 
All central laboratory data will be reported in International System of Units (SI Units) and Conventional 
Units (CV Units). Out-of-reference-range values will be flagged as high (H) or low (L) in the data 
listings.  
 
Table 2: Laboratory Evaluations 
Hematology (CBC) 
Chemistry [Fasted] (Chem-20) 
Urinalysis (UA) 
Hematocrit 
Hemoglobin 
MCH 
MCHC 
MCV 
Platelet count 
Red Blood Cell Count  
White Blood Cell Count 
White Blood Cell Differential 
(% & ABS): 
Basophils 
Eosinophils 
Lymphocytes 
Monocytes 
Neutrophils 
 
Albumin 
ALP 
ALT 
AST 
BUN 
Chloride 
Creatinine  
GGT 
Glucose 
LDH 
Potassium 
Sodium 
Magnesium  
Total Bilirubin  
Total CO2 (measured as bicarbonate)  
Total protein  
CPK 
CRP 
pH and specific gravity 
Glucose 
Ketones 
Occult blood 
Proteins 
Microscopic examination 
of sediment (including 
RBCs and WBCs) 
Bilirubin/Urobilinogen 
 
 
Source: Protocol Appendix A – Clinical Laboratory Evaluations 
 
Laboratory test variables will be summarized by treatment group and visit using descriptive statistics 
(number of patients, mean, SD, minimum, maximum, as well as mean change from baseline, standard 
error for mean change, minimum, median, and maximum). For each laboratory analyte, the baseline value 
will be defined as last scheduled or unscheduled value collected prior to the first dose of treatment. The 
descriptive statistics will be summarized for both SI and CV units.  


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 28 of 33 
ST-AD-008 version 02 
The number and percentage of patients with values below, within and above the corresponding extended 
normal range will be tabulated per visit. Shift tables (i.e., cross-tabulations of below the lower limit of the 
normal range, within the limits of the normal range and above the upper limit of the normal range at 
baseline versus scheduled visits) will be presented by laboratory test.  
In addition, shift tables for 6 liver enzyme tests (AST, ALT, alkaline phosphatase, GGT, total and direct 
bilirubin) and 3 renal function tests (BUN, creatinine, creatinine clearance) for post-baseline change in 
grade categories ≤3x ULN, >3x-5x ULN, >5x-10x ULN, >10x-20x ULN, >20x ULN will be presented. 
For bilirubin, the category is presented as two categories, <2x ULN, >2x ULN. The maximum change 
through all study will be presented as overall results and results will also be presented by visit. 
Laboratory tests with categorical results that cannot be analyzed by change from baseline or shift table 
analysis will not be included in these summaries, but will be listed. Data obtained from laboratory tests 
not required by the protocol will not be summarized, but will be listed. 
7.10.3 Vital Signs 
The following vital signs will be listed and summarized by treatment group and visit (see Appendix B for 
the scheduled data collection). 
 systolic and diastolic blood pressure (mmHg); 
 heart rate (bpm); 
 respiration rate (breaths/min); 
 body temperature (°C). 
Vital signs data and changes from baseline in vital signs will be summarized by visit using standard 
descriptive statistics for the Safety population. The baseline value will be defined as last scheduled or 
unscheduled value collected prior to the first dose of treatment.  Assessments carried out on day of first 
treatment administration are considered to have taken place before the treatment administration, if the 
corresponding times have not been recorded. For post-baseline, only data from scheduled visits will be 
included in the summary tables.  
7.10.4 Electrocardiograms 
The following quantitative ECG measurements will be taken and read centrally during the study (see 
Appendix B for the scheduled data collection): 
 heart rate (bpm); 
 RR interval (msec); 
 PR interval (msec); 
 QRS interval (msec); 
 QT interval (msec); 
 Bazett corrected QT (QTcB) interval (msec);  
 Fridericia corrected QT (QTcF) interval (msec). 
Triplicate ECG measurements will be listed for every ECG measurement, and the median value of the 
triplicate measurements will be summarized using descriptive statistics.  
Based on 12-lead triplicate ECG results as reported on the case report form (CRF) that are read centrally 
the number and percentage of patients whose median QTcF value is >500 msec and/or is >60 msec 
different from the predose baseline value will be provided for every visit. For every visit with ECG 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 29 of 33 
ST-AD-008 version 02 
measured, the median QTcF and QTcB values will be summarized with descriptive statistics for the 
following categories: 
 > 450 msec; 
 > 480 msec; 
 > 500 msec; 
 increase from baseline > 30 msec; 
 increase from baseline > 60 msec. 
The central ECG measurements at all pre-planned visits and time points and changes from baseline in 
ECG will be listed and summarized by treatment group and visit using standard descriptive statistics for 
the Safety population.  
The baseline value will be defined as last scheduled or unscheduled median value collected prior to the 
first dose of treatment. Assessments carried out on day of first treatment administration are considered to 
have taken place before the treatment administration, if the corresponding times have not been recorded. 
For post-baseline, only data from scheduled visits will be included in the summary tables.  
7.10.5 Physical Examination 
Physical examination results (normal/abnormal) and details of abnormalities will be listed for each patient 
(see Appendix B for the scheduled data collection). 
7.11 Interim Analysis 
When 75% of the randomized patients have undergone the 48- to 72-hour (ETP) response assessment, a 
blinded interim analysis is planned to estimate the percentage of patients in the study who classify as 
having a reduction in the lesion size ≥20% at the 48- to 72-hour visit compared to baseline. Based on the 
observed overall percentage, the sample size will be re-estimated as N1 using z-test with unpooled 
variance estimate. The new total sample size will be the maximum of 300 and N1, following Friede T et al 
(2007). The sponsor may increase the total sample size to attempt to ensure that an adequate number of 
ITT patients are included in the study. Since the review is blinded and the efficacy analyses will not be 
reviewed by treatment group, no adjustment of p-values is required. Nevertheless, the sponsor will take 
steps to minimize the distribution of results to avoid introducing any bias. 
8 
REFERENCES 
1 
Friede T, Mitchell C, Müller-Velten R. Blinded Sample Size Reestimation in Non-Inferiority 
Trials with Binary Endpoints. Biometrical Journal. 2007; 49: 903-916.  
 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 30 of 33 
ST-AD-008 version 02 
9 
APPENDICES 
Appendix A – Prohibited Medicines 
The following medications are prohibited:  
• Systemic antibiotics (other than aztreonam and metronidazole) or topical antibiotics at the site of the 
ABSSSI under investigation;  
• Steroids >20 mg/day prednisolone or equivalent;  
• Type IA and Type III anti-arrhythmic drugs; and  
• Local antiseptics.  
 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 31 of 33 
ST-AD-008 version 02 
Appendix B – Schedule of Events 
Procedure 
Baseline/ 
Screening/ 
Randomization 
Visit 1 
(up to 24 hours 
prior to first dose)1 
Daily until ETP 
Visit 2 
ETP 
(48 to 72 
hours post-
first dose) 
Visit 3 
Every 48 to 72 
hours until 
EOT 
Visit 4 
EOT/ 
Early Termination 
Visit 5 
(treatment duration: 
minimum 5 days, maximum 
14 days) 
TOC 
7 to 14 days 
post-EOT 
Visit 6 
LFU 
28 to 32 days 
post-first dose 
Phone Call2 
Informed consent 
X 
 
 
 
 
 
 
Medical history 
X 
 
 
 
 
 
 
Prior medications (preceding 30 days) 
X 
 
 
 
 
 
 
Concomitant medications 
 
X 
X 
X 
X 
X 
 
Review of inclusion & exclusion criteria 
X 
 
 
 
 
 
 
Complete physical examination3
 
X 
 
 
 
 
 
 
Limited physical examination4 
 
X 
X 
X 
X 
X 
 
Assessment of signs & symptoms of ABSSSI with 
digital photography5 
X 
 
X 
 
X 
X 
 
Assessment of signs & symptoms of ABSSSI 
without digital photography5 
 
X 
 
X 
 
 
 
Evaluation of adverse events6 
X 
X 
X 
X 
X 
X 
X 
Significant procedures (incision & drainage, 
debridement, amputation, suture removal, etc.) 
 
X 
X 
X 
X 
X 
 
Creatinine clearance (estimated) 
X 
 
 
 
 
 
 
LFT safety 
X 
X 
X 
 
X 
X 
 
C-reactive protein 
X 
 
X 
 
X 
X 
 
Hematology7 
X 
 
X 
X 
X 
X 
 
Clinical chemistry7 
X 
 
X 
X 
X 
X 
 
Urinalysis7 
X 
 
X 
X 
X 
X 
 
Serum pregnancy test (females of 
childbearing potential)8 
X 
 
 
 
 
 
 
Blood cultures (aerobic/anaerobic) 
X9 
X10 
X11 
X11 
 
 
 
Study medication administration12 
 
X 
X 
X13 
X14 
 
 
Blood sample for PK analysis 
 
X15 
X16 
 
X16 
 
 
ECG (at each timepoint 3 ECGs at least 1 minute 
apart will be performed) 
X 
X17 
X18 
 
 
 
 
Infection site cultures19 
X 
 
X 
 
X 
X 
 
ASO antibody titers 
X 
 
 
 
 
X 
 
Draw trough levels20 
 
 
 
X21 
 
 
 
Central randomization 
X 
 
 
 
 
 
 
Clinical efficacy assessment 
 
 
 
 
X 
X 
 
Day 28 mortality 
 
 
 
 
 
 
X 
Abbreviations: ASO = anti-streptolysin O; EOT = End of Therapy; ETP = Early Timepoint; LFT=liver function test; LFU = Late Follow-up; TOC = Test of Cure.  
1 Must be performed during the baseline visit and completed within 24 hours of study entry (first dose of study drug). 
2 Patients with high LFTs and unresolved AEs at TOC will be required to come in for an additional visit at LFU (for LFTs, blood samples will be obtained to document normalization). If duration of therapy 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 32 of 33 
ST-AD-008 version 02 
is 14 days, LFU may overlap with TOC. In this case, all LFU evaluations may take place at the TOC visit. 
3 Complete physical examination, including vital signs (includes determination of body temperature), height, weight, and a review by body systems. 
4 Limited physical examination, including vital signs (includes determination of body temperature) and excluding weight and height. 
5 Eight signs (tenderness to palpitation, erythema, edema, purulent drainage/discharge, fluctuance, induration, ulceration, and necrotic tissue) and four symptoms (localized pain, swelling, chills, and fever) of 
infection will be assessed at each evaluation and graded on a scale of 0 to 3 (0=none, 1=mild, 2=moderate, or 3=severe). The extent of the infection (to include width, length, and depth and diagram of the 
infection site) will be determined via photography at baseline, ETP, EOT, and TOC only. Photography procedures outlined in protocol Appendix B will be followed. Acetate based planimetric tracing will 
follow the procedures outlined in Appendix C. (Planimetry measurements are based upon automatic detection of pixels inside of the traced skin infection area. Pixels are converted to calibrated units based 
on the scanned resolution [e.g., 300 DPI]. Skin infection measurements will be provided in cm2.). Patients who have a worsening of clinical signs and symptoms of ABSSSI during study medication 
treatment such that additional or alternative systemic antibacterial therapy is warranted must be withdrawn from study medication. 
6 All adverse events will be recorded throughout the study period, up to and including the LFU phone call. 
7 Hematology comprises a complete blood count (RBC count, WBC count with differential counts, platelet count, hemoglobin, and hematocrit), MCH, MCHC, MCV, and CRP. Clinical chemistry comprises 
creatinine, BUN, AST, ALT, alkaline phosphatase, total bilirubin, albumin, total protein, glucose, sodium, potassium, chloride, bicarbonate, LDH, GGT, and CPK. Urinalysis comprises determination of 
pH, specific gravity, presence of blood, glucose, protein, ketones, and bile, and microscopic examination of sediment. 
8 Serum pregnancy test must be obtained immediately prior to randomization. If obtaining the serum pregnancy result would cause a delay in treatment, the patient can be entered on the basis of a negative 
urine pregnancy test result. The urine pregnancy test must be sensitive to at least 50 mU/mL of beta-hCG, pending results of the serum test. The patient must inform the investigator if she becomes 
pregnant, and study medication must be withdrawn. 
9 Obtain two sets of blood cultures (aerobic and anaerobic) 10 minutes apart from two separate peripheral sites. 
10 If patient has a blood culture that grows a Gram-negative pathogen from Visit 1 blood cultures, the patient must be withdrawn from study medication and started on the appropriate antibiotics for 
complicated bacteremia. If patient has signs of bacteremia, obtain two sets of aerobic/anaerobic blood cultures 10 minutes apart that are collected at different sites. 
11 If patient has a blood culture that grows a Gram-negative pathogen from Visit 2 blood cultures, the patient must be withdrawn from study medication and started on the appropriate antibiotics for 
complicated bacteremia. If patient has a blood culture that grows a Gram-positive pathogen from Visit 1 and/or Visit 2 blood cultures, another 2 sets of blood cultures must be obtained at both Visit 3 and 
Visit 4. If these are positive, the patient must be withdrawn from study medication and started on the appropriate antibiotics for complicated bacteremia. 
12 A window of +/- 2 hours is acceptable for infusion of study medication. For patients randomized to receive vancomycin, vancomycin dosing will be adjusted based on trough levels to maintain a trough of 
either 10 to 15 mg/L for patients with an organism whose MIC is ≤1 mg/L or 15 to 20 mg/L for patients with an organism whose MIC is >1 mg/L. Dose adjustments made due to trough monitoring will 
need to be performed in such a manner as to ensure that the blind is maintained. 
13 If the last dose of study drug falls on a day when an evaluation was not planned, an additional evaluation visit will need to be performed on that day (i.e., all EOT evaluations should be performed on the 
last day [+2 days] of drug dose). 
14 If clinically indicated (i.e., investigator may decide on a given day that a patient no longer needs treatment. In these cases, medication will not be administered, but all other EOT assessments must be 
performed.) 
15 On Day 1, before the start of first study medication infusion and within 5 to 15 minutes, 1 to 3 hours, and 5 to 7 (ensure last PK sample is taken prior to next dose) hours after the infusion. 
16 Before the start of study medication infusion at ETP and EOT, and within 5 to 15 minutes, l to 3 hours, and 5 to 7 hours (ensure last PK sample is taken prior to next dose) after the ETP and EOT infusions. 
17 On Day 1, before the start of first study medication infusion and within 10 minutes of the end of the first study medication infusion. If the median QTcF value is >500 msec and/or is >60 msec different 
from the predose baseline value, follow-up ECG tests should be performed every 1 to 2 hours until they are below these threshold values. 
18 At ETP, an ECG should be performed before the start of study medication infusion and within 10 minutes of the end of the study medication infusion. 
19 Prior to randomization, all patients (regardless of the disease type) should have appropriate cultures obtained. Deep culture samples, such as from a biopsy, needle aspiration, surgically obtained specimens, 
or punch biopsies of an area contiguous to the infected wound should be obtained. Swabs are not acceptable; cultures will be performed locally, where isolates will be retained for transport to a central 
microbiology laboratory for susceptibility testing according to CLSI-approved methodology. Note that only target pathogens will be sent to the central microbiology laboratory (therefore, 
contaminants/Gram-negative isolates [from mixed wound infections] in blood cultures do not need to be sent). If the patient is discontinued from the study due to treatment failure, a clinical specimen will 
be obtained at that time only. Additional clinical specimens will be obtained, if clinically feasible and if the patient has persistent clinical signs or symptoms, at ETP, EOT, and TOC. 
20 For vancomycin patients with a CrCL < 25mL/min, a daily level should be obtained and the unblinded team should monitor and re-dose the patient when that level is below 20 mg/L. 
21 Vancomycin patients with a CrCL ≥25 mL/min should have their vancomycin level checked with the 5th dose due to difficulty interpreting levels checked prior to achieving steady state. 
 
 


Statistical Analysis Plan  
Version: Final Amendment 2.0 
Date of Issue: 23 Mar 2017 
Motif BioSciences Protocol No. ICL-23-ABSSSI1 
 
Covance Study ID: 000000145416 
 
COVANCE INC. CONFIDENTIAL 
Page 33 of 33 
ST-AD-008 version 02 
Appendix C – Table, Figure and Listing Shells 
The table, figure, and listing shells and corresponding Table of Contents will be created in a separate file.